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Haematopoietic progenitor cells (HPCs) may attenuate the response to acute 
vascular injury by maintaining endothelial integrity and function. The aim of this 
study was to determine whether circulating HPC number and function, and 
mobilising cytokines, reflect significant carotid disease or correlate with restenosis 
following carotid endarterectomy (CEA).  
 
Methods  
Initially the assay conditions to measure HPC number and function were optimized. 
HPC numbers were measured by flow cytometry (CD133+ve/CD34+ve) and early 
colony forming unit assay (eCFU). HPC function was measured by migration assay 
and by staining for senescence associated B-galactosidase (SA-Bgal). HPC 
number and function was then measured in 62 patients undergoing CEA pre-
operatively, 1 day post operatively and 6 weeks post-operatively. Restenosis was 
assessed by duplex scanning at 3, 6 and 12 months. The circulating profile of GM-
CSF, PlGF, SDF1 and VEGF was measured by multiplex ELISA. 
 
Results 
HPC numbers (P<0.001) and eCFU counts (P=0.001) fell rapidly 24hrs after CEA. 
The percentage post-operative fall in CD133+ve/CD34+ve cell numbers negatively 
correlated with degree of restenosis at the 6 month scan (r= -0.38, p=0.013). The 




the 6 (R=-0.42, P=0.008) and 12 month scans(R=-0.49, P=0.026). The migration 
rate of HPCs isolated from pre-operative blood also negatively correlated with 
restenosis at the 6 (R=-0.5, P=0.009) and 12 month scans(R=-0.53, P=0.05). Pre-
operative SDF1 levels correlated with falls in CD133+ve/CD34+ve number (R=0.42, 
P=0.044) and eCFU counts (R=0.56, P=0.004), though not with restenosis. 
 
Conclusion 
HPC function appears to be linked to the development of carotid artery restenosis 
following endarterectomy. These data support the concept that HPCs have a role 
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1.1 Carotid artery stenosis  
 
Stroke is the third most common leading cause of death in the UK after ischaemic 
heart disease and cancer and is the principal cause of neurological disability. The 
annual incidence of stroke is 2 per 1000 and 125 000 patients will suffer their first 
stroke each year1. The annual incidence of transient ischaemic attack (TIA) is 0.5 
per 1000 2. About 80 % of all strokes are ischaemic and the remainder 
haemorrhagic (intracerebral/subarachnoid). Carotid artery atherosclerosis and 
subsequent thromboembolism of the internal carotid artery (ICA) is the most 
common cause of ischaemic stroke and transient ischaemic attacks 3 (Fig1). These 
thromboembolic events are related to plaque instability caused by plaque 
ulceration, rupture and subsequent thrombosis 4. 
 
1.1.1 Presentation of carotid disease 
A patient with carotid artery stenosis is considered symptomatic if the patient has 
transient or permanent focal neurologic symptoms related to the ipsilateral retina or 
the cerebral hemisphere. Symptoms of carotid artery stenosis include ipsilateral 
transient visual obscuration (amaurosis fugax) from retinal ischaemia; contralateral 
weakness or numbness of an arm, a leg, or the face, or a combination of these 
sites; visual field defect; dysarthria; and, in the case of dominant (usually left) 




In daily clinical practice, carotid artery stenosis is found in many patients during 
evaluation of ill-defined episodes of “dizziness,” generalized subjective weakness, 
syncope or near-syncope episodes, “blurry vision,” transient positive visual 
phenomena (such as “floaters” or “stars”) or in the investigation of carotid bruit 
found on general medical examination. These nonspecific symptoms in patients 
with carotid artery stenosis do not qualify as symptomatic ischemic events; these 
patients are considered asymptomatic even in the presence of high-grade carotid 
artery stenosis.  
 
 
Fig 1. Carotid artery stenosis.  
A. Anatomy of the bifurcation of the common carotid artery (CCA). Emboli 
generated at the plaque surface travel up the internal carotid artery (ICA) causing 










1.1.2 Investigation of carotid stenosis 
Doppler ultrasonography is the main diagnostic imaging tool used to screen for 
carotid artery stenosis. The advantages of doppler include its low cost, non-
invasive nature and accessibility. It is, however, highly dependent on operator 
experience and skill. Doppler ultrasonography has a sensitivity of 86% and a 
specificity of 87% for the detection of haemodynamically significant carotid artery 
stenosis when compared with catheter angiography 5.  
Catheter angiography is still regarded as the standard for defining the degree of 
stenosis and the morphologic features of the plaque, but this technique is neither 
feasible nor recommended in day to day practice because of its risks and costs. 
Computed tomographic angiography (CTA) and magnetic resonance angiography 
(MRA) have gained increasing popularity for use in the diagnosis of carotid artery 
stenosis, replacing conventional catheter angiography. MRA has a sensitivity of 95 
% and a specificity of 90% when compared with angiography for the detection of 
70-99% stenosis 5. CTA is a minimally invasive technique which allows significant 
stenosis to be detected not only in the cervical portion of the carotid artery but also 
in the cranial portion and down to the aortic arch. In a recent systematic review on 
the performance of non-invasive imaging modalities in the assessment of a 70-
99% stenosis, contrast enhanced MRA was the most accurate imaging modality 
(specificity 94%, sensitivity 93%) followed by CTA (94% and 76% respectively) and 
duplex (84% and 89% respectively) 6. Though practice varies between centres, 
MRA or CTA may be used as confirmatory tests after results of a Doppler study are 




1.1.3 Management of carotid disease 
 
1.1.3.1 Best medical management  
All patients with cerebrovascular disease benefit from optimisation of risk factors 
and exclusion of comorbidities, whether they are to undergo surgery or not. An 
ECG should be performed to look for occult cardiac pathology and bloods test 
performed to look for evidence of diabetes, arteritis, polycythaemia, 
thrombocytosis, sickle cell disease and hyperlipidaemia. The European stroke 
initiative 7 defined what constitiutes ‘best medical therapy’. Angina therapy must be 
optimised because the principal cause of late death is cardiac. Blood pressure 
should be maintained below 140/90 or 130/80 in diabetics. All patients 
(symptomatic and asymptomatic) should be treated with a statin unless 
contraindicated as established in the Heart Protection Study8. Treatment with 
statins cause on average a 25% relative risk reduction in: (i) any major coronary 
event, (ii) any stoke and (iii) the need for revascularisation at 5 years. This benefit 
is irrespective of age, gender or presenting cholesterol level. Patients should also 
be treated using antiplatelet therapy unless contraindicated. Aspirin remains the 
first line agent and meta-analysis suggests that it reduces the long term risk of 
stroke by 25%9. Other recommendations include optimising glycaemic control, 
stopping smoking, reducing alcohol, salt and fat intake, regular physical exercise 
and weight loss if BMI is elevated. Rapid institution of ‘best medical therapy’ after 
the presenting stroke/TIA leads to a significant reduction in the 90 day risk of 





1.1.3.2 Surgical management of carotid disease 
The role of carotid endarterectomy (CEA) in the management of patients with 
carotid stenosis has been extensively investigated and defined through large 
randomised controlled trials (RCTs). The largest of these trials are the North 
American Symptomatic Carotid Endarterectomy Trial (NASCET)11,12, the European 
Carotid Surgery Trial (ECST)13 and the Veterans Affairs Cooperative Study 
Group14. The Carotid Endarterectomy Trialist Collaboration (CETC)15, 16 have 
combined the results of these studies forming a database that includes 5-year 
outcomes from >6000 patients.  
 
CEA is not indicated in symptomatic patients with a 0-50% stenosis. In recently 
symptomatic patients (<6 months) with a 50-69% stenosis, CEA confers a 
significant benefit with a 5-year stroke risk of 28% with medical management alone 
compared with 20% when combined with surgery (relative risk reduction 28%, 
numbers needed to treat to prevent 1 stroke at 5 years is 13). CEA confers 
maximum benefit in patients who are recently symptomatic and have a 70-99% 
stenosis, with a 5-year stroke risk of 33% with medical management alone 
compared with 17% when combined with surgery (relative risk reduction 48%, 
numbers needed to treat to prevent 1 stroke at 5 years is 6). CEA does not confer 
any long term benefit in patients with near-occlusion.  
 
The decision on whether to implement invasive treatment in patients with 




comparing CEA with medical treatment for asymptomatic patients17,18. These 
showed that surgery provides only a modest benefit in stroke prevention, with CEA 
reducing the risk of stroke from 2% per year to 1% per year. In the Asymptomatic 
Carotid Surgery Trial18, surgery did not benefit patients aged 75-years or older 
because of the excess mortality rate at follow-up in these patients (a rate related to 
non cerebrovascular events such as myocardial infarction and cancer). These trials 
have been criticized because the medical treatment arm was not uniformly defined 
and did not include interventions currently considered optimal medical 
management, such as aggressive reduction in blood pressure and lipid 
concentrations. It is unknown whether current standard medical therapy can 
decrease the relative benefit from CEA in patients with asymptomatic carotid artery 




Recurrent arterial narrowing (restenosis) is the major complication limiting the 
success of revascularisation procedures. It can occur after any cardiovascular 
intervention including coronary and peripheral angioplasty19, bypass grafting20,  
endarterectomy21, and arterio-venous fistula formation22.  Restenosis is caused by 
a combination of processes. In the short term, it may be caused by elastic recoil of 
the vessel wall, thrombus formation at the site of injury, and variations in operative 
technique that lead to a smaller anastomosis or kinking of the vessel. Longer term 




involving the proliferation and migration of intimal smooth muscle cells23,24. 
Preventing intimal hyperplasia is an important therapeutic target and strategies 
include not only continued development of stent design and coating materials25,26, 
but also manipulation of the cellular response to vascular injury.   
 
 
1.2.1 The clinical impact of restenosis 
 
The overall incidence of restenosis is approximately 30% a year after coronary 
angioplasty and bare metal stenting 27 and there is a similar incidence following 
angioplasty for peripheral arterial disease 28. The risk of this complication is less 
after carotid endarterectomy (10%-20%) 29-31.  Restenosis in the coronary artery 
can lead to severe morbidity and mortality and frequently requires repeated 
treatment.  A study of over 3000 patients who had undergone coronary angioplasty 
were evaluated between 4-months to 1-year after the procedure32. Restenosis 
occurred in around 50% of patients and significantly more patients with restenosis 
than without restenosis had angina (70.7% vs 38.7%). After 6-year follow-up, the 
survival rate was similar in both groups (94%), however, restenosis was associated 
with a significantly higher rate of MI, CABG and repeat angioplasty32. Although 
these data suggest that the presence of restenosis does not confer an increase in 
mortality, a patient’s quality of life can be detrimentally affected33. In the Optimum 
Percutaneous Transluminal Coronary Angioplasty Compared with Routine Stent 
Strategy (OPUS-1) trial, restenosis was associated with more frequent angina, 




carotid endarterectomy carries a 1-10% risk of stroke30,31. The economic impact of 
repeated revascularisation procedures is also considerable34.   
 
1.2.2 Risk factors for restenosis 
 
The risk of restenosis is almost twice as high among patients with diabetes 
mellitus. In a study of 954 patients undergoing PCI, target lesion revascularization 
was required in 28% of patients with insulin-dependent diabetes compared with 
16.3% in individuals without diabetes35. The high risk for restenosis among patients 
with diabetes may be associated with metabolic alterations that promote 
endothelial dysfunction, accelerate intimal hyperplasia, and increase platelet 
aggregability and thrombogenicity36. There is also evidence to suggest that some 
patients may be genetically predisposed to restenosis. Genetic abnormalities 
associated with high risk for restenosis include polymorphisms in genes coding for 
angiotensin-converting enzyme inhibitor 37, glycoprotein receptor IIIa PLA1/238 and 
haptoglobin 2/2 39. 
 
The choice of material for bypass grafts has an important impact on the risk of 
restenosis. The patency rates for femoro-popliteal bypass for chronic lower limb 
ischaemia at 5 years are 66% for vein (any level), 47% for above knee PTFE and 
33% for below knee PTFE40. Lesion characteristics that may influence risk for 
restenosis include disease in saphenous vein grafts, length of the lesion, and 
minimum lumen diameter before stenting41. A larger lumen diameter after 





Table 1. Risk factors for restenosis 
 
Patient factors  
Restenosis at another treated site  
Diabetes mellitus  
Smoking 
Intervention in acute coronary syndromes  
 Genetic predisposition  
Lesion characteristics and procedural variables  
Diameter of vessel  
Length of lesion or stent  
Lumen diameter before and after procedure  
Ostial lesions  
Bypass graft material  
Total number of occlusions 
 
 
Drug-eluting stents (DES) have been developed as a means of preventing intimal 
hyperplasia following angioplasty. They appear to have reduced the early risk of 
coronary restenosis, though this still occurs in over 10% of stented vessels at 12 
months 27. DES are not suitable for all patients with coronary artery disease. 




restenotic lesions after DES, bypass graft disease, and bifurcations, continue to be 
problematic for restenosis42, 43.  DES do not improve long-term prognosis44 There 
are also concerns of an increased incidence of stent thrombosis and subsequent 
myocardial infarction in patients who have had a drug eluting stent inserted27 which 
necessitates the continuation of post-stent antiplatelet regimen.  These rare, life-
threatening complications are, in part, caused by impaired endothelial regeneration 
(re-endothelialisation), which is essential in the normal healing process of injured 
vessels 45. Sirolimus and paclitaxel are potent anti-mitotic agents that strongly 
inhibit smooth muscle proliferation and matrix growth, preventing neointimal 
formation and restenosis. Delayed vessel wall healing because of impaired re-
endothelialisation after DES stenting may go hand-in-hand with neointimal 
suppression 46. Recent evidence suggests that DES lead to impaired endothelial 
function at the site of stenting as well as in the distal segments47. 
 
It is clear that new strategies are therefore needed to prevent intimal hyperplasia 
that are applicable to the full spectrum of restenotic disease and that enhances 





1.3 Mechanisms of intimal hyperplasia 
 
Lumen loss after cardiovascular interventions can be separated into 3 distinct 
stages: early loss associated with elastic recoil, intermediate loss over several 
months caused by neointimal hyperplasia and late loss caused by negative 
remodelling (Fig 2). Animal models and human post-mortem specimens show that 
the mechanism of intimal hyperplasia is similar to that regulating wound healing48, 
49. Both processes can be divided into three overlapping phases: an inflammatory 
phase, a granulation or cellular proliferation phase, and a phase of remodelling of 
the extracellular matrix (ECM) and protein synthesis.  
 
1.3.1 Elastic recoil 
 
Elastic recoil is a dynamic and progressive phenomenon that occurs immediately 
following angioplasty and results in an immediate loss in lumen diameter.  Up to a 
34% loss in lumen diameter can be observed within 15-minutes of balloon 
inflation50. Elastic recoil may ultimately account for up to 50% of the loss in acute 
lumen gain during angioplasty51.  
 
1.3.2 Intimal hyperplasia 
 
Inflammatory phase (hours to days): Intimal hyperplasia is initiated by  factors 
which vary according to the procedure, and include vasospasm52, ischaemia 




with vein grafts which are exposed to a greater shear stress when transplanted into 
the arterial circulation54. Immediately following angioplasty, fracture of the ‘hard’ 
atherosclerotic plaque exposes the thrombogenic contents of the plaque (proteins 
such as tissue factor, vWF and collagen) to the flowing blood (Fig 2A). These 
factors lead to endothelial damage and loss and trigger platelet adhesion, 
activation and thrombin generation, and occasionally thrombus formation at the site 
of injury55 (Fig 2B). Thrombin is a potent mitogen that promotes smooth muscle cell 
(SMC) proliferation and inhibition of this coagulation factor reduces intimal 
hyperplasia in an animal model56.  
 
Activated platelets on the injured vessel surface express adhesion molecules, such 
as P-selectin, that are released from α-granules. The initial tethering and rolling of 
leukocytes on platelets are mediated by P-selectin binding to leukocyte receptors, 
such as P-selectin glycoprotein ligand-1 (PSGL-1) 57. Leukocytes adhere firmly to 
the platelets through leukocyte integrin Mac-1 (CD11b/CD18) via platelet 
glycoprotein Ibα (GPIbα) interaction and through cross-linking with fibrinogen to the 
GPIIb/IIIa receptor58 (Fig 2C). Leukocytes migrate across the platelet – fibrin layer 
and into the vessel wall, driven by chemical gradients of chemotactic cytokines, 
produced in response to injury by smooth muscle cells (SMCs) and leukocytes 
resident in the medial layer 49. Mac-1 is thought to be an important signalling 
protein in the mechanism of restenosis, as blockade of this adhesive molecule59 or 
deletion of the Mac-1 gene60 results in reduced neointimal thickening after 





Cellular proliferation phase (days to weeks): Under normal conditions, vascular 
SMCs are quiescent and exhibit low levels of proliferative activity. Vascular injury 
and the subsequent inflammatory response, trigger SMC proliferation through the 
G1/S transition of the cell cycle61, 62.  The different phases of the cell cycle are 
regulated by a series of protein complexes comprising cyclins, cyclin-dependent 
kinases (CKDs) and their cyclin-dependent kinase inhibitors (CKIs). CKIs, such as 
p27Kip1 or p21Cip1, regulate the G1/S transition through binding to cyclins 
E/CDK2 and inhibiting CDK2 activity, leading to cell cycle arrest. Arterial injury 
produces down regulation of p27Kip1, which triggers an increase in cell 
proliferation. Gene transfer of p27Kip1 or p21Cip1 into balloon-injured arteries 
produces a significant reduction in SMC proliferation and neointimal thickening62-64. 
Deficiency of p27Kip1 results in a prominent vascular phenotype with markedly 
increased neointimal thickening and inflammatory cell accumulation after 
mechanical arterial injury65. These findings suggest that p27Kip1 and p21Cip1 are 
endogenous regulators of G1 transit in vascular SMCs and inhibit cell proliferation 
after arterial injury. 
 
The cellular proliferation phase is marked by the release of growth and chemotactic 
factors from activated platelets, leukocytes, surrounding endothelial cell (ECs) as 
well as medial SMCs. These include  platelet derived growth factor A and B (PDGF 
A and B), fibroblast growth factor (FGF), insulin like growth factor (IGF), 




These stimulate the migration and proliferation of SMCs from the media into the 
neointima (Fig 2D). They also promote proliferation of surrounding ECs and their 
migration into the denuded area. This is thought to be the predominant process 
leading to re-endothelialisation 49, 66. Extracellular matrix proteoglycans and 
hyaluronan are synthesised by SMCs and participate in regulation of vascular 
permeability, lipid metabolism, and thrombosis 67. The resultant neointima consists 
of SMCs, extracellular matrix, and macrophages recruited over several weeks (Fig 
2E). 
 
Remodeling phase (3-18 months): This occurs over a longer period of time and 
involves ECM protein degradation and re-synthesis. There is a shift to fewer cells 
and an increase in the amount of ECM deposited between 9 and 18months (Fig 
2F). After this time, only ~15% of the neointimal volume is comprised of SMCs 
compared with ~60% between 3 and 9 months 68 . During this period hydrated 
proteoglycans (hyaluronan and versican) and Type III collagen are replaced by 
decorin and Type I collagen, which can lead to shrinkage of the entire artery, a 







Fig 2. The cascade leading to restenosis 49.  A, Mature atherosclerotic plaque 
before intervention. B, Immediate result of stent placement with endothelial 
denudation and platelet/fibrinogen deposition. C and D, leukocyte (neutrophils 
[neutros] and macrophages [macros]) recruitment, infiltration, and SMC 
proliferation and migration in the days after injury. E, Neointimal thickening in the 
weeks after injury, with continued SMC proliferation and monocyte recruitment. F, 
Long-term (weeks to months) change from a predominantly cellular to a less 




1.4 Role of the endothelium in intimal hyperplasia 
 
In addition to regulating vascular tone and permeability, the endothelium is 
emerging as a key modulator of the cellular response to vessel wall injury 70, 71. A 
normal functional endothelium suppresses intimal hyperplasia by inhibiting 
thrombus formation and inflammation, that trigger intimal hyperplasia, and by 
reducing SMC proliferation and migration (Fig 3).  
 
 






1.4.1 Inhibition of thrombosis and inflammation 
The endothelium maintains an antithrombotic environment on its luminal surface by 
secreting factors that inhibit platelet activation, adhesion and aggregation, such as 
nitric oxide (NO) and prostaglandin I2 (PgI2), and by expressing anticoagulant and 
fibrinolytic activity such as heparin, protein C and S, tissue factor pathway inhibitor 
(TFPI) and  tissue plasminogen activator (tPA) 72.  Nitric oxide also has anti-
inflammatory actions through the inhibition of cytokine secretion and adhesion 
molecules expression73. Mice deficient in endothelial nitric oxide synthase (eNOS) 
have markedly increased endothelial-leukocyte adhesion and accelerated 
atherosclerotic lesion formation 74. 
 
1.4.2 Inhibition of SMC proliferation and migration 
The endothelium inhibits SMC growth by acting as a selectively permeable barrier 
which protects against circulating growth factors 42. Endothelial cells also secrete 
NO, transforming growth factor-β (TGF-β), heparin and heparin-like molecules, 
which maintain SMCs in a quiescent state 75, 76. The secreted heparin also binds 
and neutralises  the mitogenic action  of  FGF 77  . The importance of NO in the 
control of vascular healing by attenuating vascular inflammation and inhibiting SMC 
proliferation and migration has been demonstrated in a rat carotid artery injury 
model 78. Endothelial nitric oxide synthase (eNOS) gene transfection not only 
restores NO production in rat carotid arteries after endothelium denudation, but 
also increases the vascular reactivity of the injured vessels. This treatment leads to 




1.4.3 Characteristics of a dysfunctional endothelium 
 
 
Endothelial dysfunction is characterised by a reduction in antithrombotic activity of 
the endothelium (the production of antiplatelet agents such as NO and 
prostacyclin, anticoagulants such as TFPI  and pro-fibrinolytic agents such as  
tPA)72,  and an increase in prothrombotic activity of the endothelium through 
increased expression of procoagulatory mediators such as plasminogen activator 
inhibitor 1 (PAI-1)72. This results in a vascular environment, which together with 
exposure of highly thrombogenic substances from ruptured or erosive plaques, 
incites thrombus formation.  
 
Dysfunction of the endothelium also results in an imbalance between vasodilator 
substances with antiproliferative properties (e.g NO) and vasoconstrictors with 
mitogenic properties (such as endothelin, thromboxane A2, prostaglandin H2 and 
reactive oxygen species) that are detrimental to the arterial wall72,79. For example, 
arterial injury in a porcine coronary stent model leads to the aberrant release of 
endothelin-1, and treatment with an endothelin receptor antagonist, reduces the 
intimal hyperplasia that normally ensues 80. The systemic and local milieu 
associated with endothelial dysfunction therefore favours cell proliferation, intimal 





1.4.4 Clinical implications of impaired endothelial function  
 
Endothelial dysfunction is considered to be a systemic process 81, 82, with 
endothelial activity in a peripheral artery reflecting systemic function. Endothelial 
function is assessed in vivo by measuring flow mediated dilatation (FMD), most 
commonly in the brachial artery 83. The change in the diameter of the artery is 
assessed by inflating a cuff around the arm to produce shear-induced endothelial 
nitric oxide.  
 
Direct measurement of coronary endothelial function involves local delivery of 
acetylcholine via coronary catheter followed by video assisted measurements in 
coronary calibre 84. Acetylcholine causes a dose-dependent dilation of coronary 
arteries in subjects without coronary disease, whereas in patients with coronary 
disease, a "paradoxical" vasoconstriction is observed, indicating an impaired 
endothelium-dependent vasomotion 85. This vasoconstriction also occurs in a 
progressive manner depending on the degree of endothelial dysfunction 70. The 
invasive nature of this technique has resulted in its restricted use. 
 
Endothelial dysfunction is observed in the presence of major cardiovascular risk 
factors, including aging, smoking, diabetes mellitus, hypercholesterolemia and 
hypertension86. The presence of multiple risk factors is associated with a 
progressive worsening of endothelial function in a step wise manner 87. Cardiac 
events in patients with mildly diseased coronary arteries only occurred in those 




Patients with impaired endothelial and endothelium-independent coronary vaso-
reactivity as shown by increased vasoconstrictor responses to acetylcholine 
infusion and cold pressor testing, have a significantly higher incidence of 
cardiovascular events84. They also have significantly blunted vasodilator responses 
to increased blood flow and the intracoronary injection of nitroglycerin84.  
 
Given the systemic nature of endothelial dysfunction, the question arises as to 
whether peripheral vascular function may also serve as a prognostic marker. 
Clinical studies have now addressed this question and have demonstrated that 
peripheral endothelium-dependent vasodilation, measured in response to 
acetylcholine or as flow-dependent vasodilation, has profound and independent 
prognostic implications83, 89. Prospective analysis of brachial artery vasodilation in 
patients undergoing vascular surgery83, shows that preoperative, flow-dependent, 
endothelium-mediated dilation is significantly lower in patients with a postoperative 
event, compared with those without an event, and this is an independent predictor 
of outcome. Analysis of forearm blood flow in response to acetylcholine in patients 
with coronary disease 89 showed that the increase in forearm blood flow in 
response to acetylcholine was an excellent prognostic indicator i.e. the subsequent 
event rate was high in those with blunted responses to acetylcholine. 
 
The relationship between endothelial function and acute vascular injury has been 
investigated in patients with single-vessel CAD undergoing percutaneous coronary 
intervention (PCI) with bare metal stenting71. Flow mediated dilation (FMD), 




versus those without restenosis with 4% of patients with FMD ≥ 7% developing in-
stent restenosis versus 28% of those with FMD <7%. Multivariate analysis revealed 
that FMD was the strongest independent predictor of restenosis.  
 
Measurement of FMD in the brachial artery before and six months after PCI in 
patients who had elective PCI 90 revealed that an impaired FMD at follow-up was 
strongly associated with restenosis, independent of other clinical and angiographic 
variables known to be associated with restenosis. Initial FMD was not associated 
with subsequent restenosis.  
 
These studies demonstrate that the endothelium is important in regulating the local 
response to acute and chronic vascular injury, and that endothelial dysfunction 
may exacerbate neointima formation. Enhancing re-endothelialisation and 
endothelial function after injury may therefore have the potential to reduce the 
formation of neointima. 
 
 
1.5 The bone marrow as a source of neointimal cells 
 
Until a decade ago, it was thought that the formation of postnatal blood vessels as 
well as the neointima was exclusively dependent on the proliferation and migration 
of local endothelial and vascular smooth muscle cells91. It has since been 




marrow, are responsible for the replenishment of hematopoietic blood cells, there 
is a similar stem or progenitor cell, termed an Endothelial Progenitor Cell (EPC), 
that regenerates the endothelium and participates in vessel formation92. There 
have been a number of studies in animal models and man to support this concept. 
 
1.5.1 Bone marrow transplant studies in animals 
 
 
The contribution of bone marrow derived cells to the neointimal lesion has been 
demonstrated using bone marrow transplant in conjunction with mouse models of 
vascular injury 93-96. One of the earliest studies of this phenomenon used bone 
marrow cells expressing β-galactosidase (the product of the LacZ gene, easily 
identified as blue following addition of the substrate, X-gal to the tissue section), 
from ROSA26 mice transplanted into wild-type mice in which arterial injury was 
subsequently induced94. Histological analysis of the neointimal lesion at specified 
time points revealed the presence of LacZ positive, or transplanted bone marrow 
derived cells. Some LacZ positive cells expressed antigens that identified them as 
endothelial cells (CD31) while others expressed SMC markers (α-smooth muscle 
actin). A number of subsequent studies have confirmed the existence of bone 
marrow derived cells in the neointima, with 20% to 66% of the total neointimal cell 
population suggested to be of bone marrow origin 93-96. This wide range could be 
the result of the different methods of labelling bone marrow cells (BMCs) as well as 
different types of injury induced. Similar results have been found in animal vein 





1.5.2 Human studies 
 
The evidence regarding the origin of neointimal cells in humans is limited. Data 
obtained from human coronary atherectomy tissue from in-stent and post 
angioplasty restenosis, and primary atherosclerotic lesions, as well as postmortem 
coronary artery cross sections from young individuals without atherosclerosis 
appear to support the concept that these cells contribute to the neointima as 
suggested by the data from animal models. Between 2% and 30% of the 
neointimal SMC cells from all restenotic tissue specimens contained cells that 
expressed the progenitor cell marker c-kit99 and smooth muscle -actin, whereas 
the intima and media of primary athersclerotic lesions and normal arteries were 
devoid of c-kit-expressing cells 100. This supports the animal studies in showing 
that bone marrow derived cells contribute significantly to neointima formation.  
 
1.5.3 Endothelial progenitor cells  
 
Asahara et al. 101 hypothesised that an endothelial progenitor cell (EPC) may 
express cell surface markers shared by HSCs, since endothelial and 
haematopoietic cells share a similar mesodermal origin during embryonic 
development. Placing CD34+ cells (15.7% enriched) on fibronectin coated plates 
results in the formation of spindle shaped cells that express a variety of proteins 
such as CD31, vascular endothelial growth factor receptor (VEGFR-2  or Flk-1), 




CD34+/VEGFR2+ cells into a mouse model of hind-limb ischaemia results in the 
incorporatation of these cells into sites of neovascularisation in the affected limb. 
CD34+ cells, isolated from peripheral blood, umbilical cord blood and bone 
marrow92, 101 and injected into a variety of pathological conditions, are recruited to 
foci of neovascularisation, such as ischaemic skeletal muscle101-104 and 
myocardium 101, 102, 105, tumours 102, 106, as well as areas of endothelial 
denudation107, 108. These cells contribute to neovascularisation and 
neoendothelialisation through their ability to differentiate into mature endothelial 
cells, incorporate into blood vessels; and augment angiogenesis through the 
secretion of angiogenic growth factors109, 110.  These studies provided the first 
direct evidence for the existence of a putative EPC that contributes to 
vasculogenesis (i.e. de-novo blood vessel formation) post-natally, and challenged 
the traditional concept that endothelial regeneration occurs exclusively via the 
proliferation of pre-existing resident vessel wall endothelial cells. 
 
1.5.4 Defining endothelial progenitor cells 
 
Over the past 15 years there have been many studies that have suggested that 
bone marrow derived EPCs, can differentiate into mature endothelial cells (EC) 
and maintain endothelial function 111, 112. However these studies have employed a 
variety of methods to define EPCs and this has resulted in confusion as to what 




specific and unique cell surface or molecular marker that would permit prospective 
isolation of this cell.  
 
1.5.4.1 Phenotypic identification  
Many investigators have identified the EPC by fluorescence activated cell sorting 
analysis (FACS) using monoclonal antibodies  directed at a variety of cell surface 
markers which has resulted in a complicated list of EPC phenotypes (Table 2)113. 
The early phenotypic identification was based on the co-expression of both 
haematopoietic (CD34) and endothelial (VEGFR2) marker proteins113. These two 
proteins were used in most FACS analysis as earlier studies showed that CD34+ve 
and VEGFR2+ve cells were able to generate ECs in-vitro101. CD34 is expressed on 
haematopoietic stem cells, but is also expressed on activated endothelium of 
certain microvessels 114. VEGFR2 is also expressed on hematopoietic stem cells 
and mature endothelial cells 115. In order to separate EPCs from circulating mature 
endothelial cells, the stem cell marker, CD133 116, was used to discriminate EPCs 
from mature endothelial cells that do not express it. Thereafter cells expressing 
CD34, VEGFR2 and CD133, so called triple positive cells, were widely accepted as 
defining true EPCs.  
 
Many studies have used CD34, CD133 and VEGFR2 to define EPCs and have 
found that EPC number correlates inversely with risk of developing cardiovascular 
disease and prognosis in established disease 117, 118. Until relatively recently, 




had not been proven 116, 119. A recent study found no evidence that isolated human 
umbilical cord blood and mobilised peripheral blood CD34+ve/VEGFR2+ve/CD133+ve 
cells contribute to the formation of ECs in-vitro120. In-vitro haematopoiesis assays 
have shown that these cells in fact represent an enriched population of CD45+, 
myeloid hematopoietic precursors120. Though it is difficult to know exactly what the 
significance of this cell type is or to know whether it acts as a true EPC, it clearly 
has an impact on cardiovascular disease. 
 
Table 2. Surface immunophenotype of human and murine EPCs (reproduced 
from Timmermans et al.113). 
 











EPC immunophenotypes in mice 
Sca-1− Lin− cKit− cKit+CD31+ 
cKit+CD34+Flk-1  CD45−CD34+Flk-1 + 





1.5.4.2 Colony-forming Unit (CFU) assay    
The in vitro colony forming unit assays have been used by many to measure EPC 
number and function111, 121. This technique involves the culture of isolated 
peripheral blood mononuclear cells (PBMC) on fibronectin in endothelial growth 
medium. This leads to the outgrowth of colonies of endothelial like cells. Two 
distinct EPC populations have been classified according to the time at which they 
appear in culture: early EPCs and late outgrowth endothelial cells (OECs) 104 
(Table 3). Early EPCs appear in culture after 4-7 days and are similar to those 
originally described by Asahara et al. 101 while OECs appear much later in culture, 
after 14–21 days122. These two different populations of cells are also 
phenotypically and morphologically distinct (Fig 4). Early EPCs (CFU) are clearly 
evident from three days onwards. The emergence of cobblestone shaped cells is 











Table 3. Characteristics of human EC-like cells and OECs 113 . 
 
EC-like cells OECs 
(EPCs, ECs, CFU-ECs, CACs, early 
outgrowth CE-EPCs, early EPCs) 
(EPCs, ECs, CFU-ECs, OECs, ECFCs, 
EC-like, late EPCs, late endothelial 
outgrowth) 
1. Generated after 4–21 days in culture 1. Appear after > 7 days in culture 
2. Round (pancake) to spindle shaped 
appearance; no typical confluent 
monolayer 
2. Typical polygonal cells in a confluent 
cobblestone monolayer 
3. Express endothelial and 
haematopoietic markers (e.g. CD45, 
CD14) 
3. Express CD31, CD34, CD105, 
CD146, VE-Cadherin, VEGFR-2, but not 
the haematopoietic surface markers 
CD133, CD14 or CD45 
4. Bind UEA-1 lectin and take up LDL 4. Bind UEA-1 lectin and take up LDL 
5. Maintain haematopoietic potential 
and/or functions 
5. Have no apparent haematopoietic 
potential 
6. Have low proliferative potential 6. Bear high proliferative potential 
7. Do not generate vascular tubes in 
vitro in matrigel 
7. Generate vascular tubes in vitro/in 
vivo in matrigel 
8. Improve neovascularization in vivo 8. Improve neovascularization in vivo 
9. Originate from CD45+ haematopoietic 
lineage cells (CD34+CD45+, 
CD133+CD45+, CD34−CD45+, 
CD14+CD45+) 
9. Originate from CD45−CD133−CD34+ 










Fig 4. Sequential changes of cultured EPCs after seeding PBMCs.  
a) PBMCs immediately after plating; (b) 1 day; (c) 3 days showing a typical early 
CFU; (d and e), 10 days; (f) 21days; (g-i) OECs  grow exponentially to confluence 
showing a cobblestone-like monolayer. (From Hur et al 2004104).  
 
Early EPCs express hematopoietic-specific cell surface antigens CD14 and CD45, 
have lower capacity for EC marker expression, and appear as elongated cells in 
isolation or in colonies. Conversely, OECs can be distinguished from early EPCs 
by their lack of expression of CD14 and CD45 and their endothelial-like 
cobblestone morphology. Another important difference between these putative 




proliferation, while OECs have high proliferative potential, being capable of over 
100-fold expansion in vitro. Because of this proliferative ability, OECs are now 
considered by some to represent true endothelial progenitors. A hierarchy of late 
OECs has been identified and characterized according to their proliferative 
potential121.  
 
Early EPC and OECs also show different angiogenic properties123. Early EPCs are 
known to secrete a variety of angiogenic growth factors such as VEGF, G-CSF, 
GM-CSF and hepatocyte growth factor109, 110, but fail to independently form tubules 
or incorporate into differentiated EC tubules. They do however, augment 
tubulogenesis by differentiated ECs in a paracrine manner, even when physically 
separated by transwells123. By contrast, OECs independently form tubules and 
incorporate into differentiated EC tubules, but do not exert a significant paracrine 
angiogenic effect123.  A recent study of various bone marrow-derived cells 
demonstrated specific expression of eNOS by putative EPCs, suggesting this may 
be a means by which to identify endothelial progenitors124. However, eNOS 
expression has also been shown in a variety of cells including CD14 and CD45 
positive cells as well as embryonic stem cells 125. 
 
Despite the obvious in vitro distinction between early and late outgrowth cells, their 
in vivo or clinical significance remains unclear. Most studies have measured early 
EPC colonies and it was using this method that an inverse relationship between 




When transplanted these cells were thought to replace damaged endothelium 
and/or contribute to neovascularisation106, 126, 127. However, recent in-vivo studies 
have reported that early EPCs enhance neovascularisation and endothelialisation 
in an indirect paracrine manner109, 128.  This would reconcile data from earlier 
studies that show limited incorporation of early EPCs into newly formed vessels 
despite enhanced neovascularisation129. In contrast, late outgrowth cells have not 
been well studied in vivo, in part due to difficulties in developing a reproducible 
assay104. In animal models OECs have been shown to augment early re-
endothelialisation and thus attenuate intimal hyperplasia following wire injury130, 131. 
It has been suggested that early EPC and OECs may operate in a synergistic 
fashion to enhance neovascularisation and re-endothelialisation110. The different 
angiogenic properties of early EPCs and OECs suggests that different strategies 
may be required to optimally enhance their respective therapeutic potential.  
 
1.5.5 Identification of endothelial cells 
 
Identifying a cell as a true EC is crucial before its precursor cell can be classified 
as a true EPC. To identify ECs generated from EPCs in vivo, most reports have 
used a single marker or combination of cell surface markers that are typically 
expressed on normal vascular ECs. These include CD31, CD34, VEGFR2 and Tie-
2 and the uptake of acetylated low density lipoprotein (acLDL) and binding of a 
plant lectin - Ulex Europaeus Agglutinin-1 (UEA-1, Fig 5) 101, 111, 132. There is 
however significant overlap in the antigens expressed by various cell types. 




number of other traditional endothelial markers including VEGFR2 and Tie-2 113. A 
number of studies have also shown co-expression of a raft of other endothelial 
antigens, as well as the uptake of acLDL and the binding of UEA, by circulating 





Fig 5. Characterization of EPCs : lectin-binding, LDL-uptake. EPCs  exhibit 
UEA-1 lectin-binding (green) and acLDL-uptake (red). Merged image of both stains 





1.5.6 Comparison between EPC measuring techniques 
 
The differing ways of measuring EPCs have also been found not to correlate with 
each other 134. CFU assay numbers do not correlate with flow cytometric detection 
using antibody combinations CD34+ve/VEGFR2+ve or 
CD34+ve/CD133+ve/VEGFR2+ve, but correlate negatively with CD34+ve/CD133+ve 
numbers. CD34+ve/VEGFR2+ve numbers correlate with CD34+ve/CD133+ve/ 
VEGFR2+ve, but not with CD34+ve/CD133+ve.  It is therefore likely that the methods 
used to distinguish an EPC measure a heterogeneous group of cells/progenitors 
that consist of a number of phenotypes. Interpretation of data from flow cytometry 
or in vitro CFU assay therefore makes comparison of data between laboratories 
difficult, and may account for the discrepancies in the results from the different 
studies. It is evident that the field has suffered from the use of a single term, EPC, 
to refer to BM-derived or circulating cells of diverse lineages. In light of this we 
have adopted the term haematopoietic progenitor cell (HPC) when describing cells 
that have been historically termed EPC except when studies have specifically used 
the OEC assay. The variety of cells that have been shown to share similar 
properties to HPCs, as well as the difficulties in defining them has led some to 
suggest a functional classification 135, 136. The cells must: 
 have the ability to differentiate into and function as endothelial cells. 
 contribute to post - natal vasculogenesis and/or vascular homeostasis. 





1.5.7 HPCs, vascular repair and endothelial function 
 
1.5.7.1 Evidence from animal studies 
HPCs form part of an endogenous endothelial repair mechanism that attenuates 
vascular damage by maintaining endothelial function 111, 112. Direct incorporation of 
circulating HPCs into injured vessels has been observed in animal models of 
arterial injury137, 138 and following arterial and vein graft transplantation97, 139 . In a 
model of transplant atherosclerosis, regenerated endothelial cells from arterial 
grafts are found to originate from recipient circulating blood and not the remaining 
endothelial cells of the donor vessels 139. Similarly, the endothelial monolayer in a 
vein graft model which is completely lost 3 days post surgery, is subsequently 
replaced by circulating endothelial progenitors97.  
 
HPCs are also thought to mediate vascular repair and attenuate atherosclerosis 
progression even in the continued presence of vascular injury. Chronic treatment 
with bone marrow-derived progenitor cells from young non-atherosclerotic ApoE 
knockout (ApoE KO) mice prevents the development of the disease in aged ApoE 
KO recipients despite persistent hypercholesterolemia140.  Although the 
mechanisms involved are still not clear, HPCs appear to contribute to the 
restoration of the endothelial monolayer140.  
 
In addition to bone marrow, spleen-derived HPCs also have the capacity to repair 




endothelium-dependent vasodilatation in atherosclerotic mice, indicating that 
progenitor cells play an important role in repairing the vascular injury 141. 
 
1.5.7.2 Evidence in man 
Reduced endothelial function occurs in a progressive fashion as the number of 
atherosclerotic risk factors increases87 and each of these risk factors is associated 
with reduced HPC number and function111, 117, 119, 142-144. For example, HPCs from 
type-II diabetic patients exhibit impaired proliferation, adhesion and reduced 
angiogenic potential in vivo144. Similarly there is reduced survival, migration and 
proliferation of HPCs in aged individuals compared with younger subjects145.  
 
HPC numbers can also be used as a predictive biomarker for cardiovascular risk 
and vascular function. Patients at highest risk of developing cardiovascular disease 
(Framingham score) have fewer HPCs compared with their low-risk 
counterparts111. HPCs isolated from patients with existing coronary artery disease 
also have reduced levels and migratory activity compared with healthy individuals, 
and this is inversely correlated with the number of risk factors117.  
 
Circulating HPCs are negatively associated with the degree of carotid 
athersclerosis146 and in patients who develop coronary artery disease, there is a 
significant association between increasing numbers of HPCs and decreased risk of 





HPC numbers also inversely correlate with endothelial function in patients with 
coronary heart disease147 and healthy individuals111, although it has been  
suggested that the functional capacity of HPCs (e.g. ability to migrate towards a 
chemotactic stimulus) may be more important than their number in maintaining 
endothelial function145.  
 
HPCs and endothelial dysfunction are, therefore, thought to link cardiovascular risk 
factors and clinical events. HPC numbers rise acutely immediately after coronary 
artery bypass grafting 148, 149 and angioplasty 150 as well as after acute myocardial 
infarction 151, further supporting the concept that they form an important part of the 
acute response to endothelial damage and ischaemia. Low HPC numbers are 
associated with the most severe neurological impairment in patients who have had 
a stroke, and are also an independent predictor of poor prognosis152. These data 
suggest that HPCs are not only involved in cardiovascular disease development, 
but also with disease progression and subsequent prognosis. 
 
1.5.8 HPCs and the inhibition of neointima formation 
 
Patients who developed restenosis (defined as >40% stenosis) have a decreased 
number and increased senescence of HPCs compared with patients without 
restenosis153. Both of these groups also have fewer circulating HPC numbers than 
in patients with no coronary artery disease100, but increased number of senescent 
HPCs appears to be the only independent factor associated with in-stent 




restenosis have reduced numbers of circulating HPC when compared with those 
developing focal restenosis154. There is also impaired adhesion of HPCs in patients 
with restenosis compared with patients who have a patent stent154.  
 
Increasing the number and function of HPCs might have therapeutic potential as a 
means of augmenting the restoration of endothelial integrity and function. Physical 
exercise increases circulating HPC numbers and reduces neointima formation after 
carotid injury in mice 155. Exercise is also associated with a rise in HPC numbers in 
humans 156. 
 
Following transplantation of bone marrow transfected by a retrovirus with 
enhanced green fluorescent protein in a mouse model of neointima formation, up 
to 10% of neointimal endothelial cells (vWF+ cells) after carotid wire injury were 
also GFP+. This supports the notion that bone marrow-derived progenitor cells may 
contribute to re-endothelialisation following vascular injury108. Enhancing the 
circulating pool of endothelial progenitor cells by administering a statin, increases 
the appearance of bone marrow-derived cells (BMCs) in the injured vessel wall, 
accelerates re-endothelialisation and significantly decreases neointimal 
formation108. Mouse spleen-derived mononuclear cells also differentiate into cells 
with characteristics of HPCs. Intravenous injection of these spleen-derived HPCs 
after wire carotid injury accelerates re-endothelialisation and decreases neointimal 
hyperplasia, suggesting that HPCs have an important role in regulating neointimal 




mobilisation following injury with statins137, granulocyte colony stimulating factor 
(G-CSF)158,159 or granulocyte macrophage-CSF107 also enhances re-
endothelialisation and decreases neointima formation in animal models of arterial 
injury.  
 
Enhancing the numbers of circulating progenitor cells has not, however, always 
proved beneficial. Injecting BMCs into ApoE-/- mice, following induced hindlimb 
ischaemia, not only increases neovascularisation to these oxygen deficient 
regions, but also accelerates plaque formation and lesion size when compared with 
control groups160.  Treatment with BMC-derived HPCs results in increased lesion 
size compared with controls, while plaques have larger lipid cores and thinner 
fibrous caps. Reduced levels of the anti-inflammatory cytokine, IL10 are also seen 
in the atherosclerotic aortas161. This may be the result of the proinflammatory 
properties of these cells161. Similarly, even though implantation of an arteriovenous 
anti-CD34-ePTFE graft in pigs resulted in rapid endothelialisation within 72 hours 
and persistent endothelial graft coverage, intimal hyperplasia at the outflow tract 
was profoundly increased at 4-weeks after implantation when compared with bare 
stents162. Besides the differences between various experimental models, it is 
difficult to reconcile these findings. Overall, it seems that excessive mobilisation of 
HPCs may lead to restenosis, whereas an absence of these cells may impair re-







Fig 6. Putative role for circulating progenitor cells after arterial injury163.  
(A) Under resting conditions, circulating concentrations of the precursors of 
endothelial cell colony-forming units (EC-CFUs) and circulating 
endothelial/haematopoietic progenitor cells (EPCs) are low, particularly in patients 
with atherosclerotic disease. (B) Intra-arterial injury/stent placement initiates the 
inflammatory cascade. (C) The early response consists of mobilization of the 
precursors of EC-CFUs involving angiogenic monocytes and lymphocytes. EC-




encouraging resident endothelial cell proliferation and migration and the 
mobilization and homing of bone marrow-derived and local endothelial progenitors 
to the site of vascular injury. (D) Over a period of weeks and months, progenitor 
cells proliferate, contributing to effective re-endothelialization and the restoration of 
vascular homeostasis. (E) An inadequate EC-CFU/EPC response may lead to 
delayed re-endothelialization and persistent inflammation, thus potentiating smooth 
muscle hypertrophy and extracellular matrix deposition, leading to restenosis. (F) A 
robust response by the bone marrow leads to rapid homing of EC-CFU precursors 
to sites of vascular injury with recruitment and integration of HPCs to the 
endothelial monolayer, facilitating rapid re-endothelialization and recovery of 
normal endothelial function and vascular homeostasis. CFU = colony-forming unit; 
G-CSF = granulocyte-colony stimulating factor; GM-CSF = granulocyte-
macrophage- colony stimulating factor; HGF = hepatocyte-like growth factor; IL = 
interleukin; MMP = matrix metalloproteinase; VEGF = vascular endothelial growth 




1.5.9 HPCs and restenosis : clinical trials 
 
Stem cells and in particular HPCs have been the subject of a number of clinical 
trials attempting to reduce the risk of restenosis. These trials were motivated by the 
early animal studies which showed only the beneficial effects of enhanced HPC 
numbers on restenosis.  The HEALING-FIM and HEALING II studies (Healthy 
Endothelial Accelerated Lining Inhibits Neointimal Growth – First In Man) 25, 164, 165 
used a stent coated with the monoclonal antibody to CD34, a progenitor cell 
marker, to capture circulating HPCs. These studies were the first to clinically 
evaluate the results of an HPC capture stent but did so in de novo single coronary 
lesions in a non randomised setting. They showed that the use of such a stent is 
safe and feasible. This was also subsequently demonstrated in patients 
undergoing angioplasty with high risk angiographic or clinical features 166 and in 
patients undergoing primary angioplasty for myocardial infarction 167. No patients in 
these studies showed evidence of late stent thrombosis, although a subsequent 
study reported a patient receiving an HPC capture stent developed stent 
thrombosis 5 months after implantation 168. This suggested that until further data is 
available as to the incidence of late stent thombosis, there is a need for prolonged 
double anti-platelet therapy post-angioplasty in patients receiving the HPC capture 
stents. 
 
Randomised trials are lacking in this area. The TRIAS study (TRI-stent 




the HPC capture stents with bare metal stents in lesions at low and high risk of 
restenosis is currently underway to redress this problem 169. 
 
The safety of two methods of enhancing the progenitor cell response to vascular 
injury has been assessed in the MAGIC cell trial170. Patients with acute myocardial 
infarction were randomised in to receiving granulocyte colony stimulating factor (G-
CSF) injections for 4 days, with or without intracoronary re-infusion of peripheral 
blood stem cells harvested before angioplasty and stenting. Enrolment was 
stopped after they found an unexpectedly high rate of restenosis in patients who 
received G-CSF compared with the control group. The investigators recognised the 
possibility that progenitors may have differentiated along a smooth muscle 
phenotype. This finding prompted follow-up studies of how G-CSF might affect 
neointimal hyperplasia in animal models. In a model of rabbit iliac artery stenting, 
60 days after stenting rabbits treated with G-CSF developed significantly more 
intimal hyperplasia when compared with rabbits treated with placebo 171. At early 
time points after injury, treatment with G-CSF not only increased total peripheral 
white blood cell count, but specifically increased the number of putative HPCs 
(CD31+ve, VE-cadherin+ve, CD34+ve, KDR+ve cells) and smooth muscle progenitor 
cells (VE-cadherin+ve/a-SMA+ve or CD31+ve/-SMA+ve cells). Culture of these cells 
over 3 weeks with VEGF resulted in these cells exhibiting an endothelial cell 
phenotype (cobblestone shape and CD31 positivity); while treatment with PDGF 
resulted in a smooth muscle like cell phenotype (hill and valley morphology and -




beneficial to some types of injury (myocardial infarction), but may exacerbate 
others (arterial injury). These studies also highlight the risk of using a relatively 
non-specific factor to stimulate progenitor cell mobilisation.  
 
1.6 Other sources of neo-endothelium 
 
In addition to HPCs, there are a growing number of cell types with the potential to 
enhance endothelialisation, but with differing properties and origins. 
 
1.6.1 Mesenchymal stem cells (MSCs) 
 
MSCs are bone marrow and tissue-derived multipotent cells capable of 
differentiating into a variety of tissues including bone, cartilage, muscle and 
connective tissue 172-176. These progenitor cells also have the capacity to 
differentiate into cardiomyocytes177, endothelial cells (ECs)178, 179 and smooth 
muscle cells (SMCs)180 and can be mobilised in response to G-CSF stimulation132. 
Currently, MSCs are one of the cell types being used in clinical trials for post 
myocardial infarction cardiac regeneration therapy181, 182. It has been shown that an 
intra-myocardial injection of autologous MSCs or intravenous administration of 
MSCs can increase vasculogenesis and improve cardiac function after myocardial 
infarction in animal experiments and clinical trials181, 182.  
 
The role of MSCs in intimal hyperplasia has only been studied in animal models. 




undergoing intimal hyperplasia after arterial injury130, and up to 40% of the 
neointimal cells may be derived from MSCs 130. A substantial proportion of MSCs 
proliferate and differentiate into SMCs and ECs in the neointima130. Furthermore, 
cell therapy with OECs modulates the differentiation of MSCs toward an 
endothelial-like lineage, leading to early reendothelialisation and attenuation of 
intimal hyperplasia130. Others have reported that MSCs have the potential to 
differentiate into OECs and these cells subsequently inhibit neointimal hyperplasia 
by re-establishing endothelial integrity in injured vessels 131. Following vein grafting 
in a rat model, engrafted MSCs differentiate into endothelial cells, diminish 
neointima formation and contribute to the improvement in endothelial function183. 
MSCs, like early HPCs, may mediate cardiovascular repair, via paracrine means. 
MSCs have been shown to secrete an array of different pro-angiogenic peptides 
including HGF, insulin-like growth factor-1 (IGF-1), basic fibroblast growth factor 
(bFGF), VEGF, and angiopoeitin-1 (Ang-1) 184. These studies indicate that MSCs 
play an important role in the repair mechanism following vascular injury and have 






Fig 7. Isolation of mesenchymal stem cells from equine umbilical cord 
blood185. (a) Monolayer of rapidly expanding adherent spindle-shaped fibroblastoid 
cells compatible with undifferentiated mesenchymal stem cells (× 100). (b) Three-
dimensional, relief contrast image of cell cluster of rapidly expanding adherent 
spindle-shaped fibroblastoid cells compatible with undifferentiated mesenchymal 
stem cell morphology (× 100). 
 
1.6.1.1 Defining an MSC 
MSCs constitute a heterogeneous population of cells, in terms of their morphology, 
physiology and expression of surface antigens. Up to now, no single specific 
marker has been identified. MSCs express a large number of adhesion molecules, 
extracellular matrix proteins, cytokines and growth factor receptors, associated with 




commonly detected antigens on MSCs isolated from bone marrow are:- CD105 
(SH2; endoglin), CD106 (vascular cell adhesion molecule; VCAM-1), CD73 (SH3 
and SH4), CD90 (Thy-1) and Sca-1 187-189. MSCs do not possess markers typical 
for hematopoietic and endothelial cell lineages such as CD11b, CD14, CD31, 
CD34, CD133 and CD45 188. The absence of CD14, CD34 and CD45 antigens on 
their surface create the basis to distinguish them from the hematopoietic 
precursors. Since there are no reliable MSC markers, these cells are often isolated 
using specific cell culture conditions. Typically, a single-step purification method 
using adherence to plastic cell culture plates is employed. This results in a 
population of fibroblast-like cells (Fig 7), which are characterized as MSCs based 
on their ability to differentiate into multiple mesenchymal lineages (e.g. osteogenic, 
chondrogenic, myogenic, etc.) 190. 
 
1.6.2 The monocyte/macrophage 
 
There is growing evidence that monocytes play an important role in restenosis. The 
number of macrophages that are recruited into the injured vessel wall correlates 
with the volume of neointima in animal models42.  Blocking or gene knockout of 
either monocyte chemoattractant protein-1 (MCP-1) or its receptor CCR2, blocks 
monocyte recruitment and significantly reduces neointimal hyperplasia in animal 
models191-193. Conversely elevated levels of MCP-1 are associated with a greater 





Circulating monocytes are thought to be able to trans-differentiate into endothelial 
cells at the site of arterial injury109, 133, 195, augment neovascularisation196 and inhibit 
neointimal hyperplasia195. This contradicts the reported positive correlation 
between monocyte recruitment and intimal hyperplasia191-193. Methods of culturing 
early HPCs in vitro may in fact produce cells of the monocyte/ macrophage 
lineage109, 197. Monocytes may therefore have the potential to both enhance 
neointima formation in their capacity as inflammatory cells and to attenuate 
neointima formation in their capacity to mimic HPC function.  
 
1.6.3 Tissue resident progenitors 
 
Though the bone marrow seems to be an abundant source of progenitor cells 
recent evidence suggests that these cells may also reside in a variety of other 
tissues. Isolated spleen-derived mononuclear cells, pre-selected with an 
endothelial cell medium, demonstrated endothelial cell characteristics and formed 
tubular-like structures138. These cells could sufficiently enhance re-
endothelialisation and diminish neointima formation after carotid artery injury138. 
Bone marrow transplantation in a rat model followed by hind limb ischaemia  
resulted in non bone marrow-derived, tissue resident progenitors (particularly liver 
and intestine) contributing to postnatal neovascularization to an extent that was 
similar to that of bone marrow-derived progenitor cells198. Systemic infusion of 




vascular structures and subsequently enhanced neovascularisation and improved 
blood flow recovery in ischaemic hindlimbs198.  
Stem cells have been isolated from the non-adipocyte fraction of adipose tissue 199, 
200. These cells express both haematopoietic and endothelial markers and enhance 
neovascularisation in animal models of ischaemia via their capacity to differentiate 
into endothelial cells and their ability to secrete pro-angiogenic peptides199-201.  
Other cells capable of differentiating into an endothelial cell phenotype include 
bone marrow derived ‘side population’ CD34-ve stem cells126, cardiac tissue 
resident c-kit positive stem cells202, skeletal muscle stem cells203, and aortic 
adventitial cells204. In the latter study chimeric mice that express the LacZ 
transgene (producing the enzyme β-galactosidase) only in bone marrow cells were 
used to determine the origin of these cells. No β-gal-positive cells were identified, 
suggesting that these cells are not derived from the bone marrow. Furthermore 
aortic adventitial cells can differentiate in vitro to endothelial and smooth muscle 
cells. In vivo when applied to the adventitia of irradiated vein grafts they 
differentiate to smooth muscle cells and migrate to the neointima of the grafts204. It 
has also been demonstrated that the adult vascular wall in humans contains 
progenitor cells. High numbers of HPCs have been identified in an area between 
the medial and adventitia layer205. A complete hierarchy of HPCs can be derived 
from human vessel wall and discriminated by their clonogenic and proliferative 
potential206. These studies provide evidence that many organs contain progenitor 
cells that may serve as a circulating pool of HPCs and that a diversity of HPCs 





Fig 8.  Hypothesised origin, fate and contributors of adult-human endothelial 
cells with key surface markers207.   
 
1.7 Smooth muscle progenitors (SMPs) 
 
The proliferation of SMC in response to endothelial denudation is an important 
component leading to neoimtimal hyperplasia. Neointimal SMCs were thought to 
originate from the media91, but, much like the origin for neointimal ECs, this 
concept has been recently challenged. There is conflicting evidence from animal 
models regarding the proportion of SMCs that are derived from the bone marrow. 




but when vein segments are grafted, the SMCs that form the neointima are not of 
bone marrow origin208, 209. A possible explanation for this may be that neointimal 
SMCs are derived from medial SMCs or alternatively from progenitor cells present 
in tissues other than the bone marrow. 
 
There is now compelling evidence for a bone marrow derived, blood- borne SMP94, 
98, 210, 211, though the exact phenotype of this cell has yet to be defined. Cells 
present in the bone marrow can express smooth muscle cell antigens after in vitro 
differentiation94, 210. SMCs may also be derived from peripheral blood mononuclear 
cells when treated with platelet-derived growth factor  (PDGF)211. These express 
alpha smooth muscle actin, myosin heavy chain and calponin, as well as CD34, 
suggesting a bone marrow origin. HPCs are also capable of differentiating into 
smooth muscle cells212.  
 
1.8 Progenitor cell recruitment to sites of injury 
 
The recruitment of vascular progenitor cells to sites of neointimal hyperplasia after 
vascular injury can be conceptualized in three stages: 1) mobilisation of progenitor 
cells from bone marrow and tissue niches, 2) migration and recruitment of 
progenitor cells to the site of injury, and 3) differentiation of progenitor cells into 





1.8.1 Mobilisation of progenitor cells 
 
Stem cell niches are specific sites where stem cells reside in the bone marrow. In 
these microenvironments the cells can either remain in an undifferentiated and 
quiescent state or differentiate. In response to vascular injury or physiological 
stress, stem cells have to be rapidly mobilised and recruited to the damaged area. 
Progenitor cells are believed to be attached to bone marrow stromal cells or ECM 
through specific binding interactions, including VLA-4/VCAM-1, SDF-1α/CXCR4, 
CD44/HA (hyaluronic acid), and interactions between P-, E- and L- selectin213. 
Progenitor cells must migrate through a vascular barrier (bone marrow venous 
sinuses) that separates the hematopoietic compartment from the circulation in 
order to exit the bone marrow, and this process is controlled by disruption of these 
receptor ligand interactions. α4 and β2 integrins have a role in the interactions 
between progenitor cells and the bone marrow microenvironment, and antibodies 
to these molecules or knock-out models lead to increased progenitor cell 
mobilization 214, 215. VCAM-1 is constitutively expressed by bone marrow 
endothelial and stromal cells, and disruption of the VCAM-1/VLA-4 interaction by 
antibodies to VCAM-1 or VLA-4 ultimately leads to progenitor cell mobilisation216, 
217.  
 
Vascular endothelial growth factor (VEGF) is thought to be one of the most potent 
cytokines in stimulating endothelial cell mobilisation, proliferation, migration and 




either by local delivery219 or gene transfer26, 220 significantly reduces neointima 
formation and accelerates endothelial regeneration. This effect has not, however, 
been confirmed in patients undergoing percutaneous coronary intervention221, 
where catheter-based intracoronary VEGF gene transfer makes no difference to 
the restenosis rate. There has been considerable debate over the vasoprotective 
versus atherogenic effects of VEGF. Extensive vascular networks are well 
recognised in atherosclerotic plaques222 and balloon injured arteries223, raising the 
possibility that pro-angiogenic agents may exacerbate neointimal growth, in a 
manner  analogous to their role in tumour growth. VEGF also induces migration 
and activation of monocytes224, induces adhesion molecules225 and upregulates 
monocyte chemoattractant protein -1 (MCP-1)226, which is also angiogenic. 
 
Granulocyte macrophage colony stimulating factor (GM-CSF) 227, granulocyte 
colony stimulating factor (G-CSF) 158, stromal derived factor -1(SDF-1) 228, 
hepatocyte growth factor (HGF) 229 and nitric oxide (NO) 230 all stimulate progenitor 
cell mobilisation, growth and differentiation. Bone marrow stromal cell expression 
of eNOS is also essential for the mobilization of stem and progenitor cells 230. G-
CSF can disrupt the CXCR4/SDF-1 complex by signalling the release of proteases 
from G-CSF receptor bearing neutrophils, most notably neutrophil-elastase, 
cathepsin-G and matrix-metalloproteinase-9, which then degrades and disrupts 






The SDF-1/CXCR4 interaction is important in regulating progenitor cell survival, 
cell cycle, and mobilisation213.  Intravenous administration of exogenous SDF-1α 
as well as treatment with a specific CXCR4 inhibitor rapidly induces progenitor cell 
mobilization in both humans and mice 233. SDF-1, VEGF and G-CSF have all been 
shown to induce MMP-9 in the bone marrow, leading to cleavage of membrane 
bound c-kit ligand (mKitL) to soluble KitL. This in turn results in increased 
progenitor cell cycling and enhanced cell motility, and ultimately leads to progenitor 
cell mobilization233, 234. Cytokine induced progenitor cell mobilisation is dependent 
on MMP-9 as this process is impaired in MMP-9-/- mice 234. This study introduced a 
paradigm in stem and progenitor cell biology whereby activation of a 
metalloproteinase serves as the decisive checkpoint for the rapid reconstitution of 
the circulating progenitor cell pool following vascular injury. 
 
1.8.2 Migration to site of injury 
 
Once in the vicinity of an injured vessel, progenitor cells interact with the damaged 
endothelial monolayer in a similar way as leucocytes interact with activated 
endothelial cells. Adhesion molecules previously known to be involved in the phase 
of rolling and firm adhesion of leucocytes are also key regulators of HPC homing. 
P-selectin and E-selectin seem to mediate the initial steps of this process. 
Activation of EphB4 in HPCs leads to a higher expression of P selectin 
glycoprotein ligand-1 (PSGL-1)235. Subsequently, increased adhesion to P-selectin 
and E-selectin is observed. sRNA for P-selectin abrogates this response indicating 




shown that E-selectin also mediates HPC-endothelial cell interactions236. β2-
integrins expressed on the cell surface of HPCs mediate the firm adhesion and 
transmigration of HPCs to the damaged endothelial monolayer. Activation of the β2 
integrins was shown to improve the homing and the neovascularisation capacity of 
HPCs in a mouse model of hindlimb ischaemia 237. 
 
In addition to playing an essential role in progenitor cell mobilisation, the SDF-
1α/CXCR4 axis is also involved in progenitor cell recruitment to sites of injury in 
models of neointimal hyperplasia 238. In the mouse wire injury model, blockade of 
SDF-1α signaling with either a SDF-1α blocking antibody, lentiviral-based local 
gene transfer of a mutant SDF-1α, or by transplantation of bone marrow cells 
deficient in CXCR4 results in decreased intimal hyperplasia, which was associated 
with decreased bone marrow derived neointimal smooth muscle cells 238. SDF-1α 
also induces platelet adhesion at the site of injury, and subsequent release of 
platelet P-selectin led to progenitor cell adhesion and recruitment238. These same 
mechanistic findings suggesting an important role of SDF-1α and platelets in 
progenitor cell recruitment were demonstrated in vivo using real-time video-
fluorescence microscopy239. This study also showed that activated platelets 
secrete high levels of SDF-1239. As platelets adhere within minutes to the exposed 
sub-endothelial surface in injured vessels, this could provide a very effective 
mechanism of mobilisation and homing of stem cells to the damaged area.  In vitro 
studies have shown that SDF-1α induces HPC and CD34+ cell migration and 




HPCs to diabetic wounds in mice 242. Placental growth factor (PlGF) is known to 
have potent effects on vasculogenesis and may also be important for HPC 
function243, 244. PlGF stimulates recruitment of HPCs to areas of vasculogenesis245, 
though its role in relation to intimal hyperplasia has yet to be studied. 
 
1.8.3 Progenitor cell differentiation 
 
 
VEGF induces differentiation of both HPCs 103 and MSCs179 into cells with 
phenotypic and functional features of endothelial cells. GM-CSF227, G-CSF158 , 
SDF-1228, hepatocyte growth factor (HGF)229 and NO230 all stimulate HPC growth, 
differentiation and migration in vivo and in-vitro. It has been proposed that the 
direct cell-to-cell contact may be a stimulus of progenitor cell differentiation. 
Studies show that direct cell-to-cell contact between MSCs and cardiomyocytes or 
smooth muscle cells results in MSC differentiation into these two cell types180. Co-
culture of MSCs with HPCs drives MSCs to differentiate into endothelial-like 
cells130. Shear stress, the mechanical force generated by blood flow, can also 
effectively induce expression of endothelial-specific genes in stem cells 246, 247. 
Laminar flow can enrich both adult and embryonic stem cell populations for 
endothelial progenitors 246, 247. 
 
1.9 The case for further clinical studies 
 
The vast majority of studies on the role of vascular progenitors following arterial 




on patients undergoing coronary angioplasty100, 154. It has been shown that the 
contribution of bone marrow derived progenitor cells to the arterial wall may vary 
depending on the type of injury95. Transplantation of bone marrow cells from 
transgenic mice that globally express GFP into a wild type mice, reveals that three 
distinct types of mechanical injury produce varying degrees of bone marrow 
derived cell contribution to the arterial wall. In the first injury model, a 0.38 mm 
straight spring wire was inserted into the mouse femoral artery to denude and 
dilate the artery. This model best recapitulates endarterectomy procedures in 
humans, since it involves both vessel wall dilatation and denudation of the vessel 
intima and media. In the second model, a polyethylene tube was placed around the 
mouse femoral artery (perivascular cuff induced injury). In the last model, the 
mouse common carotid artery was ligated just proximal to the bifurcation. Wire 
injury led to large numbers of GFP+ cells in both the media and the neointima, 
whereas perivascular cuff placement and carotid artery ligation resulted in 
significantly fewer GFP+ medial and neointimal cells. The authors also studied the 
fate of the bone marrow derived cells by examining α-SMA expression. Whereas a 
significant number of GFP+ cells in the neointima and the media after wire injury 
were also α-SMA+, only a few of the GFP+ cells expressed α-SMA in the other two 
injury models. It is possible, therefore, that the response to CEA, which involves 
not only loss of endothelium, but also stripping of the media, may differ in the 
magnitude and character of progenitor cell involvement when compared to 
coronary angioplasty. The amount of injury caused by CEA may also have an 




affect the need for more distant blood borne progenitors. It is also known that 
carotid atheroma appears later in life than coronary plaques 248, this may reflect a 
mechanical difference or differences in the pathogenesis of atherosclerosis 
between small and large vessels. The shear stress in the coronary arteries is also 
different to that in the common carotid artery. These factors may all contribute to 
differences in the response to arterial injury between coronary and carotid arteries. 
 
1.9.1 Carotid endarterectomy as a clinical model 
 
The risk of restenosis after carotid endarterectomy is around 10% - 20% 29-31. This 
is difficult to define precisely because of the differing definitions and different 
duplex criteria used to assess this. Restenosis following carotid endarterectomy 
carries a low risk of stroke (1-10%) 30, 31. A recent systematic review showed that a 
second intervention (stenting or surgery) for restenosis occurred in ~3% of all 
treated arteries 249. This is comparable with the results of ECST, where <1% 
(5/558) of the surgical patients had a second CEA because of a symptomatic 
restenosis. It is evident from these studies that patients with restenosis after CEA 
generally follow a benign course. Therefore the potential direct clinical impact of 
future therapies designed to reduce the risk of restenosis is small, and this intern 
raises questions as to the value of studying restenosis in the carotid artery.  
 
We feel that carotid endarterectomy as a model has a number of advantages. The 
low re-intervention rate allows us to study the impact of an isolated arterial injury 




relatively superficial artery, we can assess the degree of restenosis using duplex 
ultrasound, which is accurate and safe for the patient. Furthermore the results of 
this study will give a mechanistic insight into restenosis and response to arterial 
injury and will therefore be applicable to all arteries not just to the carotid.  
 
In trying to study arterial injury and restenosis we considered and rejected other 
potential human models. Percutaneous lower limb angioplasty was rejected as it 
was felt that the type of injury, and therefore the progenitor cell response, might be 
similar to that of angioplasty in the coronary, the main difference being anatomical 
location. Patients with peripheral vascular disease also have multiple sites of 
stenosis and can have patency rates as low as 50% at 1yr 250 and therefore a high 
re-intervention rate. Preliminary investigations revealed that in our institution a very 
low number of patients have a primary angioplasty for an isolated lesion. This 
would make it difficult to study the progenitor cell response to an isolated injury and 
correlate this with restenosis without the confounding factor of previous or future 
angioplasties. Femoral endarterectomy as an alternative model was rejected due 
to low numbers and also as the procedure is often carried out in association with 









1.10 Hypothesis and Aims 
 
Blood borne vascular progenitor cells are essential components of the repair 
mechanism following arterial injury. Mobilisation and/or activity of these cells will 
influence re-endothelialisation and the generation of neointimal hyperplasia and 
thus restenosis following carotid endarterectomy.  
 
We aimed to address this hypothesis by: 
1. Carrying out a longitudinal study in which the HPC and MSC numbers and 
activity would be measured before and after carotid endarterectomy and correlating 
their numbers and function with the degree of restenosis 
2. Measuring the expression of factors that are known to mobilise these progenitor 














2. METHODS AND STUDY DESIGN 
2.1 Measurement of HPC number by flow cytometry 
2.1.1 Overview of investigations 
 
Whole blood was labelled using fluorescently conjugated monoclonal antibodies 
against CD34-peridinin chlorophyll protein (PerCP, Becton Dickinson, BD), 
VEGFR2-phycoerythrin (PE, R&D Systems) and CD133-PE (Miltenyi). Whole 
blood was also separately labelled with CD133 primary (Miltenyi) and a 
fluorescently conjugated secondary (goat anti-mouse fluorescein isothiocyanate 
(FITC) - Dako). Flow cytometry was carried out on a FACScan flow cytometer (BD) 
to identify and enumerate HPC numbers (CD34+/CD133+/VEGFR2). 
 
2.1.2 General methods 
2.1.2.1 Direct Immunofluorescence staining of whole blood. 
1. 500µl of whole blood was aliquoted into an Eppendorf tube. 
2. 20µl of FcR block (Miltenyi) was added and incubated for 20 mins.  
3. A given concentration of antibody (Table 4) was added, mixed well and 
incubated in the dark at 4ºC for 30 mins.  Non-immune IgG, of the same 
isotype as the test antibody, raised in the same animal, and conjugated 
to the same fluorescent probe was added to a duplicate sample of the 





4. 5mls of Pharmalyse (BD) was added to the tube, mixed well and 
incubated in the dark at room temperature for 10 mins. 
5. The tube was centrifuged at 400g for 5 mins and the supernatant 
discarded. 
6. The cells were resuspended in 5mls of stain buffer (Dulbecco’s modified 
phosphate buffered saline, Ph7.4 [DPBS], 0.09% sodium azide, 2% heat 
inactivated foetal calf serum, FCS). 
7. Wash steps 5 and 6 were repeated for a total of three washes. 
8. The pellet was resuspended in 2mls of stain buffer. 
9. Data was acquired by flow cytometry. 
 
2.1.2.2 Indirect Immunofluorescence staining of whole blood. 
1. 500µl of whole blood was aliquoted into an Eppendorf tube. 
2. AS STEP 3 IN SECTION 2.1.2.1. 
3. The blood was washed by adding 5mls of cold stain buffer, mixed and 
centrifuged at 400g for 5 minutes. The resulting supernatant was then 
discarded, and the pellet resuspended in 5mls stain buffer. 
4. Step 3 was repeated three times. 
5. The pellet was resuspended in 500µl of PBS containing 5% serum from 
the animal the secondary antibody to be used was raised in, and the 
mixture incubated for 10 mins. 
6. Fluorescently labelled secondary antibody was added to both test and 




7. 5mls of Pharmalyse (BD) was added to the tube, mixed well and 
incubated in the dark at room temperature for a further 10 mins. 
8. The tube was centrifuged at 400g for 5 mins and the supernatant 
discarded. 
9. The cells were resuspended in 5mls of stain buffer (section 2.1.2.1). 
10. Wash steps 8 and 9 were repeated for a total of three washes. 
11. The pellet was resuspended in 2mls of stain buffer. If co-staining with 
directly labelled antibodies, the pellet was resuspended in 500ul of stain 
buffer and the protocol for direct immunofluorescent staining (section 
2.1.2.1) was followed from step 2. 
12. Data was acquired by flow cytometry.  
 
2.1.2.3  Cell fixation for flow cytometry 
1. The direct immunoflourescence staining protocol (2.1.2.1) was followed 
up to and including step 7. 
2. The pellet was resuspended in 5mls  5% formaldehyde in stain buffer. 
3. The sample was incubated at room temperature for 5mins. 
4. The tube was centrifuged at 400g for 5mins and the supernatant 
discarded. 
5. The cells were resuspended in 5mls of stain buffer and steps 4 and 5 
were repeated for a total of 3 washes. 





2.1.2.4  Design of optimization experiments 
It was initially necessary to determine whether individual antibodies detected 
specific cell populations. Blood samples were therefore stained with individual 
antibodies whose binding was then optimised in the following ways.  
 Comparing different antibody concentrations (Table 4). 
 Comparing incubation temperatures -  4ºC and room temperature. 
 Comparing incubation times - 10, 20 and 30 mins.  
 
Table 4. Concentrations of antibodies used for optimization experiments. 
 
Antibody Antibody concentration (µg/ml) 
CD34-PerCP 0.125  0.25  0.5  0.75  
CD133-PE 0.03  0.17  0.33  0.50 
VEFR2-PE 0.125  0.25  0.50 0.75  
CD133 primary  0.05  0.10 0.50 1.00 
 
Both CD133 and VEGFR2 primary antibodies were both directly conjugated to PE 
(Table 4) and could therefore not be used together in a double or triple stain. 
Neither of these antibodies was available directly conjugated to the alternative 
fluorescent probe FITC. The mouse anti-human CD133 primary was therefore 
detected using a goat anti-mouse FITC conjugated secondary antibody (200µg/ml), 




then stained together with CD34-PerCP and VEGFR2-PE. This staining protocol 
was further optimised by investigating the following.  
 
1. Minimising non-specific binding in the triple stain  
Reduction of non-specific binding was carried out by including a blocking step (step 
2 direct immunofluorescent staining protocol 2.1.2.1). The following blockers were 
investigated. 
i)  FcR block (BD, UK) 
ii) 5% goat serum (Invitrogen, UK) 
iii) Mouse immunoglobulin (IgG, Invitrogen, UK, 0.5 µg/ml)  
iv) 5% bovine serum albumin(Invitrogen, UK) 
 
2. Using a mixed isotype control to check for stain specificity.  
Two methods of controlling for co-expression of the three antigens were assessed. 
i)  Conventional control, where all isotype IgG controls were added to a 
duplicate blood sample.  
ii)  Mixed control in which each primary antibody was replaced, in turn, by its 
isotype control i.e substituting CD133-FITC for it’s isotype control (IgG-FITC, 
VEGFR2-PE, CD34-PerCP); or CD34-PerCP with it’s isotype control 
(CD133-FITC, VEGFR2-PE, IgG-PerCP). 
 
3. Assessing the effect of formaldehyde fixation of the sample after staining, storing 





4. Determining the intra-assay variability. 
This was done by measuring cell numbers in 6 replicates of the same blood 
sample processed on the same day. 
 
2.1.3 Results 
2.1.3.1 The effect of varying antibody concentration, incubation time and 
temperature on the detection of single positive cells. 
The effect of varying antibody concentration on the detection of single positive cells 
using the direct immunostaining protocol is shown in Figs 9-12.  Optimal staining 
was achieved when using a concentration of 0.5µg/ml of CD34 PerCP and 
0.33µg/ml of CD133-PE. Higher antibody concentrations increase the non-specific 
binding (binding of isotype control) and as a result no overall increase in the 
number of positive cells was detected. The optimal concentration was less clear 
with the VEGFR2-PE antibody (Fig 11).  Concentrations greater than 0.5µg/ml 
showed no overall increase in the number of positive cells. However at this 
concentration the number of positive cells detected in the isotype control was very 
high (~200) giving a false positive rate of 36%. A concentration of 0.125µg/ml 
detected fewer overall positive cells, but also had a lower false positive rate of 
17%. Optimal staining for the CD133 primary antibody was achieved at a 








































Fig 9. The effect of varying CD34 - PerCP antibody concentration (Pos), with 
its isotype equivalent (Iso) on the number of single positive cells (Pos-Iso) 





































Fig 10. The effect of varying CD133 – PE (Pos) antibody concentration, with 
its isotype equivalent (Iso) on the number of overall single positive cells 







































Fig 11. The effect of varying VEGFR2-PE (Pos) antibody concentration, with 
its isotype equivalent (Iso) on the number of overall single positive cells 
(Pos-Iso) detected by flow cytometry. 



































Fig 12. The effect of varying CD133 primary antibody concentration, with its 
isotype equivalent (Iso) on the number of overall single positive cells (Pos-








































Fig 13. The effect of varying incubation time and temperature on detection of 
single positive cells. 
 
Increasing incubation time from 10 to 30 minutes increased the number of CD133 
+ve cells detected (CD133-PE, Fig 13). However, when incubated at room 
temperature there was also a rise in the number of false positives detected by the 
isotype control. This did not occur when the incubation was carried out at 4ºC. The 
optimal conditions were incubation at 4ºC for 30 minutes. 
 
2.1.3.2 Detection of Triple Positive Cells 
Whole blood was triple stained for CD133 using the IgG-FITC secondary antibody, 
indirect immunofluorescence protocol. Cells were then stained for VERGFR2-PE 
and CD34 PerCP using the direct immunofluorescence protocol.  The gating 
system used for detecting triple positive cells is shown in Figs 14a-d. Previous 




(lymphocyte and monocyte). In addition the degree of non-specific binding of the 
fluorescent antibodies within the granulocyte region obscures the signal from the 
mononuclear region. Therefore only the mononuclear region is analysed further.  
 
 
Fig 14a. Plot of forward scatter (FSC) versus side scatter (SSC) from flow 
cytometry of human blood . Area 1 represents granulocytes, 2 lymphocytes and 










Fig 14b. Dot plot of CD133 FITC (FL1) versus CD34-PerCP (FL3).  
Quadrant 1 contains cells that are double positive for CD133 and CD34; 2 cells 
that are CD34 positive only; and 3 cells that are CD133 positive only. 
 
Fig 14c. Dot plot of VEGFR2 - PE (FL2) versus CD34-PerCP (FL3).  
Quadrant 1 contains cells that are double positive for VEGFR2 and CD34; 2 cells 










Fig 14d. Dot plot of VEGFR2 - PE  (FL2) versus CD34-PerCP (FL3).  
Only cells present in quadrant 1 from Figs 14b and c were denoted as triple 
positive (CD133, VEGFR2 and CD34) cells. 
 
2.1.3.3 Comparison of conventional and mixed isotype controls 
Conventional isotype controls were compared with mixed isotype controls to 
determine the specificity of the triple stain (Table 5). Use of a conventional isotype 
control (i.e three fluorescently labelled isotype antibodies in an identical tube) 
revealed 16 triple positive cells compared with 119 triple positive cells visualised by 
the marker antibodies, giving a false positive rate of 13%. Analysis using a mixed 
isotype control gave a false triple positive rate of 14% and 16% for CD133 and 
CD34 IgG isotypes respectively. Substituting VEGFR2-PE for it’s isotype control 
(i.e CD133-FITC, IgG-PE, CD34-PerCP) resulted in a very high false positive rate 




Table 5. Mean (n=3) of the numbers of fluorescent cells stained using 
conventional and mixed isotype controls  
 






CD133-FITC VEGFR2-PE CD34-PerCP 119(±7) N/A 
IgG-FITC IgG-PE IgG-PerCP 16(±2) 13 
IgG-FITC  VEGFR2-PE  CD34-PerCP 17(±3) 14 
CD133-FITC VEGFR2-PE IgG-PerCP 19(±2) 16 
CD133-FITC, IgG-PE CD34-PerCP 72(±5) 60 
 
This experiment was repeated on eight healthy volunteers with similar results (Fig 
15). The mixed isotype control for the VEGFR2-PE (i.e CD133-FITC, IgG-PE, 
CD34-PerCP) showed consistently high numbers of false positives, compared with 
the normal isotype controls (P=0.001, paired t-test), although consistently and 


































  * **
  
Fig 15. The percentage of MNCs detected following staining for conventional 
isotype control, mixed isotype control and CD133+ve/CD34+ve/VEGFR2+ve. 
(n=8, P<0.001 for both mixed vs isotype* and vs triple**, paired t-test) 
 
In order to determine whether the high degree of false positives was only a 
problem related to theVEGFR2 antibody from R&D Systems, these experiments 
were repeated using anti-VEGFR2-PE and matched isotype antibodies obtained 
from Miltenyi, UK and BD, UK. A triple stain alongside a mixed isotype control 
found these antibodies to have a false positive rate of 54% and 59% respectively. 
 
2.1.3.4 Blocking non-specific binding in CD133/CD34/VEGFR2 triple stain 
Various blocking methods were investigated in order to reduce the number of false 
positives in the triple stain (2.1.2.4). Blocking with goat serum gave the lowest level 
of false positives (42%, false positive rate was calculated as a percentage of the 




in marked fall in the number of false positives compared with a mixed control. A 
double staining technique (co-expression of CD133 and CD34) was therefore 
adopted to define HPC’s in this study as both isotype and mixed controls had low 
number of false positives (~15%) using these antibodies (Table 5).  
 
Table 6. Comparison of blocking protocols in assessing mixed isotype 
controls staining.  
 Mean cell 
numbers (n=3) 
SEM % false positive 
Conventional 
isotype Control 
25 3 16 
FcR block   
mixed isotype 
71 4 45 
Goat Serum  
mixed isotype 
65 5 42 
Mouse IgG   
mixed isotype 
78 8 50 
BSA   
mixed isotype 
76 5 49 
Mixed isotype  
(no block) 






2.1.3.5 Optimisation of CD133/CD34 double labeling  
i) FcR blocking  The utility of the FcR blocking reagent was investigated by 
incubating paired blood samples from 5 volunteers in either 20µL of FcR reagent 
for 10 minutes followed by the primary antibody, or directly with the antibody (direct 
immunofluorescence staining protocol 2.1.2.1). FcR blocking had no significant 
effect on the number of double positive cells detected (Fig 16, P=0.68, Wilcoxon 
signed ranks test) 
 







































Fig 16. Effect of FcR blocking on CD133+ve/CD34+ve analysis (n=5, Wilcoxon 
signed ranks test) 
 
ii) Cell fixation  Paired blood samples from five volunteers were either 
processed for immediate flow cytometry (CD34/CD133 staining) or fixed in 2% 




was no significant difference between the cell numbers detected following each 







































Fig 17. Effect of fixation on CD133+ve/CD34+ve analysis (n=5, Wilcoxon 
signed ranks test) 
 
2.2.3.6 Intra-assay variability of double staining 
Six blood samples from the same volunteer were stained with CD133-PE and 
CD34-PerCP. A duplicate set of 6 blood samples from the same volunteer was 
stained with isotype controls (IgG-PE and IgG-PerCP). Assay variability for the 






Table 7. Intra-assay variability of flow cytometric analysis of HPC number 
using CD133+ve/CD34+ve staining 
 
Antibody / IgG control used Mean(SD) n=6 Variability 
CD133-PE + CD34-PerCP  150.3(±9.5) 6.3% 
IgG-PE + IgG-PerCP (isotype double) 3 (±1.2) 40% 
 
 
2.1.4  Discussion  
 
There is no consensus as to the most specific markers of an HPC as measured by 
flow cytometry. Most have defined these cells by the co-expression of both 
haematopoietic (CD34/CD133) and endothelial (VEGFR2) marker proteins. 
Detection of HPCs using a triple stain (VEGFR2/CD133/CD34) and a conventional 
isotype control (isotype IgGs in a separate tube), shows that approximately 0.05% 
of the circulating PBMNC pool is comprised of HPCs, with a low number of false 
positives (~8%). Our results with a mixed control for CD133/CD34/VEGFR2 
staining (substitution of the VEGFR2 antibody for its isotype control IgG in the 
reaction mix) suggest, however, that use of the conventional isotype control may 
grossly overestimate the number of HPCs in blood, as mixed control staining 
revealed a high number of false positives (~60%) caused by the non-specific 




antibodies from 3 manufacturers (R&D Systems, BD and Miltenyi). The high level 
of false positives may of course be the result of the staining protocols used, but I 
was unable to reduce the number of these false positives with a variety of 
protocols. Double staining using CD34+/CD133+ was optimised and adopted for all 






 The use of conventional isotype controls alone may overestimate the 
number of circulating HPCs. 
 The measurement HPCs numbers by flow cytometry may be confounded by 
the source of the VEGFR2 antibody. 
 Optimal double staining was achieved by incubating 0.5µg/ml of CD34 
PerCP and 0.33µg/ml of CD133-PE for 30 min at 4°C.  
 FcR block does not increase the specificity of staining and was therefore not 
used.  
 Cell fixation and analysis up to 16 hours later is accurate. 





2.2 HPC culture and colony forming unit (CFU) assay 
 
2.2.1 Overview of investigations 
 
Peripheral blood mononuclear cells were isolated by Ficoll gradient density 
centrifugation and placed on fibronectin-coated plates in  EGM-2 culture medium 
as previously described for endothelial progenitor cell analysis (EPC)111. The 
number of colonies was counted 5days after culture under phase contrast 
microscopy. The cultured cells were stained with Dil-acLDL (Molecular Probes) and 
ULEX Lectin (Sigma) and the endothelial markers, CD31 (Dako) and VEGFR2 
(Dako), with only double positive cells regarded as endothelial cells. In order to 
grow OECs/late HPCs a separate culture was continued for up to 4 weeks, with 
media change every other day as previously described104.  
 
2.2.2 General methods 
2.2.2.1 Peripheral Blood Mononuclear Cell (PBMNC) Isolation  
1. Blood was transferred to a sterile 50ml falcon tube and diluted with pre-
warmed Dulbecco’s modified eagle medium (DMEM) to two times the 
original volume.  





3. 25ml of the diluted blood suspension was gently layered on top of the  
Ficoll-Paque Plus.  
4. The layered solution was centrifuged at 840g for 25 mins with the brake 
on the centrifuge switched off. 
5. The PBMNC fraction is clearly seen as an opaque ring of cells (the first 
from the top of the tube, Fig 18). This was carefully removed using a 
sterile pasteur pipette, and transferred to a fresh 50 ml tube. 
6. The cells were washed by addition of pre-warmed DMEM making a final 
volume of 40ml. The cells were  centrifuged at 400g for 5 mins. 
7. The supernatant was discarded and the cells resuspended and washed 
as described in step 6.  
8. The cell pellet was resuspended in EGM-2 supplemented with the Bullet 
Kit system (Clonetics) and 5% FCS (Sigma) [called EBM-2] to a volume 
one quarter the original volume of blood. 
9. Cell numbers were counted using a haematocytometer and adjusted to 








Fig 18. Ficoll gradient isolation of mononuclear cells 
 
2.2.2.2 Haematopoietic progenitor cell culture 
1. Six-well plates were pre-coated with 1ml of fibronectin solution (10g/ml 
in M199 culture medium - Sigma, UK) per well and incubated overnight 
at 4ºC. Chamber slides (Nunc, UK) were also similarly treated by coating 
with 0.5mls fibronectin solution. 
2. Any excess fibronectin solution was aspirated and the plates placed in 
an incubator (37°C) for 10 mins. 
3. 4mls (1 x107 cells per well) of the mononuclear cell suspension (step 9 
section 2.2.2.1) was pipetted into each well. Alternatively 2mls of the cell 
suspension was added to each chamber of the fibronectin pre-coated 
chamber slides. 




5. The non-adherent fraction was removed at 48hrs by gently aspirating the 
fluid and replaced with 2mls pre-warmed EBM-2. 
6. Half the volume of medium was changed every 48hrs thereafter. 
7. HPC colony forming units (eCFU) were counted at day 5 under phase 
contrast microscopy. 
8. Cell culture was continued in order to grow OECs/late HPCs with media 
change every 48hrs for up to 4 weeks. 
 
2.2.2.3 Dil-acLDL and lectin staining 
 
1. After 5 days of culture, HPCs  grown on chamber slides (Nunc) were 
washed twice with 1 ml warmed sterile phosphate buffered saline. 
2. The cells were incubated with 5µg/ml of Dil-acLDL (Molecular Probes) in 
warmed EGM-2 (Cambrex) at 37°C for 1 hour. 
3. The cells were washed twice before fixation with 2%  
paraformaldehyde in PBS for ten minutes.  
4. The cells were washed twice before incubation with Lectin from Ulex 
europaeus agglutinin (Lectin UEA-1, Sigma) – 10µg/ml in PBS for 1hr in 
the dark at room temperature. 
5. The slides were washed twice with PBS and mounted in Vectashield 
(mounting medium containing the blue fluorescent nuclear stain, DAPI, 
Vector Laboratories). 




2.2.2.4 Immunohistochemical staining with CD31 and VEGFR2 
 
1. HPCs grown on chamber slides for 5 days were washed twice with 1ml 
warmed sterile PBS before being fixed with 2% paraformaldehyde in 
PBS for ten minutes. 
2. The slide was washed twice with PBS. 
3. Primary antibody(s) and control(s) were made to the required dilutions 
(CD31(Dako) 1 in 40, VEGFR2(Dako) 1 in 200 -  in PBS containing 5% 
normal serum from the same species the secondary antibody was 
raised in. 
4. 1ml of this solution was added to each chamber slide. Control isotype 
IgGs at the same concentrations as primary antibody were added to a 
duplicate chamber. 
5. The slide was incubated for 30 mins at room temperature and  washed 
twice with PBS  
6. Fluorescently labelled secondary antibody(s) were made to the 
recommended dilution(Goat anti-rabbit (Dako)1:750, goat anti-mouse 
(Dako,) 1:100) in PBS with 5% serum from the animal the secondary 
was raised in,  
7. 1 ml of the solution was added to the chamber slides and incubated in 
the dark at room temperature for 30 minutes. 
8. The slides were washed twice with PBS and mounted in Vectashield  




2.2.2.5 Optimisation experiments for HPC-CFU growth 
The following experiments were carried out in order to optimise the CFU assay. 
 
 Assessing different batches and sources of FCS. Foetal calf serum obtained 
from Sigma, UK – 3 batches; Hyclone, UK, 3 batches; and Gibco, UK, 2 
batches were assessed at varying the concentration in the EBM-2. (20%, 
10%, 5%) 
 Batch testing the fibronectin used to pre-coat the wells (from Sigma,Gibco, 
BD) 
 Pre-plating the PBMNC. This involved incubating the non-adherent fraction at 
48hrs in 12-well plates.  At step 5 (section 2.2.2.2), wells were vigorously 
pipetted and the non-adherent cells were collected, washed with warmed 
PBS before being re-suspended in EBM-2. Cells were plated at a 
concentration of 5 x 106 cells per well in a fibronectin-coated 12 well plates. 
 Assessing the effect of changing the plating concentration of PBMNCs in step 
3 of 2.2.2.2 (HPC CFU culture, 5x106,  2.5x106, 1.25x106, 6x105  cells/ml). 
 Assessing the intra-assay variability and inter-observer error of the eCFU 
assay. 
2.2.3 Results 
2.2.3.1 HPC-eCFU assay 
MNCs from healthy volunteers were isolated and eCFU cultures commenced 




day 5. HPC cultures at day 1 did not stain for Dil-acLDL, Lectin, CD31 or VEGFR2. 
By day 5 cells had the typical appearance of spindle shaped endothelial cells 
(Fig19a) and stained double positive for CD31 and VEGFR2 (Fig19b), and for Dil-











Fig 19b. Day 5 HPC culture stained with VEGFR2 (green) and CD31(red). 
Yellow orange fluorescence also shows dual stained cells. Blue fluorescence 
denotes nuclear stain. (x40 mag) 
 
 
Fig 19c. Day 5 HPCs stained using Dil-acLDL(red) and lectin-FITC 





Batch testing of FCS and fibronectin from different companies showed that there 
were important differences between sources of these reagents in terms of success 
rate of the eCFU assay. Colony growth only occurred in the presence of a specific 
batch of FCS and fibronectin obtained from Sigma (Fig 20a). Other batches of FCS 
and fibronectin did not yield eCFUs though most supported the growth of spindle 
shaped cells. Colonies began to grow at day 3 and were clearly recognisable by 
day 5 (Fig 20a and 22) after which time they began to disperse.  
 
Pre-plating the PBMNCs and culturing the non adherent fraction after 48 hrs as 
has been previously described111 did not result in eCFU formation. In addition 
CFUs did not appear when cell concentrations were below 2.5 x106 cells/ml (1x107 
per well, Table 8). Changing the culture media with fresh EBM-2 more frequently 
than every 48 hrs had no effect on the formation of CFU’s. 
 






Fig 20b. eCFUs stained using Dil-acLDL(red) and lectin-FITC (green/yellow). 
Blue fluorescence denotes nuclear stain. (x10) 
 






 mean(SD) n=4 
Intra-Assay 
Variability 
5 x 106 30 (±3) 10% 
2.5 x 106 18 (±2) 11% 
1.25 x 106 0 - 





Varying the concentration of FCS in EBM-2 from 5% to 20% did not significantly 
affect the CFU number (Spearman rank correlation R=0.31, P=0.68) (Table 9). The 
intra-assay variability was approximately 10%. 
 
Table 9. The effect of changing FCS concentration on the growth of eCFUs. 
 
Concentration of 





5% FCS 23.8 (±1.7) 7% 
10% FCS 24.3 (±2.9) 12% 
15% FCS 23.3 (±2.2) 9% 
20% FCS 24 (±2.6) 11% 
 
 
The inter-observer error was determined by growing eCFUs from five healthy 
volunteers. Two different observers were then asked to independently count the 
number of colonies in the same set of wells. The inter-observer error was <5% 




























Fig 21. The inter-observer error of the eCFU assay (mean of n=3, Pearson 
correlation). 
 
2.2.3.2 Culture of OECs/ late HPCs 
From the published literature we were aware of the sequential changes that might 
be expected from the culture of eCFUs and subsequently OECs. In our culture, as 
presented in section 2.2.3.1, the appearance of early CFUs occurred between day 
3 and 6 (Fig 22 A-C). After 10 days there was no obvious cobblestone appearance 
developing and a gradual loss of cells (Fig 22 D-F) which was contrary to published 
accounts104. We therefore investigated the changes in some of the assay 
conditions in order to grow OECs. These changes included (as per section 
2.2.2.5):- 
(i) changing the initial plating concentration of PBMNCs; 
(ii) varying the concentration of FCS in the culture medium; 




(iv) pre-plating the PBMNC and culturing the non-adherent fraction at 48 hrs in 
12-well plates (section 2.2.2.2 and 2.2.2.5).  
 
OECs formed in less than 10% of MNC cultures from the same healthy volunteer 
(n=4 for each assay condition in 2.2.2.5) but was not reproducible for any given set 
of assay conditions. To date we have been unable to culture OECs from the 
peripheral blood in a reproducible manner. 
 
Fig 22. CFU formation over a 28 day period following seeding with isolated 
PBMCs  (A) 2 days. (B) 4 days. (C) Six days - showing a typical early HPC-CFU. 
(D)10 days after plating. (E -F) 14 and 28 days - showing a gradual loss of cells 









2.2.4  Discussion  
 
Numerous assays have been developed to culture mononuclear cells in order to 
isolate putative progenitor cells (PCs) that differentiate into ECs in-vitro and assay 
for colony forming capacity92, 101, 111, 118, 121. Two major cell types have been been 
shown to emerge from these cultures: (i) eCFUs, which display a mixed 
endothelial-haematopoietic/monocytic phenotype109, 121, 128 and (ii) OECs (late 
CFU) cells with a high proliferative potential that display typical endothelial 
characteristics110, 121, 122. We have successfully managed to reproduce and 
optimise the eCFU assay by growing colonies of spindle shaped cells from MNCs. 
Furthermore we have shown that these cells express CD31, VEGFR2, Dil and 
Lectin after 5 days in culture, which are not expressed at day 1. These results 
appear to confirm evidence in the literature that a population of cells present in the 
initial plated fraction progress to an endothelial-like phenotype101, 111, 132. It also 
confirms that circulating endothelial cells (CEC) were not the source of our day 5 
endothelial like cells. 
 
OEC growth was not reproducible and was achieved in less than 10% of attempted 
cultures. Many groups have published on successful OEC growth from both 
peripheral blood and umbilical cord blood110, 121, 122, 128. Our attempts proved highly 







 Adherent PBMCs did not stain with the EC markers (Dil/Lectin or 
CD31/VEGFR2) at 1 day. This suggests that HPCs and not circulating 
endothelial cells (CECs) were the origin of the colonies that formed by 5 
days. 
 eCFU growth did not occur below an initial plating concentration of 2.5 x 106 
cells/ml. This concentration was therefore used in all subsequent assays. 
 eCFU growth was highly dependent on the source of FCS and fibronectin 
 eCFU growth did not depend on the percentage of FCS present in EBM-2 
and therefore we have chosen to use 5% 
 The intra-assay variability of the CFU assay was~10% 






2.3 HPC Function 
2.3.1 General methods 
2.3.1.1 HPC Migration Assay  
The migratory capacity of HPCs toward a VEGF concentration gradient was 
examined using a modified Boyden chamber system254. 
 
i. Filters (1µm, BD Falcon HTS Fluoroblok) were coated in a solution of 
fibronectin (10g/ml in M199 culture medium – Sigma, UK) at least 24 hrs 
before the assay. Before use, the filters were washed with DMEM and 
placed into 24-well plates (BD Falcon).   
2 Isolated PBMCs were grown as per the eCFU assay procedure (2.2.2.2) 
3 After 5 days in culture, the culture media was gently aspirated and the cells 
were washed twice with pre-warmed sterile PBS. 
4 Cells were incubated with 3mls of DMEM supplemented with 2% charcoal 
treated FCS containing 5µg/ml of Calcein AM (Molecular Probes, UK) for  
2hrs at 37oC.  
5 Cell detachment from the plate was carried out by first washing the cells 
twice with pre-warmed sterile PBS followed by addition of 1ml of Accutase® 
solution (Invitrogen) and incubation for 5 mins at 37oC.  The plate was gently 




6 The detached cells were treated with 2mls pre-warmed DMEM to neutralise 
the Accutase. The cell suspension was then transferred into sterile 15ml 
conical-bottom tubes (Falcon, BD). 
7 The suspension was centrifuged at 400g for 5mins at 22 oC , and the pellet 
resuspended in pre-warmed DMEM and centrifuged once more at the same 
speed. 
8 After a second wash the pellet was resuspended in pre-warmed DMEM 
containing 3.5mg/ml BSA and the cell numbers adjusted to 105 cells/ml.  
9 300µl of the cell suspension was placed into the top chamber of each 
Fluoroblok insert.  
10 Simultaneously, 1ml of the test solution (50ng/ml recombinant VEGF protein 
[R and D systems] in DMEM containing 3.5mg/ml BSA) or control solution 
(DMEM containing 3.5mg/ml BSA) was placed in the lower chamber.  
11 The wells were incubated at 37oC and fluorescence intensity measured 
every hour using a bottom reader fluorimeter (Perkin-Elmer Victor 3). 
 
2.3.1.2 Senescence Assay 
HPC senescence was measured by staining for senescence-associated β-
galactosidase activity 255. 
 
1. Isolated PBMCs were grown as per the CFU assay procedure in 
fibronectin-coated chamber slides (Nunc) (see 2.2.2.2).  After 5 days in 




2. 1ml of pre-warmed 300µM chloroquine (ImaGene Green Kit, Molecular 
Probes) in EBM-2 medium (Cambrex) was added to the cells in each 
well and incubated for 1hr at 37oC.  
3. Neat C12FDG (ImaGene Green Kit – Molecular Probes) substrate was 
added to the chamber slide directly to achieve a final concentration  of 
33µM, the solution was gently mixed, and incubated for 1hr at 37oC. 
4. The cells were washed twice with pre-warmed PBS before being fixed 
with 2% paraformaldehyde in PBS for ten minutes.  
5. The slide was washed twice with PBS. 
6. The chambers were removed and the slide mounted with Vectorshield 
containing DAPI.  
7. The slides were viewed under a fluorescent microscope. HPC 
senescence was quantified as a percentage of the total number of cells 
staining positive for β galactosidase. 
 
2.3.1.3 Optimisation experiments 
The following experiments were carried out to optimise the migration assay 
(section 2.3.1.2). 
 Use of microvascular endothelial cells (MVEC’s) as positive controls. 
 Use of 0.5mmol EDTA, 1%Trypsin EDTA, and Accutase to determine 




 Comparison of different concentrations of VEGF to induce optimal 
migration (25, 50, 75ng/ml). 
 
2.3.2 Results 
2.3.2.1 Migration Assay 
A typical curve produced from the migration of cultured HPCs (from a healthy 
volunteer) towards VEGF or a control solution is shown in Fig 23. It can be seen 
that there is migration of HPCs in the absence of a chemotactic agent such as 
VEGF (control curve). Addition of VEGF (50ng/ml) to the solution in the bottom 
chamber significantly increases the migration rate of HPCs (P<0.001, ANOVA). 
Migration appeared, however, to equalise by 24hrs. The effect of the chemotactic 
stimulus was therefore expressed as a percentage increase in the fluorescence in 
response to the VEGF solution compared to the control solution at 4hrs (peak 
migration rate). The intra-assay variability for this was 12% (n=6 HPC isolates, 
























Fig 23. A typical migration curve for HPCs from a single patient showing 
positive (VEGF 50ng/ml) and control curves (n=3 at each point). 
 
The effect of varying the concentration of VEGF on the migration of HPCs cultured 
from healthy volunteers is shown in Fig 24. The highest concentration of VEGF 
(75ng/ml) induced the greatest migratory response (VEGF:control fluorescent 
ration of 1.34, i.e an increase of 34% over control, P<0.001, ANOVA),  with no 
response over control levels from the lowest concentration of VEGF, (25ng/ml, 1% 
migration, P=0.43, ANOVA). There was no difference in the migration of HPCs 


























Fig 24 The effect of varying the concentration of VEGF on migration of HPC’s 
(mean of triplicates at each concentration).  
 
2.3.2.2 Senescence assay 
Fig 25 shows a typical stain for SA-Bgal activity in cultured HPCs. Only cells 
brightly fluorescent green were counted as positive for B-galactosidase. The B-
galactosidase positive (green) and total number of cells (staining with the nuclear 
stain DAPI) were counted in 10 random fields. The number of B-gal positive cells 
was then expressed as a percentage of the total number of cells. The intra-assay 
variability was 15% (6 different slides grown from the same healthy volunteer). The 
inter-observer error (correlation between two observers over 5 different slides of 
HPCs each grown from a different healthy volunteer) was 12% (Pearsons 










The isolated HPCs in this study were shown to migrate to a VEGF chemotactic 
stimulus. There was a threshold concentration at which migration was increased, 
which was 50ng/ml. Above this concentration the overall migration did not increase 
significantly with increased concentrations of VEGF. By 24hrs the migration of 
HPCs in both the VEGF and control wells were similar, suggesting that all cells had 
passed through the filter by this time. The baseline migration in the control wells 
clearly shows that these cells may migrate through the filter in the absence of a 
stimulus. HPCs are known to secrete a number of growth factors such as VEGF 
and SDF-1256. These factors may have stimulated their slow migration in an 




VEGF, acting as a supraphysiological stimulus. Alternatively in the absence of a 
VEGF concentration gradient, HPCs may have migrated randomly across the 
fibronectin, (used to coat both sides of the 1µm filter) and with time, would have 
accumulated on the underside of the filter.  
 
2.3.4 Conclusion 
 HPCs migrate in response to VEGF, but there appeared to be no 
improvement in this response above 50ng/ml. 
 The migration was greatest at 4hrs, and equilibrates with that of the controls 
by 24hrs.  
 The intra-assay variability of the migration assay was 12%. 




2.4 Mesenchymal Stem Cells 
2.4.1 Overview of investigations 
2.4.1.1 MSC number 
Whole blood was stained as per the direct immunofluorescence protocol (2.1.2.1) 
using antibodies against CD34 – PerCP and CD45 – FITC, and either CD73-PE, 
CD90-PE or CD105-PE, in order to detect cells that were CD45-ve/CD34-ve/ 
CD73+ve/CD90+ve/CD105+ve i.e. identified as being of non-haematopoietic lineage, 
and analysed by flow cytometry. MSCs were defined as those cells that were 
CD45-ve /CD34-ve  and  CD73+ve or CD90+ve or CD105+ve 187 .  
2.4.1.2 MSC activity 
Isolated mononuclear cells were plated onto plastic dishes in DMEM culture 
medium containing 10% FBS. Adherent cells were incubated and passaged for up 
to four weeks190. Following culture cells were analysed by flow cytometry to see if 
they expressed the MSC phenotype. Senescence was to be measured as 
described above and migratory activity assessed using a PlGF concentration 
gradient 257 in a modified Boyden Chamber. 
 
2.4.2 General methods 
2.4.2.1 Mesenchymal Progenitor Cell Culture 




2. The pellet in step 7 was resuspended in low glucose DMEM (Cambrex) 
containing 10% foetal calf serum, 1% penicillin/Streptomycin (MSC 
medium),  to a volume one quarter the original volume of blood. 
3. The number of cells was counted using a haematocytometer, and the 
concentration adjusted  to 5 x 106 cells per ml. 
4. The cell suspension was incubated in 6 well plates (4mls/2x107 cells per 
well) in a 5% CO2 incubator at 37°C. 
5. The non-adherent fraction was removed at 48 hrs by gently aspirating 
the culture medium and replacing it with 2mls pre-warmed MSC medium. 
6. The medium was changed every 4 days thereafter. 
7. When the cells were 80% confluent they were passaged. Cell 
detachment from the plate was carried out by first washing the cells 
twice with pre-warmed sterile PBS followed by addition of 1ml of 
Accutase® solution (Invitrogen) and incubation for 5mins at 37oC.  The 
plate was gently tapped to encourage cells to detach. 
8. The detached cells were treated with 2mls pre-warmed DMEM to 
neutralise the Accutase. 
9.  The cell suspension was then transferred into sterile 15ml conical-
bottom tubes (Falcon, BD) and centrifuged at 400g for 5 mins at 22ºC. 
The pellet was resuspended in DMEM.  
10. After a second wash the pellet was resuspended in MSC medium and 




11. 4mls of the suspension was placed into each 25 ml flask, and incubated 
in a 5% CO2 incubator at 37°C.  
12. The cultured was continued as above.  
 
2.4.2.2 MACS magnetic labelling 
1. PBMNCs were isolated by Ficoll gradient as per 2.2.2.1. 
2. The PBMNC pellet (step 7 2.2.2.1) was re-suspended in autoMACS 
running buffer (Miltenyi) to a volume one quarter the original volume of 
blood. 
3. The cells were counted using a haematocytometer and the concentration 
adjusted  to 5 x 106 cells per ml. 
4. The cells were passed through a 30µm nylon filter to remove clumps. 
5. The primary antibody was added at the recommended dilution (mouse 
anti-human CD45 primary, Dako, 1:400) to the cell suspension, which 
was mixed well and incubated at 4ºC for 30 mins. 
6. The cells were washed by adding 10-20 times the labelling volume of the 
MACS buffer, centrifuged at 400g for 5 mins at 22ºC, after which the 
supernatant was removed. 
7. The wash step was repeated three times. 
8. The pellet was re-suspended in 80µl of MACS buffer per 107 total cells. 
9. 20µl of MACS indirect IgG Microbeads (goat anti-mouse microbeads - 
Miltenyi) was added to 107 cells. The suspension was mixed well and 




10. Cells were washed  as per step 6, three times and finally  resuspended 
in 500µl MACS buffer per 108 total cells.  
 
2.4.2.3 MACS magnetic separation  
1. An appropriate column type was chosen (MS for up to 107 total cells or 
LS for up to 108 total cells) and placed in the magnetic field of a suitable 
MACS separator.  
2. The column was prepared by washing with an appropriate amount of 
MACS buffer (MS – 500µl, LS 3mls). 
3. The cell suspension was pipetted into the top of the column. The cells 
that have not been labelled pass through. Once the cell suspension has 
passed through, the column was rinsed with appropriate amount of 
MACS buffer (MS 3x 500µl, LS 3x3mls). 
4. The filtered cell suspension was then centrifuged at 400g for 5 mins at 
22ºC, after which the supernatant was removed and the cells 
resuspended in MSC medium. 
 
2.4.2.4 Optimisation Experiments for Cell Culture 
The following experiments were carried out to determine the optimal cell culture 
conditions.  
 The initial plating concentration of PBMNCs in step 3(2.4.2.1) was varied   (5 




 The concentration of FCS in the MSC medium was varied (2.4.2.1 step 2 - 
20%, 10%, 5%) 
 Batch testing FCS (from Sigma, Gibco, Hyclone) 
 Complement depletion of FCS (heating for 30 mins at 60°C) 
 CD45 cell depletion using MACS microbead cell separation (CD45 mouse 




2.4.3.1 Measuring MSCs by flow cytometry 
Whole blood from healthy volunteers was stained as per the direct 
immunofluorescence protocol (2.1.2.1) in order to detect MSCs. Flow cytometric 
analysis revealed that after the CD34-ve/CD45-ve cell fraction was selected (Fig 26a) 
we were unable to detect any cells expressing CD90 (Fig 26b). We also failed to 
detect CD34-ve/CD45-ve/ CD73+ve cells (Fig 26c) or CD34-ve/CD45-ve/CD105+ve cells 
(Fig 26d). Varying the antibody concentration, incubation temperature or incubation 
time had no effect on the detection of MSCs in the peripheral circulation. We were 





Fig 26a. Dot plot of CD45-FITC (FL1) versus CD34-PerCP (FL3) 
Area 1 contains cells that are double positive for CD45 and CD34  
Area 2 contains cells that are double negative for CD45 and CD34  
 
Fig 26b. Dot plot of CD34 - PerCP (FL3) versus CD90 - PE (FL2) 








Fig 26c. Dot plot of CD34 - PerCP (FL3) versus CD73 - PE (FL2) 
Only cells that were CD34 and CD45 negative (area 2 in Fig 26a) are shown. 
 
Fig 26d. Dot plot of CD34 - PerCP (FL3) versus CD105 - PE (FL2) 




2.4.3.2 Mesenchymal Progenitor Cell Culture 
MSC isolation was attempted by culturing peripheral blood MNCs from healthy 
volunteers (2.4.2.1). The cultured cells (Fig 27) did not demonstrate the rapid 
proliferative characteristics as described in the literature, even after cell passage. 
FACS analysis of 4 week old cells (Fig 28) that had been passaged once showed 
that all cells were CD45 positive and therefore not MSCs. In order to rule out 
experimental error the following experimental conditions were altered:  initial 
plating concentration of PBMNCs; the concentration of FCS in the culture medium, 
and source of FCS; complement depletion of serum; and depletion of leukocytes 
using CD45-linked MACS microbead cell separation. None of these changes 
resulted in the growth of MSCs. 
 
 
Fig 27. Light microscope picture of cells (x20) from MSC culture (day 14). 





Fig 28. Dot plot of CD45-FITC(FL1) versus CD90-PE(FL2).  All cells were CD45 
+ve and none were CD90 +ve. 
 
2.4.4 Discussion  
 
The culture of mononuclear cells on plastic dishes in DMEM containing 10% FBS 
and subsequent passage190 has been shown to result in a population of fibroblast-
like cells, which have been characterized as MSCs based on their ability to 
differentiate into multiple mesenchymal lineages (e.g. osteogenic, chondrogenic, 
myogenic, etc.) 190. We have been unable to measure MSCs in the circulation 
through FACS analysis or using the same cell culture technique. There are several 
possible reasons why this might have occurred. The methods used for their 
detection were those previously used to identify MSCs in the bone marrow190, 258. 




events that stimulate mobilisation from the bone marrow such as myocardial 
infarction259 or fractures260. The latter study also failed to identify them in the 
control groups of pre- and post-menopausal women, and elderly patients with 
osteoarthritis. Our group of patients and healthy volunteers may simply have no 
circulating MSCs or have so few that they lay below the detection threshold of our 
measurement systems. Alternatively there may have been a methodological 
problem that prevented us from detecting these cells. Positive controls are 
sometimes used in these instances. We had access to patients with long bone 
fractures that according to the literature would have been more likely to have 
circulating MSCs 260, but even in this cohort, less than half of the patients have 
raised circulating MSC numbers. This inconsistency would have introduced 
variability into our analyses making interpretation of results difficult if these patients 
were used as positive controls.  
 
2.4.5 Conclusion 
 We were unable to measure MSCs in the peripheral blood by flow cytometry 
or cell culture. 
 This may be as a result of their low numbers in the circulation which lies 
below the detection threshold for our assays 
 This may also be a result of methodological problems which we were unable 





2.5 Cytokine measurement  
 
The plasma concentrations of the cytokines VEGF, GM-CSF, SDF-1, and PLGF 
were analysed by multiplex ELISA (Searchlight, Pierce Biotechnology, UK). 
SearchLight Protein Array Technology is a multiplexing sandwich-ELISA system 
based on chemiluminescent detection of analytes whose respective capture-
antibodies are spotted in arrays within each well of a 96-well microplate. The 
protein binding to the capture antibody in an array can be detected directly. As 
many as 16 analytes (4 x 4 array in each well) can be measured per well, meaning 
that 16 cytokines or other biomarkers can be assayed simultaneously with each 
50 µl sample. 
Compared with traditional ELISA, multiplex arrays have a number of advantages 
261 including:- 
a) high output multiplex analysis 
b) less sample volume needed 
c) efficiency in terms of time and cost 
d) ability to evaluate the levels of one given inflammatory molecule in the context of 
multiple others 
e) ability to reliably detect different proteins across a broad dynamic range of 
concentrations. 
 
We used the custom sample testing service which allowed us to select individual 
cytokines. 4mls of sodium citrate anticoagulated blood was centrifuged at 1500g at 




0.25mls were placed in eppendorf tubes. Samples were snap frozen in liquid 
nitrogen and stored at -80 ºC until analysis.  
 
2.6 Quantification of risk of further stroke 
 
The Oxford Risk Tables (www.stroke.ox.ac.uk) were used to predict the 1yr and  
5yr absolute risk of ipsilateral ischaemic stroke (as a percentage) in patients with a 
recently symptomatic carotid stenosis. The program is based on the results of Cox 
regression model of patients who had been randomised to medical treatment in the 
European Carotid Surgery Trial (ECST)13, 262. This involves five variables that were 
both significant predictors of risk in the ECST model 262 and yielded clinically 
important subgroup treatment effect in pooled analysis16. The model from which 
the tables were derived have been validated against the NASCET trial16. The five 
variables are: sex, age, time since last symptomatic event, type of presenting event 
and carotid plaque surface morphology. The risk prediction produced by the model 
is not a prediction of likely benefit from endarterectomy. The procedural risk and 






2.6.1 Oxford risk tables definitions  
Degree of stenosis This refers to the maximum degree of linear stenosis at or 
around the symptomatic carotid bifurcation by method of measurement used in the 
NASCET trial and the Carotid Endarterectomy Trialists’ Collaboration 12.  
  
Time since last event: refers to the most recent ipsilateral vascular symptomatic 
event. Accepted values for this variable are limited to between 7 days and 180 
days.  
  
Primary symptomatic event. This refers to the most “severe” ipsilateral vascular 
event during the previous 6 months (major stroke > minor stroke > multiple 
cerebral TIAs > single cerebral TIA > monocular TIA or retinal artery occlusion). 
Major stroke - defined as a non-disabling stroke with residual neurological 
symptoms after 7 days. 
Minor stroke - defined as a stroke with symptoms lasting between 24 hours and 7 
days. 
TIA - defined as an event with symptoms lasting up to 24 hours. 
  
Plaque surface morphology- irregular or ulcerated plaque surface. This is 
based on the surface morphology of the symptomatic carotid plaque as visualised 
on conventional arterial angiography, which was the imaging investigation of 
choice in the ECST. A patient with strong evidence of lipid rich or 




as having irregular or ulcerated plaque. Imaging is used as a substitute to histology 
in the program based on evidence that angiographically irregular and ulcerated 
plaque has been shown to be highly correlated with lipid-rich unstable or ruptured 
plaques on histology263 The program assumes that it will be used by 
clinicians/surgeons before CEA and therefore the actual morphology of the plaque 
will not be known. Since all patients in our study underwent CEA, we were able to 
enter data on the exact morphology of the plaque. 
 
 
2.7 Study Design  
 
St Thomas’ Hospital forms part of the Guy’s and St Thomas’ NHS Foundation 
Trust and is a tertiary referral centre for the treatment of a variety of vascular 
diseases. In excess of 50 carotid endarterectomies (CEA) are carried out each 
year. The aim of this study was to recruit sufficient patients over a 2-year period to 
provide a sample of at least 10-15 restenotic patients. We planned to collect a 
sample of 30mls of peripheral blood on the morning of the procedure, and 1 day 
and 6 weeks post procedure, and measure HPC numbers and activity. Blood was 
collected in EDTA anticoagulated tubes and processed for flow cytometry, 
functional assays or plasma extraction within 1 hour of collection. Plasma samples 





2.7.1 Patient group  
 
All patients undergoing primary CEA at St Thomas’ were eligible for inclusion. 
Subsequent exclusion criteria are outlined below. The study was carried out under 
existing ethics approval ‘Tissue and blood samples for the study of aortic and 
peripheral vascular disease  -  pathogenesis and  circulating markers (occlusive 
disease) – EC 03/098 St Thomas’ Hospital Ethics Committee’. (Appendix A). 
Patients were identified from the theatre lists and approached 24 hrs prior to the 
proposed collection of the first blood sample (i.e the day before surgery). The 
patient was provided with an information sheet and informed consent was 
obtained.  
 
Symptomatic patients were defined as those that had experienced a sudden onset 
of loss of global or focal cerebral function, which was either permanent (stroke) or 
lasted less than 24 hours (TIA - including amaurosis fugax). Asymptomatic patients 
were defined as those who had never experienced symptoms. All patients had an 
internal carotid artery stenosis >70% demonstrated via duplex ultrasonography 




2.7.2 Duplex assessment of restenosis 
 
All patients who have CEA at St Thomas’ Hospital currently have surveillance 
duplex scanning at 3, 6 and 12 months as part of their routine clinical follow-up. 
Internal carotid stenosis was graded from the absolute peak systolic and diastolic 
velocities in the ICA and the ratio of peak systolic velocities in the ICA and 
common carotid artery (CCA)264. These criteria have been validated against 
angiographicaly measured stenosis using the NASCET technique265 and recently 
formed part of the recommendations for the reporting of ultrasound investigations 
of the extra cranial arteries produced by a Joint Working Group formed between 
the Vascular Society of Great Britain and Ireland, and the Society for Vascular 
Technology of Great Britain and Ireland266. PSV ratios (ICA/CCA) of 2.0, 2.5 and 
3.4 were used to identify stenoses of 50, 60 and 70 per cent respectively. PSV 
ratios of >4 and >5  identified stenoses of >80 and >90 per cent respectively 264, 266. 
The data on the degree of restenosis at the different time intervals was not 
collected until the end of the study period. 
 
2.7.3 Exclusion criteria 
Acute/ chronic inflammation as evidenced by a raised white cell count or C-reactive 
protein, subsequent episode of acute coronary syndrome or myocardial infarction, 
subsequent episode of critical lower limb ischaemia as defined by the onset of rest 






2.7.4 Data collection 
All data was collected prospectively and included (i) clinical details such age, sex, 
co-morbidities, medication, presenting complaint that led to endarterectomy and 
degree of ICA stenosis; (ii) haematological variables such as differential leukocyte 
count, renal function and serum cholesterol and (iii) procedural details such as the 
use of patch repair, shunt and general or local anaesthesia. (Appendix B). 
 
 
2.7.5 Data analysis and power calculation 
The numbers of progenitor cells, their activity and the change in these end points 
over time were correlated with the presence of restenosis. All statistical analysis 
was carried out using SPSS 14.0 and all data tested for normality. Parametrically 
distributed data are given as mean ± standard deviation (SD) for population data or 
standard error of the mean (SEM) for sample data and analysed using either t-test 
or paired t-test as appropriate. Non-parametrically distributed data are given a 
median with ranges and analysed by Mann Whitney U test, or Wilcoxon Signed 
Rank test (if paired). Correlations were carried out by Spearman rank or Pearson 
rank as appropriate. Analysis by ANOVA was used when comparing temporal 
changes. Multivariate analysis was used to analyse associations between clinical 
(such as diabetes, smoking and hypertension) and haematology variables 





The number of patients (n=15) with restenosis post CEA is sufficient to give a 
power of 80-90% to detect a difference between groups with a statistical 
significance of p<0.05. This power calculation is based on an approximation of 
variation (~up to 30%) in circulating HPC numbers taken from the literature 267. A 
more than 30% difference in HPC numbers between restenosis and non-restenosis 
groups are considered important differences. The incidence of restenosis (>50%) is 
10-20% in the first year following CEA29-31. Thus a total number of between 60-100 





3. MEASURING HPC NUMBER AND FUNCTION IN 
PATIENTS UNDERGOING CAROTID 
ENDARTERECTOMY 
 
A total of 62 patients were recruited to the study. Patient recruitment began when 
the methodology for the FACS detection of CD133+ve/CD34+ve had been  
optimised. The HPC-CFU, migration and B-galactosidase assays were optimised 
later and this led to an initial cohort of patients (n=15) in which there were 
incomplete assay data sets. Figures 29 and 30 summarise the investigations 
performed on all 62 patients.  
 
Fig 29. Flow Diagram of the investigations performed on the 62 patients 




Initial Cohort incomplete assay 
data (Fig 30) 
47  
FACS, CFU, Migration & B-Gal  
24 
Pre, Post & 6 weeks post-operative 
data analysed  
22 
Pre & post-operative data 
anlaysed 
1 
Pre-operative data only 
24  





Fig 30. Flow diagram of the investigations performed on the initial cohort of 
15 patients recruited to the study 
 
The first 15 patients all had FACS analysis of circulating CD133+/CD34+ cell 
number and also had other investigations as outlined in Figure 30. The 
investigations were carried out at the three different time points (pre-operatively 
[morning of operation], 24 hrs post-operative and 6 weeks post-operative) in 8 
patients, and in a further 6 only at the pre and post-operative time points. The latter 
6 patients either refused to have the 6 week blood sample taken (4) or did not 
attend the follow up appointment at all (2).  A further patient had blood taken but 
the cultures became infected and therefore further analysis was not possible.  
 
The following 47 patients recruited to the study had the full set of investigations i.e. 







Patients 4-8  
FACS, 
CFU assay 
Patients 9-15  
FACS, CFU &  
B-Gal assays 
 
All Pre & post-operative 
 
2  Pre & post-operative 
 3 Pre, Post & 6 weeks  
post-operative  
1-Pre 
1 Pre & post-operative 





number of time points that this set of investigations were done (Fig 29). 24 patients 
had the full set of investigations performed at the three different time points i.e pre 
and post-operatively and 6 weeks post-operatively. A further 22 patients had the 
full set of investigations at the pre- and post-operative time points, but not at the 6 
week follow up. These 22 either refused to have further blood taken at the 6week 
follow up (12) or did not attend the 6 week follow-up (10). A single patient having 
had the full set of investigation on the pre-operative sample refused to have any 
further blood taken. The numbers included in the following analysis will therefore 
vary and reference should be made to Figures 29 and 30 for clarification.  
 
3.1 Patient demographics and procedural details 
 
The 62 patients recruited to the study had a mean age of 71yrs (±8.5SD) and 
consisted of 44 males and 18 females. 20 patients had suffered from strokes and 
20 from transient ischaemic attacks (including amaurosis fugax) within the 6months 
prior to CEA.  22 patients were classified as asymptomatic in the last 6 months. Of 
these patients 18 had never experienced symptoms. The mean stenosis of the 
internal carotid artery was 79%(±11) on the ipsilateral side and 56%(±25) on the 
contralateral side to endarterectomy. The mean time from symptoms to 
endarterectomy was 7.4 weeks (±11.5).  
The atherosclerotic risk factors in the study group are given in Table 10. 
Hypercholesterolaemia (92%), smoking (73%) and hypertension (76%) were the 




platelet agents aspirin (46) or clopidogrel (16). The cholesterol lowering statins 
were taken by 57 of the 62 patients, with the remaining 5 having stopped them in 
the past because of side effects. Patients were also on a number of anti-
hypertensive medications including β-blockers (27), diuretics (21), ACE inhibitors 
(28), angiotensin II receptor antagonists (7) and Ca channel antagonists (24). All 
patients with hypertension were on 1 or more antihypertensive medications.  
 
Table 10. Atherosclerotic risk factors in patient group 
 
 
Risk Factors % of patients 
Hypertension 76 
Diabetes 24 
Ischaemic Heart Disease 43 
Smoker 73 
High Cholesterol 92 
Peripheral Vascular Disease 19 
Renal Failure 7 
 
 
Pre-operative differential leukocyte counts are given in Table 11. Comparison of 
leukocyte counts pre and post-CEA showed that there was a rise in total leukocyte 
numbers (x109cells/L, mean±SD), 8.2(±2.2) n=62 to 10.4(±3.4) n=53, P<0.001). 




(5.4(±2.2) to 8.0(±3.5), P<0.001); a reduction in lymphocyte numbers (1.9(±0.72) to 
1.5(±0.48), P<0.001); and a small, but non-significant increase in the monocyte 
count (0.67 (±0.18) to 0.72(±0.32), P=0.28, all paired t-test).  
 








Total leukocyte ( x109 cells/L) 8.2(2.2) 10.4(3.4) <0.001 
Neutrophils ( x109 cells/L) 5.4(2.2) 8.0(3.5) <0.001 
Lymphocytes ( x109 cells/L) 1.9(0.7) 1.5(0.5) <0.001 
Monocytes ( x109 cells/L) 0.67(0.2) 0.72(0.3) NS 
 
 
The majority of CEAs (84%) were carried out under general anaesthesia. There 
was a slight predominance of left sided CEA (61%). Patch angioplasty following 
endarterectomy was performed in 63% of patients and only 37% of patients 
needed an intra-operative carotid shunt (Table 12). There was one stroke and one 
TIA intra-operatively, and one patient had to return to theatre because of post-
operative bleeding. There were no mortalities or other complications within the 12 




Table 12 Procedural characteristics 
 
Procedure % of patients 
Left side 61 
Patch  63 








There was an 11.3(±4.7)% 1 year risk and a 27.8(±11)% 5 year risk of a further 
ipsilateral ischaemic stroke for symptomatic patients (n=40) as assessed using the 
Oxford tables. There were no correlations between the 1yr and 5yr risk of stroke 
and pre-operative circulating CD133+ve/CD34+ve cells (n=40, R=-0.01, P=0.95 and 
R=-0.001, P=0.99), eCFU number (n=38, R=0.08, P=0.64 and R=0.06, P=0.73), 
HPC migration capacity (n=29, R=0.06, P=0.77 and R=0.07, P=0.72) or HPC 
senescence (n= 35, R=0.15, P=0.38 and R=0.17, P=0.33) all analysed using 
Spearman’s rank correlation). There were no significant relationships between 
other clinical parameters (such as co-morbidities) and operative parameters (such 








 cell number following  
endarterectomy 
 
Circulating CD133+ve /CD34+ve cells (per 200,000 PBMNC) were measured by flow 
cytometry in 62 patients undergoing CEA pre-operatively, in 61 patients post-
operatively and in 34 patients at 6 weeks post-operatively. There was a significant 
reduction in circulating CD133+ve /CD34+ve cell numbers 1 day post-operatively, 
with no significant change from 1 day post-operatively to 6 weeks post-operatively 
(P<0.001, Friedmans Test, pre-op vs 24hr post-op, P<0.05, 24hr post-op vs 6wks 
post-op, P>0.05, and pre-op vs 6 weeks post-op, P<0.05, Dunn’s post test, Table 
13 and Fig 31). Analysis of CD133+ve and CD34+ve individual cell populations 
revealed a similar pattern (Table 13 and Fig 32, 33). 
 
The post-operative changes varied greatly between patients. CD133+ve /CD34+ve 
cell numbers fell 24hrs post-operatively by a median of 28%, with a range from a 
fall of 75% to a rise of 50% (Fig 35). The change from postoperative levels to 6 
week levels were also highly variable. The median rise was 28% with the range 





Table 13. Changes in CD133+ve/CD34+ve, CD133+ve and CD34+ve cell 
populations pre-operatively, 24hr and 6 weeks post-operatively (number of 
cells/200,000 PBMNCs; * Friedman’s test). 










CD133+ve/CD34+ve 111(32-508) 82 (8-293) 73 (24 - 436) <0.001 
CD133+ve 128(35-527) 99(25-326) 102(29-554) <0.001 
CD34+ve 151(33-594) 122(10-413) 86(15-455) <0.001 
 




























Fig 31. Changes in the number of PBMNCs expressing both CD133 and CD34 
pre-operatively, 24hr and 6 weeks post-operatively (Bars=interquartile range, 



























Fig 32. Changes in the number of PBMNCs expressing CD133 pre, 24hr post 
and 6 weeks post-operatively (Bars=interquartile range, Friedman’s Test) 
























Fig 33.  Changes in the number of PBMNCs expressing CD34 pre, 24hr and 6 





3.4 eCFU assay 
 
HPC number was measured by eCFU assay in 58 patients pre-operatively, in 57 
patients post-operatively and in 33 patients at 6 weeks post-operatively. There was 
a significant reduction in eCFU numbers (mean [±SD]) 1 day post-operatively 
followed by a rise to pre-operative levels by 6weeks post-operatively (16(±3.5), 
13(±3.5) and (16(±3), pre-op, 1 day post op and 6 weeks post-op respectively, 
P=<0.001, ANOVA, pre-op vs 24hr post-op, P<0.05, 24hr post-op vs 6wks post-op, 
P<0.05, and pre-op vs 6wks post-op, P>0.05, Bonferroni’s post test, Fig 34). The 
post–operative change in eCFU number varied greatly between individuals (similar 
to that seen for circulating CD133+ve/CD34+ve cells). The mean(±SD) percentage 
fall from pre to post-operative levels was 17.4 (±14)% with a range varying from a 
fall of 50% to a rise of 9%. The mean rise from post-operative to 6 weeks levels 
was 29(±27)% with a range varying from a fall of 13% to a rise of 125%. The 
variation in the percentage change from preoperative to postoperative levels in 





























































Fig 35. Distribution in the percentage fall of CD133+ve/CD34+ve cell and eCFUs 






















Fig 36. Correlation of pre-operative CD133+ve /CD34+ve number with eCFU 
number (Spearman’s correlation). 
 
The similar pattern of change in post-operative CD133+ve/CD34+ve cell number and 
eCFU number led us to investigate the relationship between the two variables. 
There was no direct correlation between CD133+ve/CD34+ve cell number and eCFU 
number  (R=-0.17, P=0.18, Fig 36). 
 
3.5 HPC migration 
 
HPC migration was measured in 47 patients pre-operatively, in 39 patients post – 
operatively and a further 24 of these also had measurements at 6 weeks. The 
migration capacity of HPCs was expressed as the percentage increase in the 




vehicle control (baseline). There was no significant change in the HPC migration 
capacity post-operatively or at 6 weeks (P=0.72 ANOVA, P>0.05 for all group 
comparisons - Bonferroni’s post test, Table 14). 
 
Table 14.  Migration of HPCs isolated from the blood of patients undergoing 





intensity above baseline 
SD 
Pre-operative 19.7 10.2 
1 day post-operative 20.2 9.4 
6 weeks post-operative 21.7 10 
 
3.6 HPC senescence 
 
HPC senescence was measured in 54 patients pre operatively, in 46 patients post-
operatively and a further 26 of these also had measurements at 6 weeks. The 
mean (±SD) pre-operative progenitor cell senescence was 26.2 (±4.2)%. There 
was no significant difference in the HPC senescence measured pre-operatively, 
post-operatively and 6 weeks post-operatively (P=0.7 - ANOVA, P>0.05 for all 





Table 15. Senescence of HPCs isolated from the blood of patients 
undergoing CEA pre, post and 6 weeks post-operatively (P=0.7, ANOVA). 
 
HPC senescence % Senescence (mean) SD 
Pre-operative 
26.2 4.2 
 1 day post-operative 
25.6 5.2 




3.7 The relationship between restenosis and HPC number 
and function  
 
3.7.1 Restenosis after CEA 
 
Postoperatively, 51 patients attended for the 3 month scan, 44 for the 6 month 
scan, and 24 for the 12 month scan. There was a significant progression in the 
degree of ICA stenosis over this period (median(range) 3 months – 16(15-70)%, 6 
months - 30(15-90)%,  12 months - 40(16-80)%, P<0.001, Kruskal Wallis, Fig 37). 
Post test (Dunns) showed that there was a significant change (P<0.05) from 3 to 6 






















Fig 37. Percentage restenosis following CEA as measured by Duplex 
ultrasonography at 3 (n=51), 6 (n=44) and 12 (n=24) months post-operatively 
(Bars = median, Kruskal Wallis test) 
 
3.7.2 Pre-operative circulating HPC number and restenosis 
 
Significant restenosis (i.e. ≥50%) was seen in 6 out of 51 (11%) patients at 3 
months, 15 out of 44 (33%) patients at 6 months and 8 out of 24 (33%) patients at 
12months. There was no significant difference in the number of pre-operative 
circulating CD133+ve/CD34+ve cells in patients who developed <50% restenosis 
compared with those that developed >50% restenosis (Table 16) at the 3month 
scan (P=0.5, Mann Whitney U test). This was also the case for restenosis at 6 
month (P=0.43, Fig 38); and at 12 month scans (P=0.27, all Mann Whitney U test). 




restenosis at the 3, 6 and 12month scans (Table 16) and for 1 day post-operative 
and 6 weeks postoperative counts. 
 
Table 16. Pre-operative CD133+ve/CD34+ve cell and eCFU counts in patients 
with restenosis <50% compared with ≥50% at the 3, 6 and 12 months scans. ( 













cells numbers       










































































Fig 38. Pre-operative CD133+ve/CD34+ve cell count in patients with 



















Fig 39. Pre-operative eCFU count in patients with restenosis at 6 months 





3.7.3 Post-operative change in HPC number and restenosis 
 
Patients who developed a restenosis of <50% had a significantly greater post-
operative fall in CD133+ve/CD34+ve cells when compared with those that developed 
restenosis of ≥50% at the 6 month scan (P=0.044, Table 17, Fig 40), but not at the 
3 month or 12 month scans (P=0.66 and P=0.95 respectively, all Mann Whitney U 
test, Table 17). Patients with a restenosis of <50% at the 6 and 12month scans 
also had significantly greater falls in eCFUs post-operatively when compared with 
those who had ≥50% restenosis at these times (P=0.003, Fig 41 and P=0.03, all t-
test, Table 17). However this difference was not present when comparing the two 






























Fig 40. The post-operative percentage fall in CD133+ve /CD34+ve cells in 





Table 17. Percentage fall in CD133+ve/CD34+ve  cell and eCFU numbers 24hr 
post-operatively in patients with restenosis <50% compared with ≥50% at the 
3, 6 and 12 months scan ( # Mann Whitney U test;  *Students t-test) 
 
Post-op scan time 
(months) 
 






































































Fig 41. The post-operative percentage fall in eCFU number in patients 
developing restenosis at 6months (t-test)  
 
When restenosis was analysed as a continuous variable, there was a negative 
correlation between the percentage fall in circulating CD133+ve/CD34+ve cell 
numbers post-operatively and the degree of restenosis at 6months (P=0.013, 
Table18), with greater falls associated with a smaller degree of restenosis 
(Fig.42B). There were no significant correlations between these variables at 3 and 
12months (Fig 42A and Fig42C). The post-operative fall in CFU number also 
correlated negatively with degree of restenosis at 6 (P=0.008, Fig 43B) and 






Table 18 Association between the post-operative change in HPC number and 
function and restenosis as a continuous variable at 3, 6 and 12 months (R= 




Duplex Scan Time (months) 
    3  6 12 
CD133+ve/CD34+ve 
post-op change (%) 
  
R -0.26 -0.38 -0.01 
P value 0.071 0.013 0.97 
N 48 41 23 
eCFU R -0.07 -0.42 -0.49 
post-op change (%) P value 0.66 0.008 0.026 
  N 45 38 20 
HPC Migration R -0.22 -0.48 -0.53 
  P value 0.172 0.007 0.05 
  N 39 31 14 
HPC Senescence R 0.27 0.33 0.10 
  P value 0.081 0.05 0.70 
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% Restenosis at 12months










































Fig 42. The relationship between post-operative percentage fall in CD133+ve 
/CD34+ve cell  number  and restenosis as a continuous variable at: A) 3 
months: B) 6 months; C) 12 months  (R=Spearman’s Rank Correlation) 
A
























































Fig 43. The relationship between post-operative fall in HPC-CFU number and 
restenosis as a continuous variable at:  A) 3 months; B) 6 months;  C) 12 




Table 19. Percentage rise in CD133+ve/CD34+ve  cell and eCFU numbers 1 day 
to 6 weeks post-operatively in patients with restenosis <50% compared with 
≥50% at the 3, 6 and 12 months scan. ( # Mann Whitney U test;  *Students t-
test) 
 
Post-op scan time 
(months) 
 





















































There was no significant change in CD133+ve/CD34+ve cell number from 1 day post-
operatively to 6 weeks post-operatively (section3.4). There was no significant 
relationship between the magnitude of this change and restenosis at 3, 6 or 12 
months (Table 19). Patients with a restenosis of <50% at the 6 month scan had a 
significantly greater rise in eCFUs from 1 day to 6 weeks post-operatively when 
compared with those who had ≥50% restenosis (P=0.04 t-test, Table 19) mirroring 
the relationship observed between restenosis and the post-operative fall in eCFU 
numbers. This relationship was not present when comparing the two groups (<50% 
vs ≥50% restenosis) on the 3month (P=0.6) and 12 month scans (P=0.06, both t-
test). 
 
3.7.4 HPC function 
 
Preoperative HPC migration was significantly higher in patients who had <50% 
restenosis at 6 and 12 months compared with those that had >50% restenosis 
(P=0.01, Fig. 44 and P=0.02 respectively, t-test, Table 20). There was no 
difference in HPC migration at 3months (P=0.45) HPC migration correlated 
negatively with restenosis as a continuous variable (Table 18) at 6 months (R=-
0.48, P=0.007, Fig. 45B) and 12months (R=-0.53, P=0.05,  all Spearman’s Rank 
Correlation, Fig 45C). There was no correlation between HPC migration and 
degree of restenosis at 3months (P=0.17, Fig 45A). 
 
There was no association between HPC senescence and restenosis (<50% vs 




Table 20). There was no significant correlation between HPC senescence and 
restenosis as a continuous variable at any of the scan times (Table18).  
 
Table 20. HPC migration and senescence of pre-operatively isolated cells 
from patients who developed restenosis <50% compared with those who 





    (months) 
Restenosis P-value * 
 











































































Fig 44. Pre-operative HPC migratory capacity in those patients with a 
restenosis of <50% and >50% at 6 months (t-test). 
A



























































































Fig 45. The relationship between pre-operative HPC migration and restenosis 
as a continuous variable at:  A) 3 months; B) 6 months; C) 12 months 




3.8 Cytokine levels and restenosis 
 
The circulating levels of cytokines known to be involved in HPC mobilisation and 
chemotaxis were measured in the cohort of patients that had the full set of HPC 
investigations at all three time points (i.e. pre-, 24hrs and 6 weeks post-operatively, 
n=24, Table 21).  GM-CSF and PlGF levels fell 24hrs post-operatively before rising 
at 6wks, however these changes were not significant (P=0.47 and P=0.46 
respectively, ANOVA, Fig 46). SDF-1 levels fell significantly post-operatively and 
rose to pre-operative level by 6weeks (P=0.003 Repeated measures ANOVA, Fig 
46, P<0.05 – pre-op vs 24hr post-op and P<0.05 - 24hr post-op vs 6wks post-op, 
P>0.05 – pre-op vs 6wks post-op, Bonferroni’s post test) The circulating levels of 
VEGF increased 24hrs post-operatively and continued to rise by 6weeks (P=0.028, 
Repeated measures ANOVA, P>0.05 – pre-op vs 24hr post-op, P>0.05 - 24hr 
post-op vs 6wks post-op, P<0.05 – pre-op vs 6wks post-op, Bonferroni’s post test, 
Fig 46). There was no association between any of the cytokine levels and the 
degree of restenosis when analysed as either a binary end point (i.e <50% vs 
≥50%) or as a continuous variable (Table 22). 
 
Pre-operative SDF-1 levels correlated with circulating CD133+ve/CD34+ve cell 
numbers pre-operatively (R=-0.46, P=0.025, Fig 47) and both the post-operative 
percentage change in CD133+ve /CD34+ve numbers and percentage change in CFU 
number (R=0.42, P=0.04, Fig 48 and R=0.56, P=0.004, Fig 49, respectively, both 




correlation between these variables and the levels of GM-CSF, PlGF and VEGF 
(Table 23). 
 
Table 21. Serum concentrations of GM-CSF, PlGF, SDF-1  and VEGF  pre, 




Cytokine concentration (pg/ml) (mean±SD)    
P-value * 
 




GM-CSF 458(±1177) 211(±232) 358(±585) 0.47 
PlGF 42(±86) 25(±24) 39(±68) 0.46 
SDF-1 951(±312) 763(±270) 924(±262) 0.003 










































































































Fig 46. Serum concentrations of (A) GM-CSF; (B) PlGF; (C) SDF-1; (D) VEGF;  
Pre-operatively (pre), 24 hrs post-operatively (post) and 6 weeks post-





Table 22. The correlation between pre-operative serum concentrations of 
GM-CSF, PlGF, SDF-1 and VEGF and restenosis as a continuous variable at 









 GMCSF  R value -0.18 -0.14 -0.29 
P value 0.43 0.56 0.42 
N 22 19 10 
PlGF   R value -0.401 -0.19 -0.50 
P value 0.06 0.43 0.15 
N 22 19 10 
SDF  R value 0.18 0.22 0.35 
P value 0.42 0.37 0.32 
N 22 19 10 
VEGF  R value 0.18 0.16 -0.07 
P value 0.43 0.51 0.84 







Table 23. The correlation between serum concentrations of GM-CSF, PlGF, 
SDF-1  and VEGF and the post-operative percentage change in eCFU and 
CD133+ve /CD34+ve cells (R=Spearman’s rank correlation). 
 
Cytokine (pg/ml) 
% Change in 
eCFU 
% Change in 
CD133+ve /CD34+ve  
cells 
 GMCSF pre R value -0.06 0.24 
P value 0.77 0.26 
N 24 24 
PlGF pre R value -0.02 0.18 
P value 0.94 0.41 
N 24 24 
SDF pre R value 0.56 0.42 
P value 0.004 0.04 
N 24 24 
VEGF pre R value -0.05 0.05 
P value 0.82 0.82 








































Fig 47. Correlation between pre-operative blood SDF-1 levels and pre-
operative circulating CD133+ve /CD34+ve cell numbers (R=Spearman’s 
correlation) 













































Fig 48. Correlation between pre-operative blood SDF-1 levels and the post-








































Fig 49. Correlation between pre-operative circulating SDF-1 levels and the 
post-operative percentage change in eCFU number (R=Spearman’s correlation) 
 
3.9 Multivariate analysis 
 
Binary logistic regression analysis was used to look for variables that 
independently predicted restenosis >50% at 3, 6 and 12 months. All variables that 
were found to have a significant relationship with restenosis in the univariate 
analysis were put forward into the multivariate analysis. No factors were found to 
independently predict restenosis >50%. Further analysis was carried out using 
linear logistic regression analysis to find factors independently predicting 
restenosis as a continous variable. Again none of the factors that have been found 
to be significantly correlated with restenosis on univariate analysis were 




4.  DISCUSSION 
 
4.1 Measurement of HPC number and function 
 
 
Asahara et al101 first described the out growth of a colony of endothelial cells when 
CD34 enriched peripheral blood mononuclear cells were grown in culture and 
expressed the endothelial marker, VEGF receptor-2 (VEGFR2). It was suggested 
that these cells represented a population of endothelial progenitor cells (EPCs). 
Over the past 10 years there have been a number of studies that suggest bone 
marrow-derived EPCs can differentiate into mature endothelial cells (EC) and 
maintain endothelial function111, 112. EPCs have been defined by the expression or 
co-expression of various combinations of markers including CD34101, VEGFR2101 
and CD133113,116, and are thought to have the functional capacity to form colonies 
(CFUs) in vitro101, 111, 121. Early CFUs (i.e. those colonies that form between 5 and 
10days in culture) have subsequently been found to express haematopoietic cell 
surface proteins128. Mononuclear cell isolates depleted of CD34+ve cells and 
comprising myeloid cells, are, however, still able to form these colonies in-vitro197. 
It is now generally accepted that what have previously been called EPCs are likely 
to represent a heterogeneous group of primitive haematopoietic progenitor cells 
(HPCs) that express both endothelial and myeloid lineage markers120, 128, 197.  
 
The results of the present study appear to support this mixed phenotype 




functional methods of measuring HPC numbers (CD133+ve/CD34+ve cell numbers 
by flow cytometry  and eCFU count). Others have also shown that flow cytometric 
analysis using various combinations of antibodies against the markers CD34, 
CD133 and VEGFR2 did not correlate with each other or with the eCFU assay134.  
 
In contrast to early CFUs, late CFUs/OECs have a high proliferative capacity, 
generate vascular tubules in-vivo and in-vitro, and do not express haematopoietic 
markers 113, 121.  The phenotypic definition of OECs has yet to be established and 
this limits the use of flow cytometry in measuring this rare cell type.  In this study 
we were unable to refine the methodology for growth of late EPCs/OECs (sections 
2.2.3.2 and 2.2.4) to give a reproducible assay and we therefore proceeded with 
measuring eCFUs only in our patients. The eCFU assay measures both the 
number and function (ability to form colonies of an apparently endothelial-like 
phenotype) of HPCs. A combination of eCFU and structural phenotypic analysis by 
flow cytometry (CD133+ve/CD34+ve) has been used by many251-253 to measure 
changes in what were thought to be EPCs. Our choice of flow cytometric markers 
in this study was hampered by difficulties encountered with the VEGFR2 antibody 
as well as access to a flow cytometer with more than 3 colour capability. The 
combination of eCFU and flow cytometric enumeration of CD133+ve/CD34+ve cells 
is, however, likely to represent HPC populations that others have found important 
in the pathophysiological response to vascular injury251-253 and that may therefore 




4.2 HPC number and function and risk of stroke 
 
 
High circulating HPC numbers are associated with improved endothelial function111 
and a reduced risk of developing cardiovascular disease111, 117. Reduced 
circulating HPC numbers are also associated with a significantly higher incidence 
of cardiovascular death, unstable angina, and myocardial infarction143. HPCs have 
been shown to mobilise to the site of trauma-induced injury268. In the context of 
carotid disease, HPC numbers are significantly higher in patients following 
ischaemic stroke than in at-risk control subjects152, though others have shown 
reduced numbers when compared with control subjects269. A reduced circulating 
HPC number (measured within 48hours of an ischaemic stroke) is associated with 
a poorer prognosis152. These data led us to investigate the link between HPC 
number and function and carotid disease. We were unable to demonstrate a 
relationship between HPC number or function and the 1yr and 5yr risk of further 
ipsilateral stroke as measured by the Oxford tables. We were also unable to 
demonstrate any relationship between any other clinical or operative parameters 
and HPC number and function. One possible explanation may lie in the 
heterogeneity of our study population, particularly with reference to the time from 
symptomatic event to endarterectomy which was 7.4(±11.5). This meant that we 
were measuring HPC number and function at greatly variables times from the 
symptomatic event, and subsequently trying to correlate this with the risk of further 
stroke. Our study population was also heterogeneous with regards to other clinical 




a patch or shunt). Subgroup analysis of HPC number and function would have 
been under powered and as a result was not attempted.  
 




CEA led to an acute fall in the number of HPC-eCFUs in the acute post-operative 
period (1day) followed by a recovery of eCFU numbers to pre-operative levels by 
6weeks post-operatively. Levels of CD133+ve, CD34+ve and CD133+ve/CD34+ve 
expressing cells remained depressed following CEA, although there was no 
significant change in the migratory capacity or senescence of the eCFU-derived 
HPCs .  The acute post-operative fall in HPC numbers following CEA confirms the 
findings of Stein et al270 who studied changes in circulating HPC numbers following 
peripheral (carotid and femoral) endarterectomy. It is in contrast, however, with the 
rise that occurs in the acute phase following injury caused by coronary artery 
bypass grafting (CABG) 148, 149 or balloon angioplasty 150, 271 and after ischaemic 
stroke 152 and myocardial infarction 151. Angioplasty and coronary bypass could 
induce some degree of ischaemia that leads to mobilisation of HPC numbers, as 
coronary angioplasty does not promote mobilisation of progenitors in the absence 
of myocardial necrosis272. During endarterectomy, it is possible that the circle of 
Willis protects the cerebral circulation from ischaemia and so the main stimulus is 
that of endothelial damage alone. Endarterectomy also leads to a large area of 




We postulate that this may lead to recruitment of HPCs to the site of 
endarterectomy138 in an attempt to re-endothelialise this area. In the absence of an 
ischaemic stimulus, this may overwhelm the capacity to mobilise these cells from 
the bone marrow within the first 24hrs following surgery, leading to the fall in HPC 
population numbers. Alternatively it is possible that there may have been a rise in 
HPC numbers following endarterectomy that occurred either within hours or over a 
much longer time scale (days). By measuring HPC number at 24hrs we may simply 
have missed the rise seen following other cardiovascular interventions.  
 
Our inability to detect changes in HPC function may be because our assays were 
not sensitive enough to detect small changes in function or because function is a 
property that does not change in the response to acute endothelial injury.  This is 
unlike the situation during chronic diseases such as atherosclerosis or 
hypertension, where there is a significant change in function140, 254, 273. 
 
4.4 HPC number and function and restenosis 
 
We report an incidence of restenosis (>50%) of 11% at 3 months, 33% at 6 and 12 
months. This is higher than the previously reported incidence of 10-20% in the first 
year following CEA29-31.  A high drop out rate was encountered as only 24 of the 62 
patients recruited to the study attended the 12 month follow up scan duplex scan 
and therefore this higher than expected rate of restenosis could be a type-II 




was to recruit sufficient patients to allow our sample population to include 15 
patients with restenosis at 6 and 12months. This would be sufficient to give a 
power of 80-90% to detect a difference between groups with a statistical 
significance of p<0.05. We achieved this at 6months, but not at 12months where 
the high rate of non-attendance resulted in only 8 patients who had >50% 
restenosis at this time. This again suggests that analysis of the relationship 
between HPC number and function and restenosis at 12months is at risk of a type-
II error.  
 
There was no association between either the number of the pre-operative 
CD133+ve/CD34+ve population or the number of HPC-eCFUs and the development 
of restenosis 3, 6 or 12months after carotid endarterectomy. We also found no 
evidence that HPC senescence influenced the development of restenosis. This is 
contrary to patients who developed restenosis following coronary angioplasty, who 
have a decreased number of eCFUs and increased numbers of senescent cells 
compared with patients who do not develop restenosis153. Multivariate analysis 
shows that an increased number of senescent HPCs is the only independent factor 
associated with in-stent restenosis153. Patients with angiographically demonstrated, 
diffuse in-stent restenosis have reduced numbers of HPCs (eCFU assay) when 
compared with those developing focal restenosis154.  
 
Increased HPC migratory capacity did appeared to protect against restenosis at 




was analysed as either an absolute number (i.e <50% vs ≥50%) or as a continuous 
variable.  This is the first study to show that there is a direct relationship between 
HPC migratory capacity and the development of restenosis. HPC migration and 
proliferation are correlated with endothelial dysfunction145, and reduced endothelial 
function is an independent factor predicting restenosis following coronary 
angioplasty71. Our findings support the notion that progenitor cell function rather 
than their number is important in maintaining endothelial function and attenuating 
restenosis. 
 
The variability in the magnitude of the post-operative fall in CD133+ve/CD34+ve and 
eCFU numbers between patients led us to examine the relationship between these 
falls and the development of restenosis following CEA. We found that a greater 
acute post-operative fall in both eCFU and circulating CD133+ve/CD34+ve cell 
number was associated with reduced restenosis. This relationship existed whether 
restenosis was analysed as an absolute (<50% vs >50%) or continuous variable. 
Although a post–operative fall in CD133+ve/CD34+ve HPC number following CEA 
has previously been demonstrated270, the results of the present study show that 
this fall has a significant association with the degree of restenosis that 
subsequently develops.  These data and the association between restenosis and 
enhanced HPC migratory capacity that we have shown, have led us to speculate 
that the fall in circulating HPC numbers may reflect the rapid recruitment of HPCs 
to the site of endarterectomy. A more rapid fall in HPC number represents faster 




This notion is also supported by the results of studies that show enhanced re-
endothelialisation and decreased neointima formation in animal models of arterial 
injury following infusion of culture-expanded autologous progenitor cells138, 157, or 
following their mobilisation after injury using statins108, 137, granulocyte colony 
stimulating factor (G-CSF)158, 159 or granulocyte macrophage-CSF107. Patients who 
develop restenosis after coronary angioplasty also have a lower circulating number 
and increased senescence of progenitor cells100, 154,153.  The findings of the present 
study provides further evidence to support the hypothesis, generated from both 
animal 107, 108, 137, 138, 157-159 and other human100,153,154 studies, that HPC activity 
inhibits neointimal hyperplasia. 
 
4.5  Cytokine Analysis 
 
 
The cytokine response that leads to HPC mobilisation and recruitment may be 
different between interventions that lead to endothelial damage alone, such as 
endarterectomy, and those that also induce some degree of ischaemia such as 
CABG. In order to characterise the cytokine response to endarterectomy we 
measured serum levels of GM-CSF, PlGF, SDF-1 and VEGF pre-operatively, 
24hr and 6weeks post-operatively. Of these, only VEGF and SDF-1 levels 
showed significant changes following CEA. The levels of VEGF rose in the 
immediate post-operative period and continued doing so at 6weeks. This is similar 
to the pattern described following coronary artery bypass149. The pattern of change 




immediate post-operative fall followed by a rise at 6weeks.  Although the levels of 
the cytokines measured did not correlate with restenosis, our data suggests that 
SDF-1 levels may have an important role, as the pre-operative levels of this 
cytokine were  strongly correlated with the post-operative fall in both circulating 
CD133+ve/CD34+ve cells number and eCFU populations. SDF-1 stimulates 
progenitor cell mobilisation, growth and differentiation228. Interaction with its 
receptor CXCR4 is thought to be important in regulating progenitor cell survival, 
cell cycle, and mobilisation213 and this facilitates progenitor cell recruitment to sites 
of injury in models of neointimal hyperplasia238. SDF-1 binds to platelets at the 
site of injury, triggers CXCR4- and P-selectin-dependent arrest of progenitor cells 
on injured arteries 238,239. Rapid adhesion of platelets to the exposed sub-
endothelial surface in injured vessels could provide a very effective mechanism of 
mobilisation and homing of stem cells to the damaged area as platelets are seen 
early in the inflammatory response.   In vitro studies show that SDF-1α induces 
HPC and CD34+ve cell migration, and CD34+ cell adhesion240, 241. Taken together 
with our earlier results (showing that a greater fall in both CD133+ve/CD34+ve  cell 
number and eCFU number is associated with a reduced incidence of restenosis) 
our studies provide a possible mechanistic paradigm. Higher pre-operative SDF-1α 
levels lead to increased SDF-1α driven homing of progenitor cells to the site of 
injury resulting in a greater post-operative fall in progenitor cell number, enhanced 





4.6 Critique and Future Studies 
4.6.1 Patient recruitment 
 
The aim of this study was to recruit sufficient patients over a 2-year period to 
provide a sample of at least 10-15 restenotic patients. Our power calculation 
(section 2.7.4) in addition to the approximate rate of restenosis from the literature 
led us to conclude that between 60-100 patients would be required to give a power 
of 80-90% to detect a difference if there was one in HPC number and function 
between those that restenosed and those that did not. Departmental data from 
previous years showed that around 50 CEAs a year were performed at St Thomas’ 
Hospital. However during the study period this fell to closer to 30 CEAs a year. 
This led to a total cohort of only 62 patients, and as mentioned earlier (section 4.4) 
along with the low level of attendance at the 12 month scan led to the possibility of 
a type II error when looking at restenosis at 12 months.  
 
We are uncertain as to why the number of CEAs has fallen over the study period. 
This may be related to changing patterns of referral within the region or 
alternatively the effects of best medical management (section 1.1.3.1) in reducing 
the incidence of symptomatic carotid artery disease. We became aware of this 
reduction in the number of CEAs 12 months into the study. We sought to establish 
collaboration with St George’s Hospital and this was agreed, but the Ethics and 






Further studies will take these experiences into account and although multicentre 
studies are more difficult to manage (particularly in relation to the rapid handling of 
blood for subsequent analysis by FACs or for cell culture), this will be essential in 
order to maximise patient numbers and reduce the chances of a type II error. 
 
4.6.2 Progenitor cells and clinical symptoms 
 
We have demonstrated a possible link between HPC number and function and 
symptomatic carotid artery stenosis, but this was only a correlation between the 
two variables and possible mechanisms of this association were not studied. We 
hypothesise that enhanced HPC number and function could lead to enhanced 
plaque neovascularisation, instability and therefore embolic symptoms. This 
hypothesis is difficult to test in animals as although one model of spontaneous 
plaque rupture has been reported274 it is far from universally accepted. In humans 
unstable plaque is available for analysis of vascularity and the cells associated with 
this vascularity (using techniques such as immunofluorescence and confocal 
microscopy) only following an ‘event’. It is difficult therefore to say whether the 
presence of any progenitor cells is the cause of the instability. An alternative 
explanation for the link between symptomatic carotid artery disease and HPC 
number and function is that the rise in the latter is an acute phase response to the 
unstable plaque or ischaemic cerebral tissue found in symptomatic patients. It 
would be interesting to investigate the effect of removing "symptomatic" elements 
from plaque on HPC number and function. This could be done by measuring these 




what effect changes to brain perfusion have on HPC number/function and cytokine 
profile independent of making a large wound and endarterectomising the vessel. 
 
 
4.6.3 What is an HPC? 
A major limitation of this and similar studies is in defining an HPC. The methods 
used to enumerate these cells use combinations of a variety of markers (including 
CD31, CD34, VEGFR2, CD62E, CD133, cKit and CD45) and cell culture 
techniques (early and late CFUs), which makes it impossible to compare studies 
that attempt to associate HPCs with cardiovascular conditions and outcomes. 
Though this was evident at the time we began this study what has become 
apparent over the course of the work is that these techniques clearly measure 
different cells populations112, 120, 121, 128, 134. For example it was once generally 
accepted that the eCFU assay and CD133+ve/CD34+ve/VEGFR2+ve phenotypic 
identification by flow cytometry, were two techniques that could be used to identify 
EPCs. Subsequent studies have shown that these techniques measure a 
heterogeneous group of primitive haematopoietic progenitor cells (HPCs) that 
express both endothelial and myeloid lineage markers120, 128, 197. We and others134 
have also shown that eCFU analysis and flow cytometric analysis do not correlate 
suggesting that CD133+ve/CD34+ve cells and those responsible for eCFU formation 
represent different subsets of HPCs. This raises several important questions:- 
 What are these different subtypes? 




 What are their relative contribution to re-endothelialisation and therefore to 
the development of restenosis? 
 
Although the results of this thesis suggest that cells that form eCFUs and 
CD133+ve/CD34+ve cells may have role in the attenuation of restenosis, it has 
clearly failed to answer the question above. Details of the studies that showed the 
heterogeneity of EPCs and the methods that were used to identify them were 
published during the course of this study, and we were unable therefore to 
investigate the importance of these cells (as possible subset of the HPC), given the 
long-term follow up analysis that we were dependent on in the context of 
restenosis. For example our study relied on performing the same set of 
investigations on the entire study population and to change the methodology half 
way through would have rendered any correlation between HPC analysis and 
restenosis impossible. 
 
There are a variety of cells that have the capacity to enhance re-endothelialisation 
either by differentiating into endothelial cells or by secreting factors that promote 
re-endothelialisation. This raises the question as to which is the optimal cell 
population to be targeted in any putative local cell enrichment therapy to inhibit 
restenosis. This will depend both on the particular qualities of the cells and the 
clinical situation. For example, late CFUs have a very high proliferative potential, 
but take extended time to appear in culture conditions121. Early CFU’s do not 




maybe the optimal choice when time is a limiting factor. Conversely late CFUs and 
mesenchymal stem cells are clearly better suited for ex-vivo expansion given their 
higher proliferative potential121. The characteristics of the different candidate cells 
and the optimal culture conditions clearly need to be more accurately defined 
before useful clinical trials can be instigated.   
 
To address this, future studies should concentrate on developing a better 
understanding of the precise phenotype and function of cells, as well as the local 
and circulating cytokine milieu that contribute to the maintenance of the 
endothelium and integrity of the vessel wall following injury. This may be obtained 
by developing genetically modified mice carrying markers of specific cell 
phenotypes or knockout/knock-in of specific cytokines postulated to be important in 
this process. A good example of this is the elucidation of monocyte heterogeneity, 
with sub-populations of this myeloid cell expressing different phenotypic markers 
and different functions e.g. the patrolling monocyte275 . 
 
The colony forming unit is known to be composed of cells of myeloid121 
endothelial101 and T cell lineages276 . However, it remains unclear from our study 
which of these cell types is responsible for the correlation between CFU number 
and restenosis. Further characterisation (flow cytometric and genomic) should be 
carried out in an animal model and isolation of individual cell types and their use in 




mice) of arterial injury would allow the analysis of their relative importance to the 
process of re-endothelialisation and the inhibition of restenosis.   
 
4.6.4 HPCs or Endothelial microparticles? 
 
Many studies have used CD34, CD133 and VEGFR2 to define HPCs and have 
found that HPC number correlates inversely with risk of developing cardiovascular 
disease and prognosis in established disease 117, 118. However the use of modern 
polychromatic flow cytometry (PFC) has called into question not only the true 
identity of these cells as discussed above, but also whether cells identified using 
older flow cytometry machines and staining protocols are cells at all. PFC involves 
the use of up to eight different fluorophores in a single analysis, allowing multiple 
antigens to be detected and for dead or enucleated cells to be excluded from the 
analysis. Using a modern PFC protocol a recent study found that true EPCs were 
extremely rare in the circulation277. Reverting back to older staining protocols, the 
same group then used the cell sorting facility to separate these cells and using an 
electron microscope found that many of these so called cells were in fact 
microparticles and extracellular vesicles277. These results are difficult to reconcile 
with earlier papers from the same group120, 278 that demonstrated that cells 
identified using flow cytometry could be subsequently grown in culture into 
endothelial colony forming units278 and also differentiated into haematopoietic cells 
of varying lineage120.  However we must acknowledge that at least some of the 
‘events’ recorded using our flow cytometry protocols may have been microparticles 




Endothelial microparticles (EMP) are vesicles of less than 1µm in diameter that are 
released from the plasma membranes in response to endothelial activation, injury 
or apoptosis279. Elevated levels of circulating microparticles have been detected in 
pathological states associated with vascular dysfunction as measured by 
endothelium-dependent vasodilatation and/or alteration of responsiveness of 
vascular smooth muscle to vasoconstrictor stimuli 280. Elevated levels of EMPs, 
mostly defined as CD31+/Annexin-V+ or CD31+/CD42- microparticles, have been 
found in various vascular disorders including coronary, peripheral and 
cerebrovascular diseases281-284. Moreover, EMPs accumulate in atherosclerotic 
lesions and influence propagation of atherosclerosis 285. It is possible therefore that 
EMPs may have an important role to play in regulating endothelial function and 
therefore intimal hyperplasia. 
 
Future studies should concentrate on using polychromatic flow cytometry to stain 
for a panel of antigens. This would allow various subsets of HPCs to be identified 
and correlated with restenosis. In addition EMP markers such as CD31+/Annexin-
V+ or CD31+/CD42- should be used to measure microparticles and study their 
response to arterial injury and restenosis. 
 
4.6.5 The role of SDF-1 
 
The correlation between SDF-1 levels and the magnitude of post-operative fall in 
HPCs led us to the hypothesis that higher pre-operative SDF-1  levels lead to 




neo-endothelialisation and reduced neointima formation. SDF-1 may therefore 
have therapeutic potential.  The MAGIC cell trial has alerted us to the dangers of 
systemically injecting a relatively non-specific factor to stimulate progenitor cell 
mobilisation.  This could be avoided by using adenoviruses (probably adeno 
associated viruses that have less immunogenic and more long lasting activity) or 
microcapsules to deliver SDF-1 to the site of arterial injury in animal models 286. 
 
4.6.6 Failure to grow OECs and MSCs 
 
Our intention at the start of this study was to measure the number and function of 
eCFUs, OECs (late CFUs) and MSCs. It was not possible to replicate the methods 
given in the literature for isolation of OECs121 or MSCs190  and as a result we 
managed only to study eCFU number and function. Both OECs and MSCs have 
the potential to influence restenosis130, 131, 183 and future studies should therefore 
concentrate on refining the research methodology to allow the role of these 
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Appendix A - Ethics approval and consent form 
St Thomas’ Hospital Research Ethics Committee  
 
CONSENT FORM FOR PARTICIPATION IN RESEARCH PROJECTS & CLINICAL TRIALS 
 
 Title of Project: Tissue and blood samples for the study of aortic and peripheral vascular 
disease  -  pathogenesis and  circulating markers (occlusive disease) 
Principal Investigator:  Burnand  KG                                             
Other Investigator/s S Abisi, E Sullivan, S Patel                                           
Enrolling patients:                                     
Ethics Committee 
Code No: EC03/098 
Version No:                       Date:                                                                       
 Outline explanation:  
We would like to invite you to take part in a study on the causes of why arteries block or 
swell and why clots occur.  
You are coming into St. Thomas' hospital to have an operation to repair arteries that have 
furred-up with fat (also called plaques). The plaques that build up in these arteries can 
become unstable and split, giving rise to symptoms that you may be experiencing. We are 
interested in how these plaques form, finding a way of detecting which plaques are about 
to split, as these can be removed by surgery, and why some arteries block while other 
swell up.   We wish to take a sample of your blood sample and to measure levels of 
substances that are thought to be important in plaque formation and splitting. We also 
wish to analyse the plaque that is removed as part of your surgery. 
    We would be grateful if you agreed to take part in our study by consenting to: 
1. allowing us to measure the size of your artery using a scanner which involves moving a 
small probe on the surface of your skin. This is a routine, safe and painless procedure. 
2. allowing us to use the tissue that is being removed from your artery as part of your 
operation and that would normally be thrown away;  
3. allowing us to take an extra blood sample. This can be done either when you are having 
blood taken as part of your routine care or while you are asleep during your operation. 
The amount of extra blood will be no more than 10 ml (2 teaspoons).  
4. allowing us to take a 30mls blood sample at your first 5 follow-up appointments 
after your operation. The tissue and blood may be analysed at St. Thomas' Hospital using 
a variety of different techniques, some of which may include genetic analysis. This will 
involve investigating the differences in the composition of genes that we feel may be 
important in effecting changes in the artery wall, compared with the same genes in people 
who do not have arterial problems. The samples will be anonymised (coded) and your 
identity will only be known by the investigators. All information will be kept in the strictest 
confidence. The sample or the extract from it will be kept for analysis until it is depleted. 
We wish to stress, however, that by signing this agreement, you will relinquish ownership 
of any blood or tissue removed as part of your operation and you should not expect to 
benefit financially from any commercialisation of the research results. You will be referred 





We would like to stress that you are under no obligation to take part in this study 
and that if you do decide to take part, you may stop at any point. Your decision will 
not affect your treatment. 
Thank you for considering our request. 
 




 of (address)  
_______________________________________________________________________
_ 
I hereby consent to take part in the above investigation, the nature and purpose of 
which have been explained to me.  Any questions I wished to ask have been 
answered to my satisfaction.  I understand that I may withdraw from the 
investigation at any stage without necessarily giving a reason for doing so and that 
this will in no way affect the care I receive as a patient 
 
 SIGNED (Volunteer)  ________________________________  Date  
___________________ 
 













Title of Project: Tissue and blood samples for the study of aortic and peripheral 
vascular disease  -  pathogenesis and circulating markers 
 
Name of Researcher: Mr Sanjay Patel 
 
       Please initial box 
1. I confirm that I have read and understand the information sheet dated 15/5/07          
      (version 4) for the above study. I have had the opportunity to consider the  
      information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,    
      without giving any reason, without my medical care or legal rights being affected. 
 
3.   I understand that relevant sections of any of my medical notes and data collected during   
      the study, may be looked at by responsible individuals          
      from regulatory authorities or from the NHS Trust, where it is relevant to my taking   
      part in this research.  I give permission for these individuals to have access to my records.                             
                                                                                                                                             
4.   I agree to take part in the above study.    
 
________________________ ________________ _______________ 





_________________________               ________________                   ________________ 
Name of Person taking consent Date  Signature 




_________________________ ________________                    _______________ 
Researcher   Date  Signature 





Appendix C  - Data Collection 
Sheet 
Study No     
 The Role of Vascular Progenitor Cells in Restenosis 
     
Hospital No  Date of Procedure   
Date of 
Sympoms     
DOB  CEA:   
Sex  Indications   
  Stenosis  Ipsi: Contr: 
BP (Treated?)  Patch or Primary Closure 
 
 
NIDDM/ IDDM  Local/General 
IHD  Shunt 
Smoking status   
Cholesterol    
PVD/CVA   
Renal Faliure     
    
Medication     
     
     
     
     
     
White Cell Count     
C-reactive 
Protein     
Renal Function     
Serum Cholesterol    
HDL/LDL     
Changes since last visit    
     
Acute Limb ischaemia?    
MI/ ACS     
Other surgery     
     
Follow Up     
Date of next sample Date of next scan   









Op DOB Age Sex 
Hyper-
tension Diabetes 
CEA066 Z602543 27.04.06 22.01.31 75 Male Yes no DM 
CEA067 1193199D 27.04.06 05.10.29 77 Female Yes NIDDM 
CEA068 1162248L 27.04.06  71 Male Yes NIDDM 
CEA077 Z742372 12.07.06 03.10.33 73 Male Yes no DM 
CEA078 4371698B 20.07.06 30.09.20 86 Female Yes NIDDM 
CEA079 1813882F 26.07.06 18.04.38 68 Female No no DM 
CEA080 0605206G 28.07.06  65 Female Yes no DM 
CEA082 4401101Z 15.08.06 20.03.31 75 Male Yes no DM 
CEA085 4397599C 30.08.06 11.02.50 56 Male Yes no DM 
CEA086 0825459C 27.09.06 27.08.37 69 Male Yes NIDDM 
CEA087 1609846J 28.09.06 19.02.40 66 Male Yes no DM 
CEA088 1983323D 28.09.06 30.05.44 62 Male Yes NIDDM 
CEA091 4396210X 02.11.06 12.08.37 69 Male No NIDDM 
CEA092 4428833C 01.11.06 14.01.28 78 Male Yes no DM 
CEA093 1405865T 02.11.06 05.08.21 85 Female Yes no DM 
CEA094 1142857Z 02.11.06 05.11.34 72 Male Yes no DM 
CEA095 1335568X 07.11.06 06.02.36 70 Female Yes no DM 
CEA096 4410677B 08.11.06 24.06.45 61 Female Yes no DM 
CEA097 4429010P 09.11.06 03.01.46 60 Male Yes no DM 
CEA100 Z758272 30.11.06 05.04.25 81 Male No NIDDM 
CEA101 4327740G 30.11.06 11.09.37 69 Male Yes NIDDM 
CEA102 4429556F 01.12.06 14.10.37 69 Male Yes no DM 
CEA105 4471146W 24.01.07 16.07.26 80 Male Yes no DM 
CEA106 0366578S 21.02.07 16.09.25 82 Male No no DM 
CEA107 Z236279 22.02.07 14.05.37 69 Female Yes NIDDM 
CEA108 1609825B 15.03.07 18.08.33 73 Female Yes no DM 
CEA109 2211068L 24.04.07 05.10.52 64 Male No no DM 
CEA110 1275109G  28.11.35 71 Male No no DM 
CEA111 4487659W  29.04.30 76 Male Yes no DM 
CEA112 4256621D 04.05.07 20.11.41 65 Female Yes no DM 
CEA113 4490242E  22.06.45 61 Male Yes no DM 
CEA114 Z010582 16.05.07 16.03.23 84 Male Yes no DM 
CEA115 1288000U 24.05.07 13.04.40 67 Female No no DM 
CEA116 4514641W 24.05.07 13.10.29 77 Female Yes no DM 
CEA117 4501618R 24.05.07 16.02.36 71 Female Yes NIDDM 








Op DOB Age Sex 
Hyper-
tension Diabetes 
CEA120 1433802F 13.06.07 08.09.40 67 Female Yes NIDDM 
CEA126 2239612G 30.07.07 22.12.35 72 Female No no DM 
CEA127 4541559G 30.07.07 29.02.40 67 Male Yes no DM 
CEA128 1372408J 09.08.07 16.01.24 83 Female Yes no DM 
CEA129 4546778D 09.08.07 10.06.46 61 Female Yes NIDDM 
CEA130 4548033S 15.08.07 21.09.44 67 Male Yes NIDDM 
CEA131 4555650K 16.08.07 14.03.34 73 Male Yes no DM 
CEA132 Z676521 18.08.07 15.05.19 88 Female Yes no DM 
CEA133 4418582X 29.08.07 19.03.32 75 Male No no DM 
CEA134 2248991W 18.09.07 25.03.47 60 Male Yes no DM 
CEA135 2254153G 25.10.07 26.04.54 53 Male Yes no DM 
CEA136 4579477G 25.10.07 20.08.41 66 Male No no DM 
CEA137 4595987W 20.11.07 25.02.28 79 Male Yes no DM 
CEA138 4498914E 21.11.07 03.10.52 55 Male No no DM 
CEA139 1466038E 02.12.07 09.01.41 66 Male Yes NIDDM 
CEA140 Z376513 13.12.07 12.03.29 78 Male No no DM 
CEA141 4602162W 20.12.07 19.03.43 64 Male Yes no DM 
CEA142 22587097 20.12.07 06.12.44 63 Male No no DM 
CEA143 Z448913 15.02.08 03.03.32 75 Male Yes NIDDM 
CEA144 0862345T 15.02.08 20.06.43 64 Male No no DM 
CEA145 Z612772 12.02.08 04.03.30 77 Male Yes no DM 
CEA146 Z576760 20.02.08 10.05.20 87 Male Yes no DM 
CEA147 0290543B 21.02.08 14.12.23 84 Male Yes no DM 
CEA148 0308220X 21.02.08 22.05.45 62 Male Yes no DM 
CEA149 4612392X 13.03.08 23.01.24 83 Male No no DM 





Study No IHD Smoker 
High 
Cholesterol PVD Renal Failure 
CEA066 No IHD Ex Smoker Yes no No 
CEA067 No IHD Ex Smoker Yes no No 
CEA068 Angina Ex Smoker Yes no No 
CEA077 No IHD Ex Smoker Yes Yes No 
CEA078 No IHD Ex Smoker Yes no No 
CEA079 No IHD Non Smoker Yes no No 
CEA080 No IHD Current Smoker Yes no No 
CEA082 No IHD Ex Smoker Yes no No 
CEA085 No IHD Ex Smoker Yes no No 
CEA086 MI Current Smoker Yes no No 
CEA087 MI Current Smoker Yes no No 
CEA088 No IHD Ex Smoker Yes Yes Yes 
CEA091 MI Ex Smoker Yes no No 
CEA092 MI Ex Smoker Yes no No 
CEA093 No IHD Non Smoker Yes no Yes 
CEA094 No IHD Non Smoker Yes no No 
CEA095 MI Current Smoker Yes no No 
CEA096 No IHD Current Smoker Yes Yes No 
CEA097 No IHD Current Smoker Yes Yes No 
CEA100 MI Non Smoker No no No 
CEA101 Angina Non Smoker Yes no No 
CEA102 No IHD Ex Smoker Yes no No 
CEA105 No IHD Ex Smoker No Yes Yes 
CEA106 MI Non Smoker Yes no No 
CEA107 MI Non Smoker Yes no No 
CEA108 MI Non Smoker Yes no No 
CEA109 No IHD Ex Smoker No no No 
CEA110 MI Current Smoker Yes no No 
CEA111 No IHD Ex Smoker Yes no No 
CEA112 No IHD Non Smoker Yes no No 
CEA113 No IHD Ex Smoker Yes no No 
CEA114 Angina Ex Smoker Yes no No 
CEA115 MI Non Smoker No no No 
CEA116 MI Ex Smoker Yes Yes No 
CEA117 No IHD Non Smoker Yes no No 
CEA119 No IHD Current Smoker No no No 




Study No IHD Smoker 
High 
Cholesterol PVD Renal Failure 
CEA126 No IHD Non Smoker Yes no No 
CEA127 No IHD Ex Smoker Yes no No 
CEA128 No IHD Ex Smoker Yes no No 
CEA129 Angina Ex Smoker Yes Yes No 
CEA130 MI Ex Smoker Yes no No 
CEA131 No IHD Ex Smoker Yes no No 
CEA132 No IHD Non Smoker Yes no No 
CEA133 No IHD Ex Smoker Yes Yes No 
CEA134 No IHD Non Smoker Yes no No 
CEA135 No IHD Current Smoker Yes no No 
CEA136 Angina Ex Smoker Yes no No 
CEA137 No IHD Ex Smoker Yes no No 
CEA138 MI Ex Smoker Yes no No 
CEA139 No IHD Current Smoker Yes no No 
CEA140 MI Current Smoker Yes Yes No 
CEA141 Angina Current Smoker Yes no No 
CEA142 No IHD Non Smoker Yes no No 
CEA143 MI Ex Smoker Yes Yes No 
CEA144 No IHD Current Smoker Yes no No 
CEA145 Angina Ex Smoker Yes Yes No 
CEA146 No IHD Ex Smoker Yes no Yes 
CEA147 MI Ex Smoker Yes no No 
CEA148 MI Non Smoker Yes no No 
CEA149 Angina Ex Smoker Yes Yes No 






Study No Aspirin Warfarin 
Clopid-
ogrel Statin ACEi ATIIAnt Digoxin 
B -
Blocker 
CEA066 Yes No No Yes no No No No 
CEA067 Yes No No Yes no Yes No No 
CEA068 Yes Yes No Yes Yes No No Yes 
CEA077 Yes No No Yes no No No No 
CEA078 Yes No No Yes no Yes No Yes 
CEA079 Yes No Yes Yes Yes No Yes No 
CEA080 Yes No No Yes no Yes No No 
CEA082 Yes No No Yes no Yes No No 
CEA085 Yes No Yes Yes Yes No No Yes 
CEA086 Yes No No Yes Yes No No No 
CEA087 Yes No No Yes no No No Yes 
CEA088 Yes No No Yes no No No Yes 
CEA091 Yes No No Yes no No No Yes 
CEA092 Yes No No Yes no No No Yes 
CEA093 No Yes No Yes Yes No No Yes 
CEA094 Yes No No Yes no No No No 
CEA095 No Yes No Yes Yes No No Yes 
CEA096 No No Yes Yes Yes No No No 
CEA097 No Yes No Yes Yes No No No 
CEA100 Yes No No Yes no No No Yes 
CEA101 Yes Yes No Yes no No No Yes 
CEA102 Yes No No Yes no No No No 
CEA105 No No Yes No Yes No No No 
CEA106 Yes No No Yes no No No Yes 
CEA107 No Yes No Yes Yes No No Yes 
CEA108 No Yes No Yes Yes No No No 
CEA109 Yes No No No no No No No 
CEA110 Yes No No Yes no No No Yes 
CEA111 No Yes No Yes Yes No No No 
CEA112 Yes No No Yes Yes No No Yes 
CEA113 Yes No No Yes Yes No No Yes 
CEA114 Yes No Yes Yes no No No No 
CEA115 No No Yes No no No No Yes 
CEA116 Yes Yes No Yes no No No Yes 
CEA117 No No Yes Yes Yes Yes No No 
CEA119 Yes No No No Yes No No No 




Study No Aspirin Warfarin 
Clopid-
ogrel Statin ACEi ATIIAnt Digoxin 
B -
Blocker 
CEA126 Yes No No Yes no No No No 
CEA127 Yes No No Yes Yes No No No 
CEA128 Yes No Yes Yes Yes No No No 
CEA129 No No Yes Yes Yes No No Yes 
CEA130 Yes Yes No Yes no Yes No Yes 
CEA131 No Yes No Yes Yes No No No 
CEA132 Yes No No Yes no No No No 
CEA133 No Yes No Yes no No No No 
CEA134 Yes No No Yes no No No No 
CEA135 Yes No No Yes no No No No 
CEA136 Yes No No Yes no No No No 
CEA137 No Yes No Yes no No No Yes 
CEA138 Yes No No Yes no No No No 
CEA139 Yes No No Yes Yes No No No 
CEA140 Yes No No Yes Yes No No No 
CEA141 Yes No No Yes no No No Yes 
CEA142 Yes No No Yes no No No No 
CEA143 Yes No No Yes Yes No No Yes 
CEA144 Yes No No No no No No No 
CEA145 No Yes No Yes Yes No No No 
CEA146 Yes No No Yes Yes No No No 
CEA147 Yes No No Yes Yes No No Yes 
CEA148 Yes Yes Yes Yes Yes No No Yes 
CEA149 Yes No No Yes no No No Yes 

















CEA066 No no CVA 50 100 7 
CEA067 yes Yes Asymptomatic 80 60 0 
CEA068 No no TIA 79 40 7 
CEA077 yes no CVA 79 49 5 
CEA078 yes no CVA 50 100 10 
CEA079 No no TIA 70 30 7 
CEA080 No no CVA 80  7 
CEA082 No no CVA 90 49 7 
CEA085 No Yes TIA 70 40 8 
CEA086 No Yes CVA 70 20 7 
CEA087 yes Yes Asymptomatic 75 16 0 
CEA088 yes Yes CVA 70 60 7 
CEA091 No no TIA 90 50 24 
CEA092 yes Yes TIA 90 100 24 
CEA093 No no TIA 79 79 7 
CEA094 yes Yes Asymptomatic 70 50 0 
CEA095 No no 
Amaurosis 
Fugax 80 75 16 
CEA096 No no Asymptomatic 90 100 9 
CEA097 No Yes Asymptomatic 90 50 0 
CEA100 No no 
Amaurosis 
Fugax 70 40 6 
CEA101 No Yes 
Amaurosis 
Fugax 70 70 60 
CEA102 yes Yes Asymptomatic 70 40 0 
CEA105 yes no 
Amaurosis 
Fugax 99 50 41 
CEA106 No no CVA 70 30 14 
CEA107 No no TIA 75 60 7 
CEA108 yes Yes TIA 90 100 8 
CEA109 No no CVA 70  1 
CEA110 No no TIA 85 15 8 
CEA111 yes no TIA 65 20 28 
CEA112 yes no TIA 75  2 
CEA113 No no CVA 80 40 8 
CEA114 No Yes Asymptomatic 90 60 0 















CEA116 No no CVA 75 50 3 
CEA117 No Yes CVA 80 50 27 
CEA119 No Yes TIA 80 40 12 
CEA120 yes Yes TIA 80 30 4 
CEA126 yes no CVA 90 20 2 
CEA127 yes Yes CVA 80 50 1 
CEA128 No Yes TIA 70  12 
CEA129 yes Yes Asymptomatic 90 75 0 
CEA130 yes Yes Asymptomatic 90 80 0 
CEA131 No no TIA 70 20 8 
CEA132 No Yes CVA 70 30 2 
CEA133 No no TIA 85 20 1 
CEA134 No no CVA 90  1 
CEA135 No no TIA 95 65 2 
CEA136 No no Asymptomatic 90 80 0 
CEA137 No no CVA 90 80 2 
CEA138 No no Asymptomatic 49 100 0 
CEA139 No no Asymptomatic 90 80 0 
CEA140 No no TIA 90 90 4 
CEA141 No no Asymptomatic 80 70 0 
CEA142 No no CVA 80  5 
CEA143 No no Asymptomatic 70 30 0 
CEA144 No no CVA 70 50 8 
CEA145 yes Yes Asymptomatic 79 40 0 
CEA146 yes Yes CVA 85 75 3 
CEA147 No no Asymptomatic 70 50 0 
CEA148 yes no CVA 70  7 
CEA149 yes Yes Asymptomatic 99 80 0 
CEA150 No Yes Asymptomatic 75 60 0 















d Risk Side Patch LA/GA Shunt 
CEA066 Ulcerated/Irregular 11.4 28.3 Right No Patch GA Shunt 
CEA067 Ulcerated/Irregular   Left Patch GA No Shunt 
CEA068 Ulcerated/Irregular 15.9 38 Right No Patch GA No Shunt 
CEA077 Ulcerated/Irregular 8.3 21.2 Left Patch GA Shunt 
CEA078 Smooth 6.5 16.8 Left Patch GA Shunt 
CEA079 Ulcerated/Irregular 5.6 14.9 Left Patch GA Shunt 
CEA080 Ulcerated/Irregular   Left No Patch GA No Shunt 
CEA082 Ulcerated/Irregular 15.4 36.9 Right No Patch GA No Shunt 
CEA085 Ulcerated/Irregular 7 18.2 Left Patch GA No Shunt 
CEA086 Ulcerated/Irregular 20 48.5 Left Patch GA Shunt 
CEA087 Ulcerated/Irregular   Right Patch GA No Shunt 
CEA088 Ulcerated/Irregular 15.4 36.9 Right No Patch GA Shunt 
CEA091 Ulcerated/Irregular 9 22.8 Left Patch GA Shunt 
CEA092 Ulcerated/Irregular 9.1 30 Left No Patch GA Shunt 
CEA093 Smooth 5 12.8 Right No Patch LA No Shunt 
CEA094 Smooth   Right No Patch GA Shunt 
CEA095 Smooth 5 12.1 Right Patch GA No Shunt 
CEA096 Ulcerated/Irregular   Left Patch GA Shunt 
CEA097 Ulcerated/Irregular   Left No Patch GA No Shunt 
CEA100 Ulcerated/Irregular 16.3 38.7 Right No Patch GA No Shunt 
CEA101 Ulcerated/Irregular   Right Patch GA No Shunt 
CEA102 Ulcerated/Irregular   Right No Patch GA No Shunt 
CEA105 Ulcerated/Irregular   Right Patch GA Shunt 
CEA106 Ulcerated/Irregular 14 34 Right Patch GA Shunt 
CEA107 Smooth 8 20.5 Left Patch GA Shunt 
CEA108 Smooth 7.9 20 Right Patch GA No Shunt 
CEA109 Ulcerated/Irregular 10.5 26.4 Left Patch LA No Shunt 
CEA110 Ulcerated/Irregular 12.9 31.7 Left Patch GA Shunt 
CEA111 Ulcerated/Irregular 5 11.1 Left Patch LA No Shunt 
CEA112 Ulcerated/Irregular 9 22.8 Left No Patch GA No Shunt 
CEA113 Ulcerated/Irregular 11 27.6 Right Patch LA No Shunt 
CEA114 Smooth   Right Patch GA Shunt 
CEA115 Ulcerated/Irregular 10.6 26.5 Left Patch GA No Shunt 
CEA116 Ulcerated/Irregular 20 49.2 Left Patch LA No Shunt 
CEA117 Smooth 5 10 Right Patch GA No Shunt 













d Risk Side Patch LA/GA Shunt 
CEA120 Ulcerated/Irregular 12.1 30 Left Patch GA Shunt 
CEA126 Smooth 6.4 16.7 Left Patch LA No Shunt 
CEA127 Smooth 7.9 20.4 Left Patch GA No Shunt 
CEA128 Ulcerated/Irregular 6.7 17.3 Left Patch GA Shunt 
CEA129 Smooth   Right Patch GA No Shunt 
CEA130 Ulcerated/Irregular   Right Patch GA Shunt 
CEA131 Ulcerated/Irregular 8.4 21.4 Left No Patch GA No Shunt 
CEA132 Ulcerated/Irregular 13.4 32.8 Left No Patch GA No Shunt 
CEA133 Ulcerated/Irregular 13.5 33 Left No Patch LA No Shunt 
CEA134 Smooth 8.6 22 Left No Patch GA No Shunt 
CEA135 Ulcerated/Irregular 12.7 31.3 Right Patch GA No Shunt 
CEA136 Ulcerated/Irregular   Left No Patch GA No Shunt 
CEA137 Ulcerated/Irregular 19.4 44.8 Left No Patch LA No Shunt 
CEA138 Ulcerated/Irregular   Left Patch GA Shunt 
CEA139 Smooth   Right Patch GA Shunt 
CEA140 Ulcerated/Irregular 19.5 44.9 Left Patch LA No Shunt 
CEA141 Smooth   Left No Patch LA No Shunt 
CEA142 Ulcerated/Irregular 10.3 26 Right Patch GA No Shunt 
CEA143 Smooth   Left Patch GA Shunt 
CEA144 Ulcerated/Irregular 7.8 20.2 Left Patch GA Shunt 
CEA145 Ulcerated/Irregular   Right Patch GA No Shunt 
CEA146 Ulcerated/Irregular 18.8 43.6 Left Patch GA No Shunt 
CEA147 Smooth   Left No Patch GA No Shunt 
CEA148 Ulcerated/Irregular 15.2 36.5 Left No Patch GA No Shunt 
CEA149 Smooth   Right No Patch GA No Shunt 













cytes CRP Urea Creatinine Cholesterol 
CEA066 6.2 3.8 1.6 0.6 8 7.7 99 3.5 
CEA067 10.3 7.2 2.4 0.5 6 7.2 97 3.8 
CEA068 5 2.6 2 0.5 5 14 102  
CEA077 6.2 3.9 1.7 0.5 1 4.5 94 3.6 
CEA078 11.6 9.3 1.5 0.7 1 11.1 109 3.7 
CEA079 13.5 11.3 1.8 0.4 10 4.3 67  
CEA080 8.4 5.8 1.6 0.9 1 6.2 86  
CEA082 4 2.4 1 0.04 1 6.2 90 4.7 
CEA085 7.5 5.3 1.7 0.4 1 5.4 91 2.6 
CEA086 13.3 12.4 0.5 0.5 1 5.1 93 3.4 
CEA087 8.7 5 2.7 0.7 12 5.5 141 2.4 
CEA088 10.8 7 1.9 1.1 7 7.6 135 3.4 
CEA091 8.6 5.8 1.9 0.6 1 6.3 122 4.8 
CEA092 5.5 3.8 1.2 0.4 79 6.1 107  
CEA093 7.7 5.9 0.7 0.6 56 13.9 510 3.4 
CEA094 5.3 3.3 1.4 0.5 1 6.1 65 3.1 
CEA095 9.6 8.4 0.9 0.2 17 9.6 72  
CEA096 8.5 4.7 3.1 0.7 1 5.3 69  
CEA097 12.3 11.4 0.2 0.5 1 5.4 83 4.5 
CEA100 9.5 5.5 2.9 0.8 1 6.2 96 3.3 
CEA101 5.5 2.8 1.7 0.9 1 3.9 66 3 
CEA102 12.1 7.9 2.8 0.7 1 4.6 81  
CEA105 8.6 6.1 1.7 0.7 1 9.5 128  
CEA106 8.5 4.9 2.6 0.7 1 6.7 94 3.8 
CEA107 8.8 6.9 1.2 0.5 6 7 73 4.3 
CEA108 8.1 4.6 2.3 0.9 1 6 83 4.2 
CEA109 5.9 3.5 1.5 0.6 10 6.3 51 4.9 
CEA110 6.7 3.6 2.1 0.7 5 6.3 74  
CEA111 6.2 5 0.7 0.4 9 9.92 180  
CEA112 9.7 5.9 2.6 0.9 13 7.1 90  
CEA113 10 6.5 2.5 0.7 1 7.1 108  
CEA114 7 4.8 1.1 0.7 1 5.3 70  
CEA115 5.9 2.7 2.3 0.6 12 5.8 86 5.9 
CEA116 7.3 5.2 1.5 0.5 1 6.5 110 4.1 
CEA117 9.1 5.3 3.1 0.5 1 7.3 88  
CEA119 7.3 4.1 2.3 0.7 1 3.2 66 4.3 











cytes CRP Urea Creatinine Cholesterol 
CEA126 10.1 6.7 2.5 0.7 1 5.4 98 5.9 
CEA127 6.4 4.3 1 0.8 37 8.2 170 4 
CEA128 11.9 10.5 0.8 0.6 1 3.2 68  
CEA129 5.8 3 2 0.6 1 8.3 76  
CEA130 7.4 4.7 2 0.6 1 8.9 109 3.9 
CEA131 9.6 5.8 2.6 1 1 5.5 105 3.3 
CEA132 7.6 5.5 1.4 0.6 1 5.4 62 4.3 
CEA133 7.8 5.5 1.3 0.9 1 3.7 77 4.4 
CEA134 6.8 3.3 2.8 0.7 1 5.6 108 7.6 
CEA135 6.7 3.7 2 0.8 1 6.1 111 3.4 
CEA136 9.1 6.4 1.9 0.6 22 5.8 80  
CEA137 6.9 4.8 1.2 0.6 1 5.3 108  
CEA138 8.4 5.5 2.1 0.7 1 3.7 96 4.5 
CEA139 11.8 6.6 3.5 0.8 1 7.7 105  
CEA140 8.1 5.4 1.5 1 77 5.5 83  
CEA141 8.3 4.8 2.5 0.7 1 6 74  
CEA142 7.2 4.7 1.7 0.6 1 6.2 77  
CEA143 5.8 2.7 2.6 0.4 1 6.3 97 2.8 
CEA144 10.2 7.1 1.7 1 8 7.5 95 5.9 
CEA145 9.9 6.8 1.9 1 1 8.4 112  
CEA146 6.3 5.2 0.8 0.3 1 15.6 159  
CEA147 12.8 9.5 2.4 0.8 1 7.1 72 1.7 
CEA148 6.3 4 1.6 0.5 1 7.2 81  
CEA149 11.5 7.8 2.3 0.9 7 12.6 130 4.5 






















CEA066 195 220 162 7.5 5.1 1.5 0.8 
CEA067 527 594 508     
CEA068 177 221 159 4.5 2.7 1.4 0.4 
CEA077 137 113 80 9.7 7.2 1.6 0.6 
CEA078 63 103 42     
CEA079 80 72 70     
CEA080 199 241 193 15.2 12.9 1.2 1.2 
CEA082 191 199 175     
CEA085 168 197 148     
CEA086 121 137 110 10.3 7.1 2.1 1.1 
CEA087 64 68 55 8.4 5.7 1.9 0.5 
CEA088 95 97 76 12 8.5 1.7 1 
CEA091 172 187 141 10.1 7.4 1.8 0.6 
CEA092 211 232 189 8.9 6.4 1.6 0.8 
CEA093 122 193 131 6.3 3.2 1.1 0.7 
CEA094 109 147 102 9.2 8 0.8 0.4 
CEA095 124 81 74 16.6 14.3 1.3 1 
CEA096 60 80 55 8.4 5.5 2.3 0.5 
CEA097 255 198 161 11.6 10.6 0.5 0.5 
CEA100 44 77 46 11.1 8.3 1.8 0.9 
CEA101 92 139 71 6.6 4.2 1.5 0.8 
CEA102 434 542 429 12.3 8.1 2.6 0.9 
CEA105 238 334 229 8.6 6.1 1.7 0.7 
CEA106 487 494 457 18.7 16.8 1.1 0.6 
CEA107 51 72 51 11.3 10.1 0.9 0.3 
CEA108 194 252 181 8.2 5.4 1.6 0.8 
CEA109 212 285 212 7.5 4.8 2.1 0.5 
CEA110 81 191 65 11.9 10 1.4 0.6 
CEA111 202 251 199 7.9 6.8 0.7 0.4 
CEA112 133 155 128 7.5 5.6 1.4 0.5 
CEA113 79 112 82     
CEA114 105 180 111 15.9 14.6 0.6 0.6 
CEA115 164 161 138 9 6.2 1.7 0.8 
CEA116 188 186 122 5 3.1 1.2 0.6 
CEA117 128 72 53 10.6 7.8 2 0.5 
CEA119 101 130 57 12 9.7 1.6 0.7 




















CEA126 131 99 87 7.9 5.4 1.7 0.6 
CEA127 426 205 158 7.5 5.6 1 0.8 
CEA128 180 182 164 7.3 5.4 1.2 0.4 
CEA129 175 170 146 8.8 5.5 2.3 0.8 
CEA130 102 98 53 12.1 9.8 1.3 1 
CEA131 80 33 33 9.9 6.5 2 1 
CEA132 45 58 34 8.3 6.5 1 0.7 
CEA133 45 86 50 6.7 4.8 1 0.8 
CEA134 243 343 240 7.5 5.6 1.2 0.5 
CEA135 127 173 130 16.1 12.4 1.8 2.1 
CEA136 180 156 151 12.9 11.9 0.9 0.1 
CEA137 123 124 98 7.1 5.1 1.1 0.8 
CEA138 94 139 121 18.2 16.4 1.1 0.7 
CEA139 105 125 105 17.6 16 0.9 0.7 
CEA140 106 133 102     
CEA141 184 199 163 9.4 7.7 1 0.7 
CEA142 80 94 81 13.5 10.9 1.6 0.9 
CEA143 64 79 68 7.1 4.7 1.8 0.5 
CEA144 64 79 68 12.4 8.7 2.1 1.2 
CEA145 303 356 251 10.9 8.4 1.3 1.2 
CEA146 35 125 65     
CEA147 46 80 63 15.1 13.3 1.5 0.3 
CEA148 122 144 100 7.8 7 0.6 0.1 
CEA149 223 313 223 12.6 10.2 1.3 0.9 




















CEA066 167 218 148    
CEA067 326 407 293    
CEA068 126 159 114    
CEA077 86 109 88 77 111 71 
CEA078 92 123 85    
CEA079 211 278 224 96 116 195 
CEA080 138 215 133 106 108 85 
CEA082 178 185 142    
CEA085 109 169 86 156 164 133 
CEA086 107 132 69 137 174 133 
CEA087 27 31 23 38 44 26 
CEA088 63 82 55 107 102 76 
CEA091 96 116 79 118 131 100 
CEA092 178 203 152    
CEA093 159 190 150 170 228 161 
CEA094 83 102 59 115 142 104 
CEA095 48 43 32 82 104 73 
CEA096 25 39 19 50 82 52 
CEA097 149 138 109    
CEA100 26 54 37 51 75 47 
CEA101 60 94 55 89 90 79 
CEA102 218 288 204 364 520 363 
CEA105 173 273 177    
CEA106 259 312 252 455 554 436 
CEA107 57 69 54 79 77 61 
CEA108 194 210 180    
CEA109 179 278 181    
CEA110 34 45 25 64 77 50 
CEA111 188 248 189 233 287 206 
CEA112 148 174 138    
CEA113 96 131 97    
CEA114 58 129 61 54 122 56 
CEA115 148 140 123    
CEA116 131 129 86    
CEA117 174 109 72    
CEA119 85 112 54 76 87 50 


















CEA126 135 86 78    
CEA127 85 85 75 210 172 188 
CEA128 196 164 132 100 87 65 
CEA129 302 59 41    
CEA130 53 52 34 116 114 78 
CEA131 120 10 13 80 29 27 
CEA132 56 87 49 34 50 27 
CEA133 32 48 33    
CEA134 208 261 190 255 292 245 
CEA135 38 68 45    
CEA136 96 116 76    
CEA137 91 105 74    
CEA138 84 86 82 15 61 40 
CEA139 143 195 157 22 85 49 
CEA140 88 134 90 55 96 62 
CEA141 126 149 117 36 78 65 
CEA142 75 69 55 80 87 73 
CEA143 70 64 54 184 225 161 
CEA144 70 64 54    
CEA145 237 413 192    
CEA146       
CEA147 47 54 39    
CEA148 79 88 61    
CEA149 147 211 155    


























CEA066          
CEA067          
CEA068          
CEA077 16 10 17       
CEA078 14 11        
CEA079 16 16 14       
CEA080 15 9 14       
CEA082 12 11        
CEA085 14 12 16 18.2 14.2 26.7    
CEA086 13 11 14 29.7 33.6     
CEA087 17   23.4 19.4     
CEA088 18 16 16 23.5 21.9 24.2    
CEA091 16 10 14 22.6 29.7 31.3    
CEA092 15 16  27.1 22.5     
CEA093 16 8 18 34.1 33.1 29.8    
CEA094 18 16 16 28.3 26.8 30.2 1.04 1.08 1.12 
CEA095 14 10 12 28.2 23.3 26.7 1.26 1.29 1.22 
CEA096 17 13 16 23.6 27.5 28.1 1.1 1.12 1.14 
CEA097 12 12  19.9 16.6  1.14 1.11  
CEA100 17 10 16 32.4 28.5 26.2 1.17 1.15 1.19 
CEA101 13 11 13 24.4 26.9 22.8 1.15 1.19 1.07 
CEA102 16 12 15 22.7  27.7 1.24  1.28 
CEA105 14 10  27.9 29.3  1.19 1.17  
CEA106 16 15 16 29.5 24.4  1.16 1.16  
CEA107 16 13 18 26.4 26.1  1.23 1.16  
CEA108 12 12  28.3 22.5  1.05 1.11  
CEA109 21 11  22.9 31.4  1.29 1.25  
CEA110 11 7 12 29.8 33 35.2 1.32 1.33 1.28 
CEA111 21 18 22 26.1 27 24.2 1.17 1.19 1.16 
CEA112 22 24  23.4 25.6  1.09 1.11  
CEA113 19 19  20.4 22.1  1.14 1.1  
CEA114 10 10 10 34.1  31 1.13  1.15 
CEA115 23 21  26.1   1.17   
CEA116 16 15  33.2 37.7  1.21 1.26  
CEA117 18 11  27.5 25.5  1.33 1.28  
CEA119 19 17 18 24.9 21 26.1 1.19 1.24 1.2 
























CEA126    31.2 33.9  1.08 1.12  
CEA127 16 14 19 28.1 28.4 24.3 1.4 1.33 1.41 
CEA128 18 15 19 27.4 25.3 22.3 1.35 1.31 1.3 
CEA129 11 12  25.1 21.4  1.08 1.14  
CEA130 14 11 13 26.7   1.1   
CEA131 18 12 18 25.3 29 27.4 1.56 1.51 1.46 
CEA132 24 18 22 32.1 28.1 26.8 1.14 1.08 1.16 
CEA133 17 11  31.4 35.7  1.29 1.27  
CEA134 18 16 20 17.1  23.3 1.26  1.32 
CEA135 24 20  18.9   1.21   
CEA136 12 12  24.7 22.6  1.14 1.14  
CEA137 21 19  31.7 26  1.34 1.28  
CEA138 14 11 16 22.8 25.3 28.4 1.18 1.17 1.15 
CEA139 12 11 13 26.4 21.8 28.5 1.17 1.34 1.19 
CEA140 18 15 16 24.7 24 22 1.32 1.33 1.34 
CEA141 13 11 12 24.4 27.3 31.2 1.14 1.11 1.09 
CEA142 22 18 24 22.2 15.1 19.3 1.19 1.22 1.2 
CEA143 14 12 13 28.1 24.4 26.9 1.12 1.12 1.17 
CEA144 18 15  26.7 21.9  1.19 1.17  
CEA145 15 12  29.9   1.15   
CEA146 16 15  31.1 27.2  1.25 1.23  
CEA147 11 10  33.1 37  1.07 1.12  
CEA148 19 15  24.3 22.4  1.28 1.26  
CEA149 10 8  34.7   1.09   


























CEA066          
CEA067          
CEA068          
CEA077          
CEA078          
CEA079          
CEA080          
CEA082          
CEA085          
CEA086          
CEA087          
CEA088          
CEA091          
CEA092          
CEA093          
CEA094 133 393.8 372 15.8 23.2 33.2 1547.6 644.4 702.2 
CEA095 74.2 286.8 730.4 16 27.6 58.2 1293.2 586.8 1189.6 
CEA096 675.4 213.6 897 21.6 10 27.4 1110.8 540.2 1155.2 
CEA097          
CEA100 44.2 23.8 18.2 10.4 18.4 15.8 1599.4 
1399.
6 1506 
CEA101 302 347.4 601.4 43.2 31.8 92.6 824.8 773 834.8 
CEA102 348.2 273.2 189 31.6 45.4 25.2 835.6 823 699.8 
CEA105          
CEA106 33.8 40.6 24.2 7.6 4.6 6 1006 833.6 1288.6 
CEA107 54 916 66.8 10 37.2 13.6 952 789.8 986.6 
CEA108          
CEA109          
CEA110 126.4 77.2 70.2 15.2 12.8 12.2 1253.8 995.6 1315 
CEA111 40.6 24.2 115 4.6 6 17.4 849.4 
1333.
6 827.4 
CEA112          
CEA113          
CEA114 916 66.8 453.2 37.2 13.6 28 652.6 423.6 476.4 
CEA115          
CEA116          
























CEA119 77.2 70.2 50.2 12.8 12.2 22.2 560 746.6 776.2 
CEA120 419.6 22.4 9 23 9.2 11.8 1354.8 791.8 1164.2 
CEA126          
CEA127          
CEA128 145.6 92.8 61.8 18.2 6.6 16.8 535.4 712 766.8 
CEA129          
CEA130 16.4 94.8 8.2 10.2 17 9.4 1068.2 782 747 
CEA131 175.6 204.8 2753.8 143 
120.
6 343 1214.8 
1104.
4 1140.2 
CEA132 265.2 122.8 415.8 22.6 21.2 30.8 883.2 645 854.8 
CEA133          
CEA134 5878 714.4 916.6 
426.
6 61.8 71 799.6 661.6 717.6 
CEA135          
CEA136          
CEA137          
CEA138 115 76.2 27.2 17.4 11.2 15.2 911.4 642.2 906.4 
CEA139 453.2 453.6 412 28 34.8 23.4 848.2 630.6 780.8 
CEA140 50.2 90 24.2 22.2 24.4 7.4 1005.2 
1103.
6 1000.8 
CEA141 76.2 27.2 54 11.2 15.2 10 461.6 246.2 477 
CEA142 453.2 412 126.4 34.8 23.4 15.2 777.8 445.6 772.6 
CEA143 90 24.2 187.6 24.4 7.4 25.6 488.8 667.6 1086.2 
CEA144          
CEA145          
CEA146          
CEA147          
CEA148          
CEA149          
















CEA066     50 60 
CEA067    49 50 50 
CEA068    16  49 
CEA077    16  20 
CEA078    15   
CEA079    16 50 40 
CEA080     40 30 
CEA082    40 40 30 
CEA085     16  
CEA086     20  
CEA087    16 20  
CEA088    15 16 16 
CEA091    20   
CEA092    16 55 49 
CEA093     20  
CEA094 12.6 4.2 10.2 20 40 70 
CEA095 9.2 8.6 44.6 15 20 20 
CEA096 15 10.8 19 40 50 50 
CEA097       
CEA100 2.2 10.8 16.8 16 40 40 
CEA101 89.8 125.6 280.8 16  16 
CEA102 20 129.4 98.6 15 16 30 
CEA105     16 20 
CEA106 58.6 38.6 385.8 50 70 79 
CEA107 26 80.2 40.8 20 20 20 
CEA108    20   
CEA109      20 
CEA110 216.2 331.6 298.6 50 40 40 
CEA111 79.8 92.2 11 49 50 50 
CEA112    16   
CEA113    16 90 80 
CEA114 31.8 46.6 401.6 15   
CEA115    60 75 79 
CEA116    70 50  
CEA117    50   
CEA119 40.2 10.4 11  20  














CEA126    16 75  
CEA127    15 16  
CEA128 11.2 32 11.8 15 16  
CEA129       
CEA130 74.6 60 29.8 15   
CEA131 37.4 30.2 43.8 15 20  
CEA132 32.4 81.8 19.6 50 50  
CEA133       
CEA134 19.8 20.8 14.2 15 50  
CEA135    15 15  
CEA136    15   
CEA137       
CEA138 154.2 35.2 26.2 16 16  
CEA139 13.8 6.2 592 49   
CEA140 36 29 13.2 16 30  
CEA141 17.4 18.4 109.4 16 16  
CEA142 7 12.2 9.2 16   
CEA143 4.2 20.4 19.4 20 30  
CEA144    15 50  
CEA145    16 16  
CEA146    16 20  
CEA147    16 55  
CEA148    15 16  
CEA149    16   






Study No Complications Notes 
CEA066  DNA 6w 
CEA067  DNA 6w 
CEA068  Refused 6w 
CEA077   
CEA078  Refused 6w 
CEA079   
CEA080   
CEA082  Refused 6w 
CEA085   
CEA086   
CEA087   
CEA088   
CEA091   
CEA092  Refused 6w 
CEA093   
CEA094   
CEA095   
CEA096   
CEA097  Died Ruptured AAA(DNA) 
CEA100   
CEA101   
CEA102   
CEA105 Hoarsness/Swallowing Diff DNA 6w 
CEA106   
CEA107 Bleed post-op/ Dysphasia post-  
CEA108  Refused 6w 
CEA109  Refused 6w 
CEA110   
CEA111   
CEA112  DNA 6w 
CEA113  DNA 6w 
CEA114   
CEA115  Refused 6w 
CEA116  Refused 6w 
CEA117  DNA 6w 
CEA119   
CEA120   




Study No Complications Notes 
CEA127   
CEA128   
CEA129  PreCABG, refused 6w 
CEA130  PreCABG 
CEA131   
CEA132   
CEA133  DNA 6w 
CEA134   
CEA135  Refused 6w 
CEA136  DNA 6w 
CEA137  Refused 6w 
CEA138  Axil/Sub stent 
CEA139  L CEA 06 
CEA140   
CEA141  PreCABG 
CEA142   
CEA143 Post op CVA CVA 03 R sided,MI 01 
CEA144  DNA 6w 
CEA145 Post-op TIA, dif swollowing Aorto-bifem, DNA 6w 
CEA146  Refused post and 6 weeks 
CEA147  CABG 2004, AF Aug 05, DNA 6w 
CEA148  CABG 1994, refused 6w 
CEA149  Pre AVR, refused 6w 
CEA150  CABG 06, refused 6 w 
 
 
